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In Belgium, the annual admission number to the intensive care unit (ICU) is around 5000 
newborns and 4000 paediatric patients (infants, toddlers, children and adolescents till 
15 years of age)*.1,2 Infections affect 30% of those children, with a 25% mortality rate 
in the presence of severe sepsis and septic shock.3 This high number is not surprising 
since seriously ill children are predisposed to develop infections due to their risk factor 
profile with invasive devices, a prolonged hospital stay, frequent surgical procedures, an 
immature immune response, immunoparesis due to drugs or procedures, and prior an-
tibiotic therapy.4,5 Consequently, antimicrobial agents are amongst the most commonly 
prescribed drugs on the neonatal and paediatric ICU.6,7 
In this introductory chapter, we first discuss the impact of maturation and pathophysi-
ological changes on the pharmacokinetics (PK) of antibiotics in children*. Second, we 
focus on PK changes in children using extracorporeal techniques. This is followed by a sec-
tion considering the distinct pharmacodynamic (PD) properties of antibiotics. Fourth, we 
discuss the problem of off-label and unlicensed use in a neonatal and paediatric intensive 
care environment. Next, a concise overview of the European initiative to improve paediat-
ric drug development is given. In the final part of the chapter, we consider modelling and 
simulation strategies to optimize antibiotic dosing in critically ill children.
2.  ALTERED DISPOSITION IN THE CRITICALLy ILL PAEDIATRIC PATIENT
PK describes the drug concentration over time (‘what the body does to the drug’) at a 
specific site (e.g. blood, cerebrospinal fluid) and is described by its absorption, distribu-
tion and elimination through metabolism or excretion (ADME) .
In healthy children, drug disposition is driven by physiological processes of growth and 
development. From birth up to adulthood, every child is prone to maturational changes 
in body composition, drug metabolising enzymes, cardiac output, blood flow and func-
tion of drug eliminating organs (liver and kidneys) (Figure 1).9 Furthermore, in children 
admitted to the ICU, pathophysiological and treatment induced changes can also lead 
to alterations in PK (Figure 2).10 
* paediatric age groups according to the classification of the International Council for Harmonisation 
(ICH) : preterm newborns (less than 36 weeks of gestation), term newborns (0 to 27 days), infants and 
toddlers (28 days to 23 months), children (2 to 11 years), and adolescents (12-16/18 years).8
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The ADME properties and the extent to which they vary between ICU and non-ICU 
patients receiving antibiotics are briefly discussed here. 
2.1. Absorption 
Absorption is the process of drug transport from the site of administration to the 
systemic circulation. The extent of absorption is described by bioavailability (F), the 
fraction of the administered dose of unchanged drug reaching the systemic circulation. 
If a drug is administered intravenously, F is 100%, for other routes, this is between 0 and 
100%. Drug and patient specific factors are responsible for the rate and magnitude of 
absorption. Main drug specific factors include: particle size, solubility and dissolution 
rate, lipophilicity, ionisation state, acid dissociation constant of the drug. 11 
Figure 1. Developmental changes in physiological factors that influence drug disposition in infants, chil-
dren, and adolescents. Physiological changes in multiple organs and organ systems during development 
are responsible for age-related differences in drug disposition. CYP, cytochrome P-450; UGT, glucurono-
syltransferase (UGT); wk, week; mo, month; yr, year. (Reproduced with permission from Kearns G. et al.9, 
Copyright Massachusetts Medical Society) 
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The main patient determinants for the rate and extent of enteral absorption are gas-
tric emptying time and intestinal motility, gastrointestinal pH, splanchnic blood flow, 
intestinal secretion, absorption surface area and drug metabolism at the intestinal 
epithelium, of which maturational and pathophysiological changes are sequentially 
discussed below. 
Gastric emptying matures over a period of 6-8 months to an adult level.11 Furthermore, 
antral contractions and intestinal motor activity increase during the first weeks of life 
with possible consequences on enteral absorption. Delayed gastric emptying is estimat-
ed to be present in 50% of critically ill children, especially in neonates and infants where 
a developmental pattern further strengthens this phenomenon as described above.12,13 
Gastroparesis may occur as a side effect of opioids, while the use of naso-duodenal 
gavage feeding will bypass gastric effects.14 Similarly, chronic kidney disease can also 
delay gastric emptying time through visceral neuropathy.15 No studies have specifically 
evaluated the effect of developmental and disease related changes in gastric emptying 
and intestinal motility on absorption of antibiotics in children. Although, delayed and 
incomplete absorption in neonates and small infants have been suggested for amoxicil-
lin, rifampicin and chloramphenicol.16 In general, one could hypothesise that delayed 
gastric emptying leads to a delayed and more blunted peak concentration compared 
to a patient without delayed emptying. The clinical relevance of this depends on the 
concentration-effect profile of the compound. If a minimum effective concentration has 
to be reached, the effect could be delayed.11 
Although there are no significant differences between neonates (a few hours after deliv-
ery), infants, toddlers, children, adolescents and adults in baseline gastric pH, one should 
consider that pH will rise postprandially as milk and feedings in general have a buffering 
effect. As a consequence, during the day, neonates and children on continuous enteral 
feeding tend to more often have a basic gastric environment.17 These changes in gastric 
pH are important for acid-labile drugs like penicillin G which can be absorbed more 
efficiently in a higher gastric pH environment. Huang et al. showed that neonates tend 
to have a higher bioavailability of penicillin G as compared to older children.18 Similar ef-
fects may occur in the case of stress ulcer prophylaxis with pH modulating agents, which 
are commonly prescribed on the ICU. Little is known about the age-related changes in 
intestinal pH. 
An age-related increase in splanchnic blood flow has been observed over the first three 
weeks of life which may influence absorption rates.9 Circulatory dysfunction in cardiac 
failure (e.g. during paediatric sepsis and septic shock) leads to shunting of blood flow 
towards the vital organs like brain and heart, at the expense of other peripheral tis-
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sues (e.g. muscles, skin and splanchnic organs, kidney, liver). This cardiovascular failure 
results in a decreased forward flow (reduced tissue perfusion) and an increased back 
pressure (congestion) (e.g. in the gut circulation). Vasopressors and inotropes are often 
used in haemodynamically unstable children and are known to alter splanchnic perfu-
sion. Although several animal and clinical studies have assessed the gut-specific effects 
of these vasoactive drugs, it is not really known whether these effects are beneficial or 
detrimental in terms of gut perfusion and at what specific dose they occur.19–29 King et al. 
evaluated in a retrospective manner the tolerance of enteral feeding in patients admit-
ted to the paediatric ICU receiving cardiovascular medication. Dopamine was the most 
commonly used vasopressor. Twenty-nine per cent of patients had feedings withheld 
for a perceived gastrointestinal intolerance.30 In another study epinephrine at a dose 
more than 0.3 µg/kg/min was identified to be a significant factor for gastrointestinal 
complications in critically ill children receiving transpyloric enteral nutrition.13 One of 
the explanations for this gastrointestinal intolerance could be a body’s failure to meet 
the higher splanchnic metabolic demands when the gut is hypoperfused.12 To the best 
of our knowledge, there are no studies available investigating the impact of impaired 
splanchnic perfusion on drug absorption in children, although it is hypothesised that 
drug absorption from these sites can be erratic. 
Lipophilic antibiotics given enterally need biliary salts to be absorbed. One could 
speculate that due to maturation of conjugation and transport of bile salts up to the 
age of 4, absorption of these antibiotics increases with age (Figure 1). Patients in the 
NICU/PICU are at risk for cholestasis and acute cholecystitis due to the presence of 
sepsis, surgery and total parenteral nutrition.31,32 Also due to polypharmacy, NICU/PICU 
patients are susceptible for drug-induced cholestasis.33 Evidently, these factors may lead 
to a reduced absorption of lipophilic antibiotics. 
Villous formation normally ends at 20 weeks of gestation, rendering absorptive surface 
after birth unlikely to alter drug absorption.17,34 ICU patients are often withheld from 
enteral feeding due to intolerance. It is known that starvation and diarrhoea result in 
intestinal atrophy and it is therefore likely that cellular dysfunction in the gut potentially 
leads to  altered intestinal drug absorption.36 The knowledge of ontogeny on intestinal 
membrane transporters with regard to drug absorption is scarce. Ex vivo, pharmacoki-
netic and pharmacogenetic studies suggest transporter-specific changes from human 
fetus to the adult. To date, no clear maturation patterns have been identified.35 Diar-
rhoea may also compromise intestinal transporter activity.35 
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Due to this expected high interpatient variability in absorption processes, intravenous 
drug administration is the preferred route in critically ill children in order to avoid com-
promised drug bio-availability.14
2.2. Distribution
The apparent volume of distribution is a theoretical measure of the extent to which a 
drug will migrate into extravascular tissues.37 It is affected by developmental and patho-
physiological changes in body composition and tissue permeability, protein binding, 
regional blood flow and membrane transporters . 9,38
The younger the child the higher the extracellular and total body water content (Figure 
1), resulting in higher volumes of distribution (Vd) and lower (peak) concentrations 
of water soluble drugs (e.g. aminoglycosides, vancomycin, β-lactam antibiotics) when 
administered on a mg/kg basis. Nielsen et al. observed that preterm neonates had a 
significantly larger central Vd per kg bodyweight than term neonates.39 Increased capil-
lary permeability, increased hydrostatic pressure, or decreased plasma oncotic pressure 
due to hypoproteinemia are commonly encountered in the neonatal and paediatric 
intensive care unit (NICU/PICU) and may further increase the distribution volume (e.g. 
oedema). Lingvall et al. documented that the Vd of gentamicin was significantly higher 
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Figure 2. Major pathophysiological and treatment factors related to PK changes in critically ill children
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in blood culture confirmed septic neonates compared to non-septic cases.40  Also, in 
children with severe burns, increased capillary permeability usually leads to an increased 
Vd, as shown for vancomycin and amikacin.41,42 
Similarly, maturational changes in the overall plasma binding protein pool will have 
an impact on the unbound fraction of the drug and, therefore, the ability of drug to 
migrate into tissues. The most important plasma proteins for drug binding are albumin 
and the acute phase reactant α-1 acid glycoprotein. Albumin preferentially binds acidic 
molecules whereas α-1 acid glycoprotein tends to bind compounds with basic moieties. 
Plasma albumin concentrations and binding capacity will reach adult levels around the 
end of infancy (~2 years of age).9 Smits et al. recently evaluated protein binding of the 
highly protein-bound antibiotic cefazolin in postoperative neonates. As expected, the 
median unbound cefazolin fraction was higher than in adults.43 In states of severe illness, 
hypoproteinemia (<61 g/L) and hypoalbuminemia (<33 g/L) are frequently observed 
in children and are the result of a number of mechanisms such as increased protein 
catabolism, capillary permeability and decreased production due to liver failure. In 
contrast, α-1 acid glycoprotein levels often increase during periods of critical illness.44,45 
Besides protein concentration, the binding affinity of antibiotic to plasma proteins also 
depends on conformational changes of the protein molecule. These changes can be 
induced by changes in pH and urea concentration, phenomena likely to occur in critical 
illness.46  Likewise, changes in the ionised fraction of the drug (depending on the pKa) 
due to pH changes may alter plasma protein binding, tissue distribution, and thus Vd.
Competitive binding of co-administered drugs or endogenous substances (e.g. biliru-
bin, free fatty acids) may also have an impact on the degree of drug-protein binding. 
In preterm neonates, competitive binding of antibiotics (e.g. ceftriaxone, cefazolin) 
and bilirubin to albumin has been described.47,48 As a clinical consequence, the highly 
albumin-bound antibiotic ceftriaxone is currently contraindicated in neonates until 
a postmenstrual age of 41 weeks because of displacement of unconjugated bilirubin 
which could potentially result in kernicterus.48,49 Likewise, in the case of liver failure due 
to critical illness, hyperbilirubinemia may induce similar competitive binding interac-
tions.
Cardiac output undergoes a developmental decrease until adolescence.9 Redistribu-
tion of blood during cardiac failure, as described in the absorption section, results in 
a reduced Vd with decreased delivery of hydrophilic drugs to the capillary system and 
poor peripheral tissue penetration. In a study by Joukhadar et al., this resulted in a five 
to tenfold decrease of piperacillin distribution into fat and muscle tissues in adults. 50
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Of special note, the blood-brain barrier matures until the age of 6 months and is more 
permeable in the presence of inflammation. Both factors have a potential impact on 
antibiotic disposition when treating central nervous system infections.51 Also, the effect 
of membrane transporters in the developing BBB and blood-cerebrospinal barrier (e.g. 
P-glycoproteine P) may play an important role in the distribution of antibiotics.52,53 
2.3. Metabolism
Drug metabolism is the process by which a drug undergoes biotransformation to a 
moiety that is more readily eliminated from the body. Typically, drug metabolites are 
more polar, water-soluble molecules than the parent drug molecule, and often they are 
biologically inactive.54 However, some molecules are prodrugs and need to be active 
metabolites to exert their effect, other drugs are metabolised to molecules with a higher 
potency than the mother molecule. The liver and intestine are the main organs where 
drug metabolism occurs but also kidney and lungs may be involved.54 
Drug metabolism reactions are classified as phase I and phase II reactions and generally 
occur sequentially. Phase I reactions are typically modification reactions (oxidation, re-
duction, hydrolysis) rendering the compound more polar. Phase II reactions are conjuga-
tion reactions with hydrophilic molecules (e.g. glucuronidation, acetylation, sulphation). 
Most important group of enzymes involved in phase I reactions are the cytochrome 
P450 iso-enzymes; alcohol hydrogenase and flavine mono-oxygenase enzymes are 
other phase I reactions involved in drug metabolism.54 
Maturational trends in drug metabolising enzyme (DME) activity have been classified 
into three distinct groups: (i) a group of enzymes that are higly active before birth but 
declining shortly thereafter; (ii) a group of enzymes of which the activity rises during the 
first 2 years after birth; (iii) a group of enzymes of which the activity remains constant 
throughout life (Figure 3).54 Age-related changes may affect drug effect and toxicity 
and need to be considered when dosing antibiotics which undergo drug metabolism 
(e.g. chloramphenicol toxicity in neonates due to diminished glucuronidation capacity)
(Figure 3).55 
With regard to the impact of critical illness, Carcillo et al. observed a twofold reduced 
CYP450 mediated metabolism in children with sepsis.56 Likewise, in the case of liver im-
pairment of any origin, liver metabolism may be reduced as was illustrated by Acocella 
et al. for rifampicin in adults.57 
Due to polypharmacy in the NICU/PICU, pharmacokinetic drug-drug interactions (DDI) 
at the level of DME (e.g. enzyme induction, inhibition) are common (e.g. clarithromycin: 
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CYP3A4 inhibitor) and may lead to altered pharmacokinetics.54 Since concomitant devel-
opmental changes in drug metabolism occur, children’s vulnerability to DDI may differ 
from adults. To date, prospective studies investigating the occurrence and severity of 
drug-drug interactions in children are lacking.58 
Finally, in patients with cardiac failure or ventilated patients, a decreased cardiac output 
may reduce the hepatic clearance of drugs with a high extraction ratio through a de-
creased liver blood flow (e.g. ciprofloxacin).59 
2.4. Excretion
Drug excretion is the process by which parent drug and/or its metabolite(s) are removed 
from the body. This is mainly accomplished by the kidneys (glomerular filtration and 
proximal renal tubular secretion) and via the hepato-biliary route. Both processes un-
dergo maturational changes and can also be affected by critical illness. 
Many of the commonly used antibiotics in critically ill children are cleared by renal 
elimination. Glomerular integrity, physicochemical properties of the drug, and extent 
of protein binding determine the total amount to be filtered. Since only unbound drug 
can be filtered, the unbound fraction drives elimination of antibiotics excreted by glo-
Figure 3. Ontogeny of drug metabolizing enzymes. CYp, cytochrome P450; TPMT, thiopurine S-methyl-
transferase; UGT, UDP-glucuronosyltransferases; FMO, flavin-containing mono-oxygenase. (Reproduced 
with permission from de Wildt et al.54, Copyright BMJ Publishing Group Ltd.)
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merular filtration. In addition to glomerular filtration, drugs can be eliminated by active 
secretion in the proximal renal tubules, where transporters of cationic and anionic drugs 
are highly expressed. Weak acids and bases (i.e. most drugs) can be reabsorbed in non-
ionised forms in the distal tubule. 37
The glomerular filtration rate (GFR) matures starting from fetal organogenesis into late 
infancy. At birth, newborns experience profound hemodynamic changes. Among these 
changes, increased renal blood flow and decreased renal vascular resistance cause a 
rapid rise in GFR over the first weeks of life, with adult GFR typically attained by 2 years 
of age (Figure 1).9 Among preterm neonates, increments in GFR are much slower due 
to lower kidney perfusion, incomplete nephrogenesis and reduced nephron numbers.60 
The maturation of the active tubular secretion and reabsorption process through mem-
brane transporters is less well known but is assumed to reach adult capacity in early 
childhood.9,61 Evidently, all these maturation processes are likely to have a major impact 
on the dosing of renally cleared antibiotics in children below 2 years of age.
Besides maturation, disease characteristics also affect renal elimination capacity (Figure 
2). Acidosis and alkalosis are common in critically ill children (due to organ failure or 
alveolar hyperventilation) and may lead to changes in urinary pH. As only the unionised 
fraction is subject to tubular reabsorption, this may lead to altered drug reabsorption.37 
In patients with cardiac failure, a decreased cardiac output may induce a lower renal 
blood flow and reduced renal clearance of antibiotics.62 Also mechanical ventilation may 
alter renal drug clearance through a similar mechanism.59 Acute kidney injury (AKI) and 
chronic kidney disease (CKD) (e.g. patients with heart failure) are commonly encoun-
tered in the NICU/PICU and may directly lead to impaired renal drug clearance.63–65 Poly-
pharmacy may also lead to alterations in renal drug clearance. In critically ill neonates, 
co-administration of  the nephrotoxic non-steroidal anti-inflammatory agent ibuprofen 
led to decreased clearance of amikacin, vancomycin and gentamicin.66   
Augmented renal clearance (ARC) of antibiotics is frequently observed in critically ill 
adults. The exact pathophysiological mechanism remains unknown but an increased re-
nal blood flow (due to vasodilation and increased cardiac output) leading to significant 
alterations in glomerular filtration, tubular secretion and reabsorption are apparent.67,68 
Although the commonly used definition for ARC in adults (estimated GFR>130 ml/min) 
cannot be applied throughout the time span of renal maturation, there is some evidence 
that the concept of ARC also applies to children. Yu et al. and Gomez et al. observed 
significantly increased clearances of vancomycin and amikacin in children with burn 
wound sepsis when compared to children without burn wounds.41,42 
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3. PK ALTERATIONS IN CHILDREN USING ExTRACORPOREAL TECHNIQUES
Some treatment modalities require special attention with regard to PK changes and are 
discussed below (Figure 2).
3.1. Renal replacement therapy
During dialysis, a countercurrent dialysate flow allows for diffusion of solutes (including 
the unbound fraction of drugs) according to the concentration gradient. Ultrafiltration 
is often used, in combination with dialysis, for management of fluid overload. In this 
case, plasma water removal occurs through convection over the filter membrane using 
a hydrostatic pressure. Solutes (including the unbound fraction of drugs) follow the 
direction of removed water.37
Drug and procedure related characteristics drive drug clearance during renal replace-
ment therapy (RRT) (Figure 4).
Drugs which are predominantly cleared by the kidneys are most affected by use of renal re-
placement therapy. Typically, low-molecular weight (<500 dalton), hydrophilic (low Vd) and 
low protein-bound compounds have a high extraction ratio during dialysis and continuous 
renal replacement therapy. In the case of antibiotics, passage across the filter is usually large 
due to their small molecular weight.69 Main determinants for drug clearance related to the 
equipment and RRT technique, are the RRT mode and duration, blood, dialysis and ultra-
filtrate flow. The more rapid the blood and dialysate flow rates the better the clearance by 
diffusion. Finally, dialysis membranes differ in surface area and pore size and may be subject 
to drug adsorption, which also may have an effect on antibiotic clearance.70 
Figure 4. Determinants of drug removal during renal replacement therapies. (Reproduced with permission 
from Veltri et al.69, Copyright Springer)
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Depending on haemodynamic status, fluid status and catheter access, physicians will 
choose between intermittent haemodialysis (IDH) and continuous renal replacement 
therapies (CRRT) like continuous arteriovenous/venovenous haemofiltration (CAVH/
CVVH), continuous arteriovenous/venovenous haemodialysis (CAVHD/CVVHD) and 
continuous arteriovenous/venovenous haemodiafiltration (CAVHDF/CVVHDF). 
Due to a lack of paediatric-specific studies, dosing recommendations are often extrapo-
lated from available adult literature. As general guideline for dosing renally cleared an-
timicrobials in patients with intermittent hemodialysis (IHD), it is important to estimate 
the residual renal function and start with an appropriate paediatric dosing regimen 
according to this estimated renal clearance. If drug properties allow for drug removal 
during IHD, a post IHD dose is currently suggested.69 In NICU/PICU patients, continuous 
renal replacement therapies are most commonly used. Operating conditions are crucial 
to predict antimicrobial concentrations since over- and underdosing need to be consid-
ered.71 
3.2. Extracorporeal membrane oxygenation 
Extracorporeal membrane oxygenation (ECMO) is a cardiopulmonary bypass technique 
providing temporary respiratory and cardiac support. During ECMO, drugs tend to have 
higher volumes of distribution, mainly through haemodilution on initiation of ECMO, 
decreased plasma protein binding, capillary leakage and oedema. These phenomena 
have the greatest effect on drugs whose distribution is limited to the plasma compart-
ment.72 
Additionally, adsorption of drugs to ECMO component material may also occur and mainly 
depends on the lipophilicity of the drug, type of pump, oxygenator and circuit material.72 
Generally speaking, the higher the lipophilicity of the antibiotic, the more adsorption is 
to be expected. In an in vitro study by Wildschut et al., hydrophilic antibiotics vancomycin, 
meropenem and cefazolin showed only modest sequestration to currently used ECMO 
circuits.73 Due to the expected increase in Vd of hydrophilic antibiotics, higher vancomycin 
and gentamycin loading doses were suggested in children on ECMO.74,75 
Renal dysfunction is also common in the ECMO setting, and is usually related to the 
underlying indication. The loss in blood flow pulsatility and the inflammatory state, both 
induced by ECMO, may also affect renal function.76 Whenever renal function becomes 
erratic, ECMO is used in combination with renal replacement therapy. Hence, renal clear-
ance of antibiotics is usually impaired as was observed for cefotaxime, gentamycin and 
vancomycin and lower maintenance doses may be indicated.75
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3.3. Cardiopulmonary bypass 
The cardiopulmonary bypass (CPB) equipment and its impact on PK are similar to what 
has been described for ECMO.77 Consequently, general dosing principles of high load-
ing doses and reduced maintenance doses for hydrophilic antibiotics may also apply 
during CPB, as was suggested for cefazolin by Haessler et al.78 Adsorption of liphophilic 
antibiotics (e.g. fluorochinolones, macrolides) to the CPB material may also necessitate 
dose increments. 
Additionally, during CPB, therapeutic hypothermia is commonly used for organ protec-
tion. Due to a decreased cardiac output and reduced blood flow to tissues, this lower 
body temperature tends to reduce the Vd. This was illustrated by Kilbaugh et al. who 
observed decreased cefazolin tissue disposition into skeletal muscle during CPB with 
deep hypothermic circulatory arrest when compared to children with mild to moderate 
hypothermia.79 Indirectly, a temperature drop also leads to an increase in blood pH and 
consequent changes in the ionised fraction of the drug, another determinant of the Vd. 
Finally, during hypothermia a decreased clearance by elimination organs is expected 
due to the reduced organ blood flow and diminished enzyme activity.76 
Figure 5. Paediatric study decision tree from the Food and Drug Administration (Reproduced with permis-
sion from Dunne et al.80, Copyright American Academy of Pediatrics) ER, exposure-response curve
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4. PHARMACODyNAMICS OF ANTIBIOTICS 
PD estimates the relationship between a drug concentration and (side-) effect over time 
(‘what the drug does to the body’). Whether PD of drugs needs to be studied in children, 
in addition to the investigation in adults, depends on the information regarding: (i) how 
similar disease progression is between adults and children, (ii) how similar the response 
to intervention is between these populations, and (iii) which valid and relevant PD mea-
surements (biomarkers, outcome variables) are available (Figure 5).80 
When applying this decision tree to antibiotics (Figure 5), the Food and Drug Ad-
ministration (FDA) and European Medicines Agency (EMA) currently consider it to be 
reasonable to postulate similarities in antimicrobial PD between patient populations 
 
 
Figure 2: Pharmacokinetic and pharmacodynamic parameters of antibiotics on a 






















Figure 6. PK/PD parameters of antibiotics (Reproduced with permission from Roberts J. et al.82, Copyright 
Wolters Kluwer Health, Inc.) Cmax, peak concentration; AUC, area under the concentration time curve; T>MIC, 
time interval during which the unbound concentration remains above the minimal inhibitory concentra-
tion of the infecting organism
Table 1. PK/PD targets for antibiotics commonly used in critically ill children. 
Antibacterial PD index PD target
Amikacin-tobramycin-gentamicin-netilmicin Cmax/MIC 8-12 
Tobramycin AUC/MIC 30 
Ciprofloxacin-levofloxacin AUC/MIC >125
β-lactam antibiotics %fT above MIC 40-100 (%)
Vancomycin AUC/MIC 400
Teicoplanin AUC/MIC 75-95
Cmax, peak concentration; T, time; AUC, area under the concentration time curve; MIC, minimal inhibitory 
concentration of the infecting organism. Based on  Moore et al., Burgess D. et al., Scaglioni F. et al., Kanasawa 
N. et al. and Matsumoto K. et al.83–87
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(concentration-response), because the treatment is aimed at the infectious organism 
(which is considered to behave the same between patient populations) and not the 
host per se. Consequently, differences in PK and safety aspects are the primary focus 
for optimizing antibiotic utilization across populations.81 Three main PK/PD targets, irre-
spective of the patient population, have been defined for maximum killing of the infect-
ing pathogen depending on the properties of the antibiotic: ratio of the peak plasma 
concentration over minimal inhibitory concentration (MIC) of the infecting organism, 
ratio of the area under the concentration time curve over MIC, or time during which 
the unbound concentration remains above the MIC (Figure 6). PD targets have been 
established in in vitro and animal studies and were in most cases confirmed in clinical 
studies in adults (Table 1).
5. OFF-LABEL DRUG USE IN THE NEONATAL AND PAEDIATRIC ICU
Patients admitted to the NICU/PICU are exposed to a large number of drugs and total 
numbers increase with duration of ICU therapies and length of ICU stay.88–90 Despite 
the importance of evidence-based drug treatment in this vulnerable population, PK, 
PD and efficacy data are scarce and dosing regimens remain often empirically derived 
from adults, relatively ‘healthy‘ and/or older children. Consequently, most drugs used in 
the ICU are prescribed outside the terms of product license (off-label) or even without 
market authorization (unlicensed use). Frequencies of off-label and unlicensed use in 
the NICU/PICU between 50-85% have been reported, of which anti-infectives were one 
of the most commonly involved drug classes.88,90,91 Risk factors for receiving an off-label 
drug included young age (<5 years), chronic health conditions, acute organ failures, 
mechanical ventilation, having arterial or venous catheters, dialysis treatment and 
receiving blood products.91,92 Most commonly reported types of off-label use were the 
prescription of drugs in another dose or frequency, in a different formulation, or in an 
another age group.93
Previous research has also shown that these practices undoubtedly contribute to an 
extensive variability in dosing regimens.94 Moreover, unlicensed/off-label drug prescrib-
ing has been associated with medication errors and unpredictable responses, related to 
either toxicity or therapeutic failure.95,96 An illustrative historical example of antibiotic 
toxicity is the ‘gray baby syndrome’, due to chloramphenicol overdosing when given 
without regard for the infants’ diminished capacities for glucuronidation metabolism 
and renal excretion. These babies presented with hypothermia, vomiting, acidosis, cya-
nosis and a characteristic grey skin colour.55,97 Finally, in the case of antibiotics, adequate 
dosing is also warranted to reduce the emerging spread of resistant pathogens.98 Since 
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2011, the European Commission  (EC) and the EMA have been considering this global 
threat as a high priority. To tackle the problem, several areas were identified where 
measures have to be taken among which the appropriate use of antibiotics (including 
prescribing the appropriate dose) and development of new antibiotics.99
6. EUROPEAN PAEDIATRIC REGULATION 
6.1. Introduction
To counterbalance the lack of information on the use of medicines in children, the 
European Paediatric Regulation came into force in 2007 to ensure that “the develop-
ment of medicinal products that are potentially to be used for the paediatric population 
becomes an integral part of the development of medicinal products, integrated into the 
development programme for adults”.100 Hereby, the pharmaceutical industry is obliged 
to initiate a paediatric drug development program for every new drug compound. Any 
application for drug approval by the EMA (including new indication, pharmaceutical 
form or route of administration) must be accompanied by a paediatric investigation plan 
(PIP). This plan should include essential information on how and when the pharmaceuti-
cal company will study the pharmacokinetics and (side-)effects of the investigational 
compound in every subpopulation of children affected by the disease, including infor-
mation on the drug formulation. This plan has to be approved a priori by the experts from 
the Paediatric Committee (PDCO) of the EMA. The PDCO is composed of 5 members of 
the Committee for Medicinal Products for Human Use (CHMP), 1 member appointed by 
each European Union member state that is not represented by the members appointed 
by the CHMP, 3 members representing healthcare professionals and three members 
representing patient associations.
A (partial) waiver for paediatric drug development can be granted  by the PDCO if (i) 
the specific drug or drug class is likely to be ineffective or unsafe in part or all of the 
paediatric population, (ii) the disease or condition for which the drug or drug class is 
intended occurs only in specific paediatric age categories or adults, or (iii) the drug does 
not represent a significant therapeutic benefit over existing treatments in children. 
After the PIP has been completed and (positive or negative) results are submitted to 
the regulatory authorities, pharmaceutical companies receive a six months extension of 
their patent protection as a financial reward. 
Off-patent drugs that are developed specifically for children are eligible for a paediatric-
use marketing authorisation (PUMA). In this case, the incentive is a 10 year duration of 
market protection. To align scientific research for off-patent drugs, EMA has published 
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a priority list in 2009, which has continuously been updated in recent years.101 The 
following were always considered as high-priority areas: (i) the development of age-
appropriate formulations and strengths (even if not explicity stated), (ii) data in neonates 
for all conditions (except oncology) and, (iii) data in infants for oncological conditions 
and for refractory paediatric epilepsy syndromes. For orphan drugs, the incentive is an 
additional two years of market exclusivity.
Nine years after implementation of the Paediatric Regulation, the effect on drug devel-
opment is substantial.102 First, it had a direct positive impact on paediatric drug develop-
ment since paediatric considerations have become an integral part of pharmaceutical 
development. Since the date of commencement by end 2015, 49 new drugs were 
authorised for paediatric use, 64 new paediatric indications were authorised and 13 new 
pharmaceutical forms, all linked to the requirements of the regulation.102 The number 
has been increasing every year due to the drug development time. To date, 100 PIPs 
have been completed and more than 700 are ongoing.102 Second, also 140 updates on 
product information and 16 new paediatric indications were approved using data from 
studies already completed before 2007.102 This is a result of the mandatory submission 
by the marketing authorisation holder to the regulatory agency, as stipulated in article 
45 of the Regulation. Other achievements of the regulation include: (i) the rising quality 
of trials, in particular through the possibility to receive (free-of-charge) scientific advice 
by the EMA for pharmaceutical companies, academia and other parties developing 
medicines and, (ii) the implementation of the public availability of information on PIP 
and protocol-related information via the European clinical trials database (EudraCT) to 
omit duplication, limit the patient’s burden and prevent selective reporting. 
A substantial amount of off-patent drugs are used in children. However, in this group, 
over the last 10 years, only 2 products were granted with a PUMA, 22 PIPs have been 
agreed and 24 applications are still ongoing or were withdrawn.102
6.2. Inclusion of intensive care patients  
The PIP is defined in the regulation as a development programme “aimed at ensuring 
that the necessary data are generated determining the conditions in which a medici-
nal product may be authorized to treat in the paediatric population”.100 A condition is 
vagely defined as “any deviation(s) from the normal structure or function of the body, as 
manifested by a characteristic set of signs and symptoms (typically a recognised distinct 
disease or a syndrome)”. The approach used by the PDCO to identify the scope of PIP 
with regard to conditions to be investigated was clarified in an EMA policy document 
in 2012 and is mainly based on the system organ class classification.103 Traditionally, all 
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subsets of age groups between birth and 18 years that may be concerned should be 
specified in the PIP assessment.8 
However, despite the ICH E11 recommendation to prioritize drug development in seri-
ous or life-threatening diseases, the paediatric regulation (nor accompanying policy 
documents and inventory/priority lists) does not explicitly stipulate the need to study 
the impact of (profound) pathophysiological changes (e.g. sepsis/septic shock), treat-
ment characteristics (e.g. common drug-drug interactions, body cooling, extracorporeal 
membrane oxygenation) and/or co-morbidity (e.g. obesity) on drug PK/PD.8 
After enforcement of the regulation, a lot of attention has been paid to the gap-of-
knowledge in the neonatal subpopulation. The number of neonates to be included in 
trials has been increased by more than 25 times.102 From these numbers one can assume 
that at least, also a proportion of seriously ill neonates should be recruited. Neverthe-
less, based on safety considerations, until now, neonatal studies are often deferred until 
experience is available in older age groups (Figure 7).102 
This holds the risk that after marketing authorisation for adults is granted, the planned 
studies are delayed or never initiated and drugs remain to be prescribed off-label. There 
are two reasons for this: once the drug is authorised, the EMA has no means to enforce 
Figure 7. Involvement of children per age group within medicine developments, according to the 10-year 
report of the paediatric regulation102
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the legislation and second, once the drug is available off-label, extra patient recruitment 
problems may occur. It is an issue that is currently discussed to support earlier conduct 
of neonatal and infant studies, considering the limited relevance of a priori evidence in 
older age groups. Alongside the classification for PIPs and waivers based on therapeutic 
areas (e.g. cardiovascular diseases, dermatology, haematology, infectious diseases), a 
class of ‘neonatology and paediatric intensive care’ is currently used. This classification is 
determined within the PIP submission by the applicant. Between 2007 and end 2015 the 
number of agreed PIPs within the class of neonatology/paediatric intensive care only 
represented 2 % of agreed PIPs.102 Besides the chance that a compound  - that mainly will 
be tested in a critical care setting-  is classified only under its therapeutic area and not 
specifically under the class of ‘neonatology/paediatric intensive care’, this low number 
emphasises the room for improvement of the regulation to ensure drug development in 
this vulnerable subgroup of patients. 
Moreover, the most recently revised priority list for off-patent products only specifies 
in the area of intensive care/anaesthesiology the need to study propofol for short-term 
procedural sedation in neonates, although a referral is made to the therapeutic areas 
like cardiology, haematology, infectiology, neonatology and pain.101 In these therapeutic 
domains, only requirements are defined on age (neonates and infants), indication (e.g. 
immunocompromised patients), and type of study (e.g. PK, efficacy, safety). Similarly 
as for new drugs under development, one can assume that some of those patients will 
require intensive care depending on the patient’s individual status. Besides, some indi-
cations will almost exclusively be treated on the ICU (e.g. septic shock). However, again, 
the risk to exclude the ICU population from clinical trials poses a real threat, since PUMAs 
can be obtained without a specific obligation to include them.
As such, under the current regulation, neonatologists and paediatric intensivists still 
face the paradox that many of those paediatric clinical trials do not meet the specific 
needs in daily practice and children admitted to the critical care unit remain deprived of 
evidence-based drug use.
6.3. Research on antibiotics
In 2010, PDCO published a survey of all paediatric uses of medicines in Europe.104 One 
of the main findings of this survey was that antibiotics were extensively used off-label 
in young children. Based on the results of this study, the PDCO published in 2013 an 
inventory list of paediatric needs in the different therapeutic areas for both off-patent 
and new medicinal products. In the list of antimicrobial classes penicillins, cephalospo-
rins, macrolides, carbapenems, sulphonamides, aminoglycosides, antituberculostatics, 
ciprofloxacin, colistin and vancomycin  were listed.105
General Introduction 37
Between 2007-2015, 5 PIPs for antibiotics (vancomycin, meropenem, ceftriaxone/
sulbactam, ciprofloxacin, azithromycin) have been agreed to study in neonates and 
were mostly funded through the European Union (EU) Framework Programme 7.102 In 
general, only a minority of antibiotic PIPs were agreed (vancomycin and meropenem 
classified within the therapeutic area of neonatology/intensive care; 15 compounds 
within the therapeutic area of infectiology). This is presumably related to the fact that 
the  development pipeline with antibiotics is rather small and the financial incentive 
to study off-patent compounds (PUMA) is not encouraging enough for pharmaceutical 
companies.102,106
7. ETHICS AND BARRIERS IN CLINICAL RESEARCH IN THE NICU/PICU
As it is our collective responsibility to obtain sufficient information to develop medicines 
for children, the conduct of clinical research in neonatal and paediatric intensive care is 
necessary but poses some unique ethical and practical challenges. 
After the Second World War, the Nuremberg code stated that the voluntary consent of 
the human subject in clinical research is absolutely essential.107 Later, this statement was 
amended by the Declaration of Helsinki and allowed the parents of minor children (or 
their legal representatives) to consent, as they were thought to act according to the 
presumed will of their child.108 Several steps are distinguishable in the informed consent 
process of which objective transmission of the information by a competent physician, 
a good understanding by the parents of this information and sufficient time to come 
to a decision (without coercion) are the most important. However, the emotionally 
strained circumstances of intensive care carry an enormous potential to compromise 
this process.109 Especially in emergency and life-threatening conditions, parents are 
overwhelmed by the disease severity of their beloved child in an extraordinary environ-
ment, leading to an impaired ability to understand the proposed research and take a 
decision.109,110 Previous studies reported that parents regularly experienced recall-bias 
on the consent procedure, had difficulties understanding the proposed research and 
identified the timing and ways in which they received the information needed to be 
improved. 111–114
In randomised controlled trials (RCT) on the ICU, the concept of ‘therapeutic misconcep-
tion’ may also occur, with parents believing that giving consent for conducting a study 
is an a priori for getting better, while underestimating potential risks.115 Also under these 
circumstances, one cannot speak of a rationally given consent. 
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The EU clinical trial regulation requires that in addition to the informed consent by the 
parents, a capable minor, should assent himself or herself to participate in a clinical 
trial.116 This capability is not solely depending on the child’s age but also on experience 
(e.g. chronically ill children). Of course, in most circumstances on the ICU, the child is 
often too sick to participate in the assenting process prior to inclusion.
In Western Europe and Canada, the treating physician and person asking for informed 
consent are in most recruitment centres the same.117 Herein lies another ethical chal-
lenge with the physician balancing between the moral duty to treat his individual seri-
ously ill patient according to evidence-based guidelines and his intention to generate 
new insights and hope on a better care for future patients. This ethical conflict was nicely 
illustrated in a study in which 1050 paediatric intensivists were asked about their opin-
ion on conducting randomized, controlled trials in critically ill children.118 In this study, 
96% of respondents indicated that they believed that RCTs of potentially life-sustaining 
therapies must be performed, although only 10% indicated that they did not experience 
ethical conflict with this type of study. Eighty-four per cent indicated that earlier pub-
lished data would have the potential to bias them towards the investigational product.
Enrolment of children in clinical trials should not only be considered if scientifically 
needed but also the potential benefit of an optimised drug treatment should outweigh 
the risks and burden for the individual child.119 Both benefit, risks and burden should 
be considered in relation to the severity of the disease e.g. when studying life-saving 
therapies a higher risk level and/or burden is permittable.  In vulnerable ICU children, 
however, it is known that side-effects can be more frequent and severe and are not 
always easily predictable from other (paediatric) populations.120 Trial related burden 
should also be minimised as most ICU patients already undergo many invasive and 
painful procedures.119 
Recruitment problems were reported as the major difficulty for conducting and com-
pleting PIP studies in the 10-year report on the paediatric regulation.102 In the NICU/PICU 
environment, patient recruitment here is even more challenging due to a high popula-
tion heterogeneity and a relatively low number of admissions per single centre. Duffett 
et al. previously reported that one third of initiated PICU RCTs was prematurily stopped, 
mainly due to recruitment problems.121 Interestingly, main barriers for recruitment were 
reported as the lack of availability of parents, language barriers between physician 
and parents, and parents being overwhelmed when asked for consent as discussed 
above.114,121 Nevertheless, more than 80% of RCTs are reported as single-centre studies, 
hence compromising the likelihood of producing generalisable study results.121
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Since intensive care requires also frequent blood sampling for routine monitoring, very 
limited blood volume is available for PK/PD related purposes.110 Different guidelines 
are available which are only specified in detail for the age category preterm and term 
neonates.122–124 In particular for PK studies, the availability of a separate IV access for 
drug infusion and blood sampling often poses a challenge.
Finally, protocol deviations in this environment are common as reported in a survey by 
Morris et al. In this observational study, 65% of paediatric intensivists indicated that they 
did not adhere to the research protocol when the patient deteriorated or the parents 
asked for the study drug.118 Evidently, this practice may compromise the validity of study 
results.  
8.  MODELLING STRATEGIES TO OPTIMISE ANTIBIOTIC DOSING 
Biological models are defined as simplified representations of a biological system to 
provide knowledge and understanding of this system.125 In the field of pharmacomet-
rics, mathematical models are developed to describe and predict the drug’s PK (and/or 
PD) behaviour in animals and humans. Since many years, its role has been substantially 
increasing in the process of drug development. 
Traditional PK studies include the standard two-stage approach. In this approach, the 
individual parameters are first calculated from the individual concentration-time pro-
files. As a second step, the average of parameters and the between-subject variability 
are calculated. This approach has the major drawback that the inter- and intrapatient 
variability are not distinguishable from each other and, as such, interpatient variability 
is usually overestimated. Moreover, these studies require dense blood sampling in each 
patient which renders them difficult to conduct in a NICU/PICU setting (Figure 8).126
In a population PK modelling approach, typically, all data from all individuals are 
analysed simultaneously. The mixed effects modelling technique has been commonly 
used for this purpose. Herein, the term ‘mixed’ refers to a combination of fixed effect 
parameters and random effects parameters that are estimated. Fixed effects are the 
average PK parameters, also known as the population PK parameters (or ‘typical val-
ues’), and the parameters describing the relationship between the identified covariates 
and PK parameters. Random effects quantify variability associated with fixed effects 
parameters. Several sources of random effects are estimated: typically this includes 
between-subject and residual variability, in some cases between-occasion variability is 
of relevance as well. 
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Important advantage of a population PK analysis is that sparse and unbalanced data can 
be analysed, which are common in neonatal and paediatric intensive care patients, where 
the blood sampling volume is limited and protocol deviations are common (Figure 8).
A population model consists of a structural model, a statistical model and a covariate 
model. The structural model describes the mean trend of the data. Typically, structural 
models consist of compartmental models to describe the rates of change of drugs and/
or biomarkers. The statistical submodel includes random effects parameters (e.g. 
between-subject, residual variability and between-occasion variability) (Figure 9).
Next, covariates are evaluated to predict and thereby reduce between-subject variability 
associated with the structural model parameters. The identification and quantification 
of these covariate effects provides the basis for rational dose individualisation. 
Finally, for dose evaluation, stochastic simulations are performed using the developed 
population PK model. In combination with plausible sets of patient-specific covariates 
included in the model, individual concentration-time profiles can be generated (e.g. 
simulation of 1000 concentration-time profiles. In the case of antibiotics, optimized 
dosing regimens are selected through probability of target attainment (PTA) evaluation, 
with a target PTA of minimum 90%.127
 
Figure 8: Concentration–time profiles after IV bolus administration of the same hypothetical study drug 
using (A) the standard two-stage approach applied to a rich dataset. (B) population PK modelling approach 
applied to the same dataset using only two data points for each individual (sparse dataset). In (A) in each 
of the six individuals 10 samples are available. The different symbols correspond to different individuals. 
Each black line corresponds to a separate fit to the 10 data points of each individual. In (B) two samples 
of the 10 per subject in  (A)  are used. The different symbols correspond to the six different individuals. 
The black line illustrates the concentration–time plot based on the population mean values of the PK pa-
rameters. The grey lines show the plots of the individual patients, which are based on the population mean 
values together with the measured concentrations of the specific individual. Adapted from De Cock R. et 
al. with permission126
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Figure 9 : In panel (A) the inter-individual variability of four individuals (coloured lines) from the mean or 
typical patient (black line) is shown, after receiving the same IV dose of a hypothetical drug. Panel (B) illus-
trates the unexplained residual variability in one individual, after receiving an IV bolus dose of a hypotheti-
cal drug. The red line represents the individually predicted concentration-time curve and the red dots the 
measured concentration data points.
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As extensively illustrated in the introductory chapter, limited data on the impact of 
maturational and critical illness related changes on antibiotic disposition and effect 
are available in children. Despite global efforts to improve paediatric drug research in 
Europe, NICU/PICU patients remain “therapeutic orphans”. This knowledge resulted in 
the origin of the proposed research in this doctoral dissertation.
1. GENERAL RESEARCH OBjECTIVE
The general aim of this doctoral dissertation was to optimise drug dosing in critically ill 
children through investigation of developmental, disease and treatment related changes 
on drug pharmacokinetics, using a model-based approach. 
Based on their frequent use, off-knowledge, off-patent and (consequently) off-label sta-
tus, the following compounds were studied: amoxicillin in combination with clavulanic 
acid, piperacillin in combination with tazobactam, cefazolin and vancomycin. 
2. DRUG-SPECIFIC RESEARCH OBjECTIVES
Amoxicillin is a β-lactam antibiotic, used in combination with the β-lactamase inhibitor 
clavulanic acid to extend its spectrum. Both compounds are minimally protein bound 
to plasma proteins (~18-25%) and renally excreted. Typical indications within the PICU 
include community-acquired pneumonia, skin, soft tissue and abdominal infections. 
Limited data are available to guide its dosing in critically ill children.
Piperacillin is a broad-spectrum β-lactam antibiotic that is used in combination with 
the β-lactamase inhibitor tazobactam to extend its spectrum. Both compounds are only 
minimally bound to plasma proteins (~30%) and renally excreted. Typical indications 
within the PICU include ventilator-associated pneumonia, intra-abdominal infections 
and sepsis of unknown origin. Limited data are available to guide its dosing in critically 
children.
Cefazolin is a highly plasma protein-bound (~80%) β-lactam antibiotic that is mainly 
used as surgical prophylactic agent. CPB and renal function changes were previously 
shown to have a major impact on its disposition. To date, only sparse data on the PK of 
unbound cefazolin are available in children during CPB, and no data are available after 
paediatric cardiac surgery.
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Drug-specific objectives investigated for these compounds in Chapter 3, 4 and 
5 are:
·	 to quantitatively characterise the intravenous PK, including predictors of 
inter-individual variability
·	 to evaluate the PTA for the current standard dose regimen
·	 to develop improved evidence-based practical dosing regimens
Vancomycin is a glycopeptide antibiotic that is commonly used to treat serious Gram-
positive infections in the NICU/PICU. Plasma protein binding is ranging from 50-55% in 
healthy volunteers and non-critically ill adults. No data on protein binding are available 
in critically ill children. As only the unbound drug is pharmacologically active, alterations 
in protein binding may have an impact on target attainment rates. 
Drug-specific objectives investigated in Chapter 6 are:
·	 to quantitatively characterise plasma protein binding, including predictors of 
inter-individual variability 
·	 to compare attainment rates of three currently used targets: total (trough) 
concentration, AUC/MIC and fAUC/MIC
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ABSTRACT
Background and Objectives: There is little data available to guide amoxicillin/cla-
vulanic acid dosing in critically ill children. The primary objective of this study was to 
investigate the pharmacokinetics of both compounds in this paediatric subpopulation. 
Patients and Methods: Patients admitted to the paediatric ICU in whom intravenous 
amoxicillin/clavulanic acid was indicated (25-35 mg/kg of body weight every 6 h) were 
enrolled. Population pharmacokinetic analysis was conducted and the clinical outcome 
was documented. Clinicaltrials.gov: NCT02456974.
Results: A total of 325 and 151 blood samples were collected from 50 patients (median 
age,  2.58 years; age range = 1 month to 15 years) treated with amoxicillin and clavulanic 
acid, respectively. A three-compartment model for amoxicillin and a two-compartment 
model for clavulanic acid best described the data, in which allometric weight scaling 
and maturation functions were added a priori to scale for size and age. In addition, 
plasma cystatin C and concomitant treatment with vasopressors were identified to 
have a significant influence on amoxicillin clearance. The typical population values of 
clearance for amoxicillin and clavulanic acid were 17.97 L/h/70kg and 12.20 L/h/70kg, 
respectively. In 32% of the treated patients, amoxicillin/clavulanic acid therapy was 
stopped prematurely due to clinical failure and the patient was switched to broader-
spectrum antibiotic treatment. Monte Carlo simulations demonstrated that four-hourly 
dosing of 25 mg/kg  was required to achieve the therapeutic target for both amoxicillin 
and clavulanic acid. For patients with augmented renal function, a 1-h infusion was 
preferable to bolus dosing. 
Conclusions: Current published dosing regimens result in subtherapeutic concentra-
tions in the early period of sepsis due to augmented renal clearance, which risks clinical 
failure in critically ill children, and therefore need to be updated.
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INTRODUCTION
Appropriate antibiotic treatment is a cornerstone in the pharmacological treatment of 
critically ill children. Paediatric sepsis and septic shock reportedly affect 30% of children 
admitted to paediatric intensive care units (ICUs), with a 25% mortality rate.1 Due to 
their broad antimicrobial spectrum and relatively low toxicity, β-lactam antibiotics such 
as amoxicillin/clavulanic acid are commonly used in paediatric critical care for treating 
community-acquired infections.2 Typical indications include community-acquired pneu-
monia, skin, soft tissue and abdominal infections. 
During childhood many developmental changes occur, which influence both drug ex-
posure and drug response.3 Moreover, pathophysiological changes during critical illness 
frequently affect pharmacokinetics (PK) and pharmacodynamics (PD).4–6 To date, only 
one report on the pharmacokinetics of amoxicillin/clavulanic acid in a limited number 
of critically ill children older than 2 years (n = 15 patients) is available.7
Broader-spectrum and newer antibiotics are now being studied more extensively in this 
patient population, which may predispose clinicians towards the use of such agents.8 
Therefore, research for more-targeted and well-established therapies like amoxicillin/
clavulanic acid is highly relevant. 
The primary aims of this study were: (i) to investigate the pharmacokinetics of intrave-
nous amoxicillin/clavulanic acid in critically ill infants and children and (ii) to evaluate 
the efficiency of current and alternative dosing regimens in this population.
PATIENTS AND METHODS
Study design 
A prospective, open-label, pharmacokinetic study was conducted at the paediatric ICU 
of the Ghent University Hospital, Ghent, Belgium between May 2012 and December 
2013. Patients between 1 month and 15 years of age admitted to the paediatric ICU were 
included in whom treatment with intravenous amoxicillin/clavulanic acid was the stan-
dard of care. Patients were excluded if they required an extracorporeal circuit or did not 
have arterial or intravenous access other than the drug infusion line available for blood 
sampling. The research was conducted in accordance with the guidelines of the Declara-
tion of Helsinki and was approved by the institutional Ethics Committee (EC/2012/172). 
Written informed consent was obtained from the parents or legal representatives and 
also from the patients if they older than 12 years.
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Drug dosing and administration
Amoxicillin/clavulanic acid (Augmentin P 500/50 mg and Augmentin 1000/200 mg, 
GlaxoSmithKline, Genval, Belgium; Amoxiclav Sandoz 1000/200 mg, Sandoz NV, Vil-
voorde, Belgium) was prescribed in a dose range of 25 to 35 mg amoxicillin per kilogram 
body weight (maximum 1000 mg) every 6 h and administered intravenously over 5 to 30 
min using a calibrated syringe driver, according to current dosing guidelines.9 According 
to a standardized procedure, infusion lines were flushed with normal saline immediately 
after drug administration with a minimum of twice the dead space volume.
Blood sampling
Serial blood samples were obtained from the first and/or assumed steady-state doses 
from an indwelling catheter other than the drug infusion line (median of four blood 
samples per dose). The total number of samples collected (per patient) was limited by 
the predefined total maximum blood volume permitted for PK sampling per individual 
patient, defined as 2.4 mL/kg bodyweight.10 A full sampling scheme per dose typically 
included a sample just before dosing (t = 0), a sample immediately after dosing and 
flush, a distribution sample between 5 and 70 min after the start of the drug infusion, a 
mid-dose-interval sample 3 h after the drug infusion start time and a trough sample just 
prior to the next dose. All samples were immediately transferred on ice to the chemistry 
laboratory and centrifuged (8 min, 1885g) after which the resulting plasma was frozen 
at -80°C for a maximum of 3 months before assay.  
Drug and biochemical assays
Total plasma amoxicillin and clavulanic acid concentrations were quantified simultane-
ously using a validated ultraperformance ultrahigh-pressure liquid chromatography 
(UPLC)-tandem mass spectrometry method.11 The lower limit of quantification (LLOQ) 
was 0.5 mg/L for both compounds and the imprecision was < 15% at all levels. For the 
first 24 patients only the amoxicillin compound was quantified. Creatinine was measured 
in serum (Scr) and urine (Ucr) using the rate-blanked compensated Jaffe technique 
(Modular P and Cobas 6000, Roche Diagnostics GmbH, Mannheim, Germany). Twenty-
four-hour creatinine clearance (CrCL) was calculated using the following formula: CrCL = 
urine volume x Ucr/(1440 x Scr) (whenever a urinary catheter and 24-h urine collection 
were available). Plasma Cystatin C (CysC) was measured using the N Latex cystatin C 
assay on the Behring nephelometer II (Siemens Healthcare Diagnostics Products GmbH, 
Marburg, Germany) (intra-assay coefficient of variation [CV]: 1.4%; inter-assay CV: 5.4%) 
and was standardized according to the ERM-DA471/IFCC reference material.12  
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Pharmacokinetic analysis 
Amoxicillin/clavulanic acid pharmacokinetics were evaluated using the non-linear 
mixed-effects modeling software NONMEM version 7.3 (ICON PLC; Ellicott City, Maryland). 
The first-order conditional estimation method with the interaction option (FOCE-I) was 
used to estimate PK parameters and variability. R (version 3.0.2) and PsN (version 5.18.2) 
tools were used for pre- and postprocessing. One-, two-, and three-compartmental lin-
ear models were tested to fit plasma concentrations of both compounds independently 
using the NONMEM library ADVAN subroutines.13 Following this, a simultaneous fit of 
concentrations of both compounds was evaluated; when both analyte measurements 
were obtained from the same sample, correlations in residual error were handled using 
the L2 method in NONMEM.13 The L2 data item is used to group observations within 
an individual to indicate there may be a degree of correlation in the residual variability 
(usually residual variability assumes all observations are independent). All clearance 
parameters were scaled a priori using an allometric weight (WT) approach with a fixed 
exponent of 0.75  in combination with a Hill model using postmenstrual age (PMA) to 
describe the maturation process on clearance14:
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where CLi is the individual clearance, CLpop is the population clearance, WTmedis the 
median weight, PMA is postmenstrual age, HILL is the Hill coefficient, and Tm50 is the 
maturation half-life. All volume of distribution parameters were scaled a priori with lin-
ear weight. Between-subject variability (BSV) was described using an exponential error 
model and a proportional error model was used to describe residual variability. Between-
occasion variability (BOV) was tested on CL. For model evaluation, decrease in objective 
function value (OFV), plots of observed versus population predicted concentrations, 
observed versus individual predicted concentrations, conditional weighted residuals 
(CWRES) versus time after dose, and CWRES versus population predicted concentration 
were utilized. Parameter estimates were compared using three different methods for 
handling data below quantification limit (BQL): omitting BQL samples, setting values to 
half the limit of quantification (LOQ/2), and the M3 method, enabling estimation of the 
likelihood of BQL measurements being real BQL data.15 While body weight and age were 
included a priori as described above, CysC was then further tested, since it is known that 
amoxicillin and clavulanic acid are renally cleared.16 After this, a stepwise covariate model 
(SCM) building exercise was performed with a forward inclusion criterion of p<0.01 and 
backwards elimination criterion of p<0.005. The following covariat s were tested in the 
SCM: primary reason for admission, measures of organ function and patient severity of 
illness as described by the PELOD (Pediatric Logistic Organ Dysfunction) Score, PRISM II 
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(Pediatric Risk of Mortality) Score17,18, presence of surgery, presence of mechanical ven-
tilation, cotreatment with vasopressors and nephrotoxic medications (aminoglycosides, 
glycopeptides, diuretics, angiotensin-converting enzyme [ACE] inhibitors, nonsteroidal 
anti-inflammatory drugs, tacrolimus, cyclosporin, methotrexate), fluid resuscitation 
(>60 mL/kg per 24 h), type of catheter used for drug administration and blood sampling 
and C-Reactive Protein (CRP). Given that 35% of Scr samples were BQL, Scr and CrCL 
could not be tested as covariates on drug clearances. The final population model was 
evaluated in two ways: a nonparametric bootstrap sampling procedure (n = 1000) and a 
visual predictive check (VPC) (n = 1000). 
Clinical outcome assessment
Clinical failure in our study population was defined as premature termination of 
amoxicillin/clavulanic acid with change of antibiotic therapy or additional antibiotics 
commenced within 48 h of completion of therapy. Duration of antibiotic therapy was 
depending on the type of infection and the patient’s clinical evolution and was deter-
mined at the discretion of the attending physician.
Assessment of dose-exposure relationship
Monte Carlo simulations (n = 1000 patients) were performed for three dosing regimens 
(Table 1).9,19 Based on these simulations, the fraction of time during which the unbound 
drug concentration is above the MIC (fT>MIC) was calculated for the first dose and over 
the first 48 h of treatment. The target efficacy exposure was defined as 40% fT>MIC20 and a 
target MIC of 8 mg/L for amoxicillin was chosen as worst-case scenario, according to the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and 
Laboratory Standards Institute (CLSI) clinical breakpoints for Escherichia coli.21 As the 
EUCAST clinical breakpoint for amoxicillin was determined using a fixed concentration 
of 2 mg/L clavulanic acid, this was chosen as the target concentration for clavulanic acid 
(note that the CLSI susceptibility testing concentration was 4 mg/L). The mean protein 
binding of amoxicillin and clavulanic acid are 18 and 25%, respectively and this was used 
to simulate unbound concentration.16
Table 1. Simulated dosing scenarios
Dosing regimena Drug FDrug formulary
25 mg/kg q12h for children between 1 and 3 months 
25 mg/kg q8h for children older than 3 months
25 mg/kg q6hb
25 mg/kg q4hc
British National Formulary for Children19
British National Formulary for Children19
Sanford Guide for Antimicrobial Therapy9
aThe dosing regimen was based on the amoxicillin component and a fixed ratio of amoxicillin/clavulanic acid of 
5:1. All simulations included a bolus and 1-h infusion regimen. Abbreviations: q12h, every 12 h; q8h, every 8 h; 
q6h, every 6 h; q4h, every 4 h.
bStudy dosing regimen. 
cNewly tested dosing regimen.
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RESULTS
A total of 50 patients were included in this study; demographic, clinical and treatment 
characteristics are summarized in Table 2. Patients younger than 2 years old accounted 
for 44% of the study population (n = 22). 
A total of 325 amoxicillin and 151 clavulanic acid concentrations in plasma were avail-
able for population PK analysis. A three-compartment model for amoxicillin and a two-
compartment model for clavulanic acid best described the data (Figure 1A-B).





Age (years) 2.58 (0.08-15)
Weight (kg) 14.4 (4.07-65)
Total length of ICU stay (days) 9.5 (3-72)
PRISM II score 6.5 (0-32)







Reason for antibiotic treatment
treatment of infection 33 (66)
postoperative prophylaxis 17 (44)
Mechanical ventilationc 29 (58)
Vasopressor treatmentc 16 (32)
PELOD scored 1 (0-31)
Serum Creatinine (mg/dL)d   0.21(<0.17-1.89)
Plasma Cystatin Cd,e (mg/L) 0.63 (0.33-1.23)
Serum CRPc (mg/L) 5.4 (0.40-28.79)
aAbbreviations: ICU, Intensive Care Unit; PRISM, Pediatric Risk of Mortality; PELOD, Pediatric Logistic Organ 
Dysfunction; CRP, C-Reactive Protein. 
bValues are median (range) or number (percentage of total number of patients). 
cDuring ICU stay. 
dAt day(s) of sampling. 
eBased on values from 49 patients.
64 CHAPTER 3
BSV was supported for amoxicillin and clavulanic acid central clearance and volume 
only. Central volume values for amoxicillin and clavulanic acid were highly correlated 
(R2>0.99), so a single random effect with a scaling factor for clavulanic acid was used 
(Table 3). The correlation between amoxicillin and clavulanic acid clearance was also 
estimated. BOV was supported for amoxicillin clearance and clavulanic acid clearance. 
Since these values were highly correlated, a single random effect with scaling factor was 
also used (Table 3). The Hill coefficient on the maturation model was estimated to be 
close to 1, and no significant change in OFV was noted when it was fixed to 1. When CysC 
Figure 1A. Goodness-of-fit diagnostic plots for amoxicillin. The plots show observations versus population 
predictions and individual predictions and conditional weighted residuals (CWRES) versus time after dose 
and population predictions. In the observation versus prediction plots, a line of identity (black solid line) 
and a Loess smooth line (red solid line) were included as a reference. In the CWRES plots, dashed lines at 
+2 and -2 standard deviations from the mean (solid line) were included to indicate the expected region of 
approximately 95% of the data.
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was included as a covariate on amoxicillin and clavulanic acid clearance, it significantly 
improved the fit of the model with drops in OFV of 6.63 points for amoxicillin, and 6.61 
points for clavulanic acid. Model building to this stage was initially undertaken with the 
exclusion of BQL data, which comprised 9% of the observations. BQL data were then 
included to compare parameter estimates as described above. Given no significant pa-
rameter estimates differences were observed between BQL handling methods and the 
run time for the M3 method was more than 3-fold longer than the LOQ/2 method, the 
latter method was chosen for handling BQL. This model, with mechanistic covariates, 
Figure 1B. Goodness-of-fit plots for clavulanic acid. The plots show observations versus population predic-
tions and individual predictions and conditional weighted residuals (CWRES) versus time after dose and 
population predictions. In the observation versus prediction plots, a line of identity (black solid line) and a 
Loess smooth line (red solid line) were included as a reference. In the CWRES plots, dashed lines at +2 and 
-2 standard deviations from the mean (solid line) were included to indicate the expected region of approxi-
mately 95% of the data.
66 CHAPTER 3
















CL(L/h/70 kg) 17.97 17.83 15.33 21.30
V1 (L/70 kg) 9.07 9.00 6.41 11.66
V2 (L/70 kg) 5.43 5.75 3.57 13.45
V3(L/70 kg) 11.24 11.00 7.01 13.78
Q1 (L/h/70 kg) 35.88 34.73 12.03 60.09
Q2 (L/h/70 kg) 5.52 5.36 1.49 8.03
q in (CYSC/MCYSC)q -0.54 -0.54 -1.01 -0.14
q in COVVASO=(1+q) -0.18 -0.18 -0.28 -0.07
BSV on CL (% CV) 18.9 18.1 8.10 28.6
BSV on V1 (% CV) 48.6 46.8 30.9 66.7
BOV on CL (% CV) 14.6 13.8 7.70 20.2
Residual error (% CV) 28.7 28.4 23.4 33.1
Clavulanic acid
CLclav (L/h/70kg) 12.20 12.09 10.54 14.55
V1clav  (L/70 kg) 11.60 11.39 8.42 13.76
V2clav (L/70 kg) 9.85 10.22 8.05 13.87
Q1clav  (L/h/70 kg) 6.22 6.81 3.94 23.9
q in CYSCOV = (CYSC/MCYSC)q -0.37 -0.36 -0.85 -0.08
BSV on CLclav  (% CV) 15.6 15.6 7.8 22.6
q in BSV on V1 clav = q*BSV on V1 0.77 0.77 0.40 0.97
q in BOV on CL clav  = q*BOV on CL 0.52 0.48 -0.02 1.34
Residual error (% CV) 35 34 27 40
Amoxicillin/clavulanic acid
Hill coefficientc 1 1 1 1
TM50 (weeks) 39.90 39.10 20.66 64.29
aAbbreviations: CL, clearance; clav, clavulanic acid; V1, central volume of distribution; V2 and V3, peripheral 
volumes of distribution; Q1 and Q2, intercompartmental clearances; q, model parameter in NONMEM code; 
CYSCOV, Cystatin C covariate on clearance; CYSC, plasma cystatin C value; MCYSC, median plasma cystatin 
C value; COVVASO, vasopressor covariate on clearance (q=0 if no coadministration with vasopressors); BSV, 
between-subject variability; BOV, between-occasion variability; CV, coefficient of variation; TM50, matura-
tion half life
bNonparametric bootstrap of 953 successful runs.
cFixed value.
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Figure 2. Impact of covariates in the final model. The left-hand plot shows weight- and cystatin C-stan-
dardised amoxicillin clearance with age split by whether patients were on vasopressors. The right-hand 
plot shows weight- and age-standardised amoxicillin clearance plotted against measured cystatin C split 
by whether patients were on vasopressors. Note there is more than one clearance value per subject, since 
between-occasion variability was included. Open circles, patients not on vasopressors; open squares, pa-
tients on vasopressors. Solid line, population predicted values if the patients were not on vasopressors; 
broken line, population predicted values if the patients were on vasopressors.
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Figure 3. Stratified visual predictive check for amoxicillin (CLAV = 0) and clavulanic acid (CLAV = 1). The grey 
shaded areas are 95% confidence intervals of simulated 5th, 50th and 95th percentiles. The lines are 5th, 
50th and 95th percentiles of raw data.
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was then taken forward to the SCM, and vasopressor treatment on amoxicillin clearance 
further significantly improved the model fit for amoxicillin and therefore was retained 
in the final model. The impact of covariates is illustrated in Figure 2. The population PK 
parameter estimates and their precision are summarized in Table 3. The VPC plots are 
presented in Figure 3; the 5th, 50th and 95th percentiles of the predicted concentra-
tions closely follow the percentiles of the observed data, suggesting a good model fit 
in both cases. 












































































































































































Figure 4A. Probability of Target Attainment (PTA) (n = 1000 patients) for amoxicillin according to a bolus 
dosing regimen, presence/absence of vasopressor therapy and plasma Cystatin C value. The three simu-
lated dosing regimens were as follows: (i) 25 mg/kg every 12 h if under 3 months of age, otherwise every 8 h 
(British National Formulary for Children [BNF-C]19), (ii) 25 mg/kg every 6 h (Sanford Guide for Antimicrobial 
Therapy9), (iii) 25 mg/kg every 4 h (alternative dosing regimen). Amoxicillin target was defined as 40% of 
time above a MIC of 8 mg/L.
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Pathogens were grown in only 50% of patients and in 63.6% of patients treated for 
infection. The clinical failure in patients receiving amoxicillin/clavulanic acid treatment 
or prophylaxis was 32%; in those patients treated for infection alone, it was 34.4%. The 
main pathogens identified in patients with clinical failure were Pseudomonas aeruginosa 
(37.5%) (after which amoxicillin/clavulanic acid was switched to piperacillin/tazobactam) 
and Enterobacteriaceae (25%). No pathogen could be identified in 31.3% of patients. 












































































































































































Figure 4B. Probability of Target Attainment (PTA) (n = 1000 patients) for amoxicillin according to a 1 hour 
infusion dosing regimen, presence/absence of vasopressor therapy and plasma Cystatin C value. The three 
simulated dosing regimens were as follows: (i) 25 mg/kg every 12 h if under 3 months of age, otherwise 
every 8 h (British National Formulary for Children [BNF-C]19), (ii) 25 mg/kg every 6 h (Sanford Guide for An-
timicrobial Therapy9), (iii) 25 mg/kg every 4 h (alternative dosing regimen). Amoxicillin target was defined 
as 40% of time above a MIC of 8 mg/L.
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Probability of target attainment for amoxicillin against MIC after the first dose are pre-
sented in Figure 4 A-B. Since no significant drug accumulation was seen, the results 
from the first 48 h of treatment were similar (data not shown). When doses were pre-
scribed as a bolus according to the British National Formulary for Children (BNFc) dosing 
regimen, the Sanford Guide dosing regimen or the four-hourly dosing regimen (Table 
1), the median target attainment values for clavulanic acid after the first dose were 48%, 
66% and 96%, respectively; when the doses were given as a 1-h infusion, the median 
target attainment values were 53%, 73% and 99%, respectively.
DISCUSSION
This is, to our knowledge, the first report characterizing amoxicillin/clavulanic acid dis-
position in (critically ill) children using a population PK/PD modeling approach. Besides 
growth and maturation, renal function was found to be a significant covariate on amoxi-
cillin and clavulanic acid clearance. This finding is in concordance with data in critically 
ill adults showing both clearances to be proportional to CrCL.22 As previously discussed, 
we were not able to test Scr or CrCL as a covariate on drug clearances. However, the use 
of Scr and CrCL as markers for renal function have some major disadvantages, especially 
in children, as they are sensitive to changes in age, muscle mass, feeding and disease 
status.23,24 Moreover, in younger children, Scr is generally underestimated when using 
the standardized Jaffe analysis method.25 Finally, creatinine undergoes tubular secretion 
leading to an overestimation of glomerular filtration rate (GFR). CysC, a newer endog-
enous renal biomarker, was previously shown to be superior to plasma creatinine in 
estimating renal function in critically ill children.26,27 Second, it has been shown that CysC 
is a good renal biomarker in children with sepsis28 and that CysC-based GFR estimations 
remain accurate in children presenting with hyperfiltration (in contrast to Scr- based for-
mulae).24 Finally, CysC was found to better predict elimination of renally excreted drugs 
in adults when compared to Scr or CrCL.29–32 This is only the second report to identify 
this new biomarker as a predictor of renal drug clearance in children at the expense of 
Scr or CrCL.33 Treatment with vasopressors (mainly norepinephrine; 14/15 patients) was 
also associated with an 18% decrease in amoxicillin clearance. Although high-quality 
scientific evidence is lacking, available data for norepinephrine suggest a positive effect 
on renal blood flow in patients presenting with sepsis.34 One may hypothesize that treat-
ment with vasopressors should be considered an overall parameter reflecting critical 
illness severity, irrespective of renal function. 
The observed population estimate for amoxicillin clearance is much higher than pre-
viously reported in critically ill adults (10 L/h/75 kg) and somewhat variable between 
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doses (BOV 14.6% CV).22 A high mean clearance was previously reported in 15 seri-
ously ill children aged 2 to 14 years using a noncompartmental (NCA) PK analysis (16.99 
L/h/1.70m2).7 The elevated clearance could be explained by a state of ‘augmented renal 
clearance’ (ARC) in our study’s patient population. Although the underlying pathophysi-
ological mechanisms are yet to be revealed35, this phenomenon has been increasingly 
investigated in the critically ill adult population, including its impact on the PK and PD 
of renally cleared antimicrobials36, but ARC has –to the best of our knowledge– never 
before been described in critically ill children. The hypothesis of a ‘hyperdynamic’ status 
of our study is supported by the fact that a large proportion of measured renal biomark-
ers was undetectable (Scr) or low (CysC) compared to age-corrected reference values.37 
A plausible explanation, besides the analytical challenges for creatinine as described 
above, could be a faster renal clearance of these endogenous compounds. Moreover, 
as we observed trough concentrations from maintenance doses that remained very low 
in most patients, we could conclude that no accumulation in steady-state conditions 
was attained, probably due to the enhanced renal capacity. It is also worth noting that 
although one would expect a correlation between age and CysC below the age of 2 
years37, we were not able to identify such a relationship in our patient population. It is 
possible that maturational changes in CysC were masked in our study due to ARC. 
Regarding volumes of distribution, the observed population estimate for amoxicillin is 
similar to what has been reported in critically ill adults (27.4 L/75 kg)22 and slightly lower 
than that found by Jones et al.7 Similar trends in clearance and volume of distribution 
were observed for the clavulanic acid compound.
Of particular importance, our data challenge current paediatric dosing recommenda-
tions, as they could lead to subtherapeutic treatment in severe infections (Figure 4 A-B). 
Although our study has a small sample size, clinical outcome data from our study suggest 
that underdosing of amoxicillin/clavulanic acid could result in clinical failure in severe 
infections with Enterobacteriaceae (EUCAST and CLSI MIC breakpoints are 8 mg/L). We 
have shown that, at minimum, a dosing regimen of 25 mg/kg (based on the amoxicillin 
component) every 4 h is warranted in those infections (given as a bolus in children with 
CysC above 1 mg/L and as a 1 h infusion to children with CysC under 1 mg/L). It was 
decided not to simulate longer infusion times in order to maximize tissue penetration 
and to circumvent potential drug incompatibilities, drug stability issues and drug ad-
ministration errors with more-complex dosing regimens.39 This dosing recommendation 
is fully in concordance with Jones et al., suggesting that higher/more-frequent amoxi-
cillin/clavulanic acid dosing might be justified and needed in paediatric intensive care 
units.7 Moreover, it should be highlighted that 40%fT>MIC is a rather conservative target, 
as 100 % fT>MIC has been associated with better outcomes in critically ill adults.40 
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With regard to clavulanic acid, no clear-cut PK/PD targets are reported. As EUCAST 
clinical susceptibility breakpoints were determined in the presence of 2 mg/L clavulanic 
acid, this was chosen as the target concentration.21 We hypothesized that lower targets 
of beta-lactamase inhibitors could potentially result in higher MIC breakpoints for the 
combined penicillin antibiotic. This hypothesis is supported by the study from Liu et al. 
demonstrating that for equal piperacillin exposure, different tazobactam half-lives have 
a significant effect on antimicrobial outcome.41 Although a larger interpatient variability 
was observed than for amoxicillin, our dosing recommendation (as above) resulted in 
an acceptable target attainment with no accumulation after 48h of treatment. With 
regard to potential toxicity of higher cumulative amoxicillin/clavulanic acid daily doses, 
it should be noted that, for our optimized dosing regimen, we have specifically chosen 
not to select higher individual doses (25 mg/kg based on the amoxicillin compound) 
to eliminate potential safety risks related to higher peak concentrations. Finally, we feel 
confident that our optimized dosing regimen will not increase idiosyncratic clavulanic 
acid induced liver toxicity, as it is known that the mechanism of its toxicity is immunoal-
lergic, to some extent genetically controlled and dose independent.42 
This research has some notable limitations. First, the studied population included a 
heterogeneous group of children with regard to possible differences in (suspected) 
infecting organism and tissue involvement/penetration. Second, total drug plasma 
concentrations were mathematically corrected for protein binding instead of free drug 
concentration measurement in plasma or drug measurement at the site of infection. 
However, this simplification was previously found to be acceptable for β-lactam anti-
biotics with low protein binding like amoxicillin and clavulanic acid.43 Third, MIC values 
were not prospectively determined. Instead, a worst-case scenario using the clinical 
breakpoints for E. coli was chosen to challenge dosing regimens regardless of the infect-
ing organism. This approach is justifiable, as β-lactam antibiotics have a wide therapeu-
tic index and the consequences of potentially supratherapeutic dosing are therefore of 
less concern. Fourth, notwithstanding that a substantial number of younger patients 
were recruited, PK data from additional neonates and infants are needed to estimate 
maturation parameters more precisely on both clearances and refine dosing regimens 
in these age categories. 
In conclusion, this is the first population PK study demonstrating that the current dosing 
recommendations for amoxicillin/clavulanic acid can result in subtherapeutic treatment 
in critically ill children, thereby risking treatment failure. Besides developmental chang-
es, CysC as a (new) biomarker for renal function and co-treatment with vasopressors 
were found to be significant covariates influencing drug disposition. The findings from 
this study make a significant contribution to knowledge regarding how to optimize the 
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clinical use of amoxicillin/clavulanic acid in critically ill children. Whether these results 
of augmented renal clearance can be extrapolated to other renally cleared (β-lactam) 
antibiotics or indeed other classes of medication remains speculative and needs to be 
investigated in future research. 
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ABSTRACT
Objectives: The aim of this study was to characterize the population pharmacokinetics 
of piperacillin and tazobactam in critically ill infants and children, in order to develop an 
evidence-based dosing regimen.
Patients and Methods: This pharmacokinetic study enrolled patients admitted to the 
paediatric ICU for whom intravenous piperacillin/tazobactam (8:1 ratio) was indicated 
(75 mg/kg q6h based on piperacillin). Piperacillin/tazobactam concentrations were 
measured by a liquid chromatography-tandem mass spectrometry method. Pharmaco-
kinetic data were analysed using non-linear mixed-effects modelling. Clinicaltrials.gov: 
NCT02456974.
Results:  Piperacillin and tazobactam blood samples were collected from 47 patients 
(median age = 2.83 years; range = 2 months to 15 years). Piperacillin and tazobactam 
disposition was best described by a two-compartment model which included allometric 
scaling and a maturation function to account for the effect of growth and age. Mean 
clearance estimates for piperacillin and tazobactam were 4.00 L/h and 3.01 L/h for a 
child of 14 kg. Monte Carlo simulations showed that an intermittent infusion of 75 mg/
kg (based on piperacillin) q4h over 2 h, 100 mg/kg q4h given over 1 h or a loading dose of 
75 mg/kg followed by a continuous infusion of 300 mg/kg/24h were minimally required 
to achieve the therapeutic targets for piperacillin (60% fT>MIC>16 mg/L). 
Conclusion: Standard intermittent dosing regimens do not ensure optimal piperacillin/
tazobactam exposure in critically ill patients, thereby risking treatment failure. The use 
of a loading dose followed by a continuous infusion is recommended for treatment of 
severe infections in children >2 months of age.
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INTRODUCTION
Paediatric sepsis and septic shock reportedly affect 30% of children admitted to pae-
diatric ICU, with a 25% mortality rate.1 Early intervention with appropriate antibiotic 
treatment remains a cornerstone in the pharmacological treatment of those children.
Piperacillin/tazobactam is a broad-spectrum β-lactam antibiotic commonly used in the 
paediatric ICU for (empirical) treatment of severe infections. Typical indications include 
ventilator-associated pneumonia, intra-abdominal infections and sepsis of unknown 
origin. Despite its use, only treatment of intra-abdominal infections in children older 
than 2 years is currently approved by the European Medicines Agency.2 This means 
that clinical practice still represents off-label use of this drug combination in younger 
paediatric patients.
It is well known that the efficacy of β-lactam antibiotics most strongly relates to the 
time during which the unbound drug concentration (fT) is above the pathogen MIC of 
the pathogen. The target pharmacokinetic/pharmacodynamics (PK/PD) index (i.e. fT>MIC) 
associated with positive clinical outcomes for β-lactams in critically ill patients is a fT>MIC 
between 50% to 100% of the dosing interval.3 Recent studies reported the PK/PD ef-
ficacy index for the β-lactamase inhibitor (BLI) tazobactam to be the percentage of time 
during which the unbound concentration remains above a threshold concentration 
(fT>CT).4,5 fT>CT targets ranged from 35% to 85% of the dosing interval, depending on 
the antibiotic-BLI combination and stability of the β-lactamase. Threshold concentration 
targets were thought to depend on β-lactamase transcription level, with upper limits of 
4 mg/L used.5,6 
Piperacillin and tazobactam are predominantly excreted in unchanged form by glomer-
ular filtration and tubular secretion (piperacillin: 46% to 73%; tazobactam: 65% to 80%).7 
In addition, saturable renal elimination has been identified previously in adults.8–10 To 
date, the pharmacokinetics of piperacillin/tazobactam have been described in (pre)term 
neonates and non-ICU children, but only in a small number of children admitted to the 
paediatric ICU (n = 13 and n = 12 patients), between 1 and 9 years of age.7,11–15
Any effort to define the dose rationale in infants and young children needs to account 
for the effect of developmental processes, which are known to affect drug exposure and 
potentially treatment response.16 Moreover, the impact of pathophysiological changes 
on pharmacokinetics has been widely demonstrated in critically ill adults.17–19  The aims 
of this study were therefore: (i) to investigate the pharmacokinetics of intravenous 
piperacillin and tazobactam in critically ill infants and children and (ii) to revisit the dose 
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rationale of the drug combination and evaluate the efficacy of current and alternative 
dosing regimens in this population based on PK/PD indices. 
PATIENTS AND METHODS
Study design and ethics
A prospective, pharmacokinetic study was conducted at the paediatric ICU unit of the 
Ghent University Hospital, Ghent, Belgium between May 2012 and March 2014. Patients 
between 1 month and 15 years of age admitted to the paediatric ICU in whom treat-
ment with intravenous piperacillin/tazobactam was clinically indicated, were included. 
Patients were excluded if they required an extracorporeal circuit or did not have, other 
than the drug infusion line, an arterial or intravenous access available for blood sam-
pling. The research was conducted in accordance with the guidelines of the Declaration 
of Helsinki, was approved by the institutional Ethics Committee (EC/2012/172) and was 
registered at Clinicaltrials.gov (NCT02456974). Written informed consent was obtained 
from the parents or legal representatives as well as assent from patients older than 12 
years. Collected demographic and clinical variables included: body weight (WT), post-
menstrual age (PMA), primary reason for admission, measures of organ function and 
patient severity of illness as described by the PELOD (Pediatric Logistic Organ Dysfunc-
tion) Score, PRISM II (Pediatric Risk of Mortality) Score, type of catheter used for drug 
administration and blood sampling, presence of mechanical ventilation, co-treatment 
with vasopressors and nephrotoxic medications (amikacin, ibuprofen, diclofenac, van-
comycin, teicoplanin), presence of surgery, fluid resuscitation (>60 mL/kg per 24 h), and 
C-Reactive Protein (CRP).20,21
Drug dosing and administration
Piperacillin/tazobactam (Tazocin® 2 g/250 mg and Tazocin® 4 g/500 mg, Pfizer, Belgium) 
was prescribed in a dose of 75 mg piperacillin per kilogram body weight (maximum 
4000 mg) every 6 h and administered intravenously over 5 to 30 min using a calibrated 
syringe driver, according to current dosing guidelines.22 Immediately after drug admin-
istration, infusion lines were flushed with normal saline with a minimum of twice the 
dead space volume.
Blood sampling
Serial blood samples were obtained from 1st and/or assumed steady-state doses from 
an indwelling catheter other than the drug infusion line. The total number of samples 
collected (per individual patient) was limited by the predefined total maximum blood 
volume permitted for PK sampling (i.e. 2.4 mL/kg body weight).23 A typical sampling 
Piperacillin/tazobactam dosing in critically ill children 83
scheme included blood sampling just before dosing (t = 0), immediately after dosing 
and flush, between 5  and 70 min after the start of the infusion, at 3 h after the start of 
the infusion and a trough sample just prior to the next dose. All samples were immedi-
ately transferred on ice to the chemistry laboratory and centrifuged (8 min, 1885g) after 
which the resulting plasma was frozen at -80°C for a maximum of 3 months before assay. 
Drug and biochemical assays 
Piperacillin and tazobactam total plasma concentrations were quantified simultane-
ously using a validated UPLC-tandem mass spectrometry method.24 The lower limit of 
quantification (LLOQ) was 0.5 mg/L for both compounds and the imprecision was < 15% 
at all levels. For the first 29 patients, only the piperacillin compound was quantified. 
Plasma Cystatin C (CysC) was measured using the N Latex cystatin C assay on the Behring 
Nephelometer II (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany) 
(intra-assay coefficient of variation [CV]: 1.4%; inter-assay CV: 5.4%) and was standard-
ized according to the ERM-DA471/IFCC reference material.25 Creatinine was measured in 
serum (Scr) using the rate-blanked compensated Jaffe technique (Modular P and Cobas 
6000, Roche Diagnostics GmbH, Mannheim, Germany). 
Pharmacokinetic analysis
The pharmacokinetics of piperacillin/tazobactam was evaluated using non-linear mixed 
effects modelling. Data were analysed using the first-order conditional estimation 
method with the interaction option (FOCE-I), as implemented in NONMEM version 7.2 
(ICON PLC; Ellicott City, Maryland). R (version 3.1.1) and PsN (version 3.5.3) were used for 
pre- and post-processing of the data as well as the creation of graphical and statistical 
summaries. One-, two-, and three-compartment disposition models with zero order 
input were tested to  characterize the time course of plasma concentrations of both 
compounds independently using the ADVAN subroutines.26 For piperacillin, first-order 
(FO), Michaelis-Menten (MM) and FO+MM elimination were also evaluated.  A decrease 
in objective function value (OFV) of 3.84 points (p<0.05) or more was considered statisti-
cally significant assuming a χ2 distribution for nested models. Goodness-of-fit included 
visual inspection of the following plots: observed versus population predicted concen-
trations, observed versus individual predicted concentrations, conditional weighted 
residuals versus time, conditional weighted residuals versus population predicted 
concentrations. 
A log-normal distribution was assumed for the between-subject variability (BSV), 
whereas additive and proportional models (and a combination of both) were tested 
to describe residual variability in the data. Interoccasion variability (IOV) was tested on 
clearance and central volume of distribution of piperacillin.
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 Covariate model building
Continuous covariates were evaluated using a linear or exponential equation (equation 1):
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In this equation �� represents the individual parameter estimate of the ith subject, ���� 
represents the population parameter estimate, COV is the covariate of interest and k the 
exponent which is fixed to 1 for a linear function and estimated for an exponential function. 
Binary covariates were tested using the following equation (equation 2): 
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where m was estimated for one of the dichotomic covariate values (e.g. males).  
Body weight was a priori included as a covariate using a power function with a fixed exponent 
of 0.75 on clearance and 1 on volume parameters. Furthermore, as children below the age of 2 
years were included, a Hill function based on postmenstrual age was tested to describe 
maturation on clearance (equation 3):  
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where Fmat represents the maturation function, PMA the postmenstrual age, Hill the Hill 
coefficient d scribing the steepness of the function, and TM50 the maturation half-life.27
The potential impact of remaining covariates was explored by visual inspection of 
post-hoc individual PK parameter estimates and deviations from population-predicted 
PK parameters (ETAs) versus covariate plots. Only clinically relevant associations were 
considered: gender, serum cystatin C, PELOD score, PRISM score, admission reason and 
co-medication related covariates for clearance, and age, gender, PELOD score, PRISM 
score and admission reason for volumes of distribution.
To account for the age effect in serum cystatin C values, data from Fischbach et al. and 
Randers et al. were used as reference (i.e. typical value) for each age (Tcystatin C). 28,29 An 
exponential decline was found, according to following equation (equation 4):
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Above the age of 1.3 years, a typical constant value of 0.8 mg/L was used. 
Possible influence of serum cystatin C on clearance was subsequently evaluated using measured 
serum cystatin C values (Mcystatin C ) and according to following equation (equation 5): 
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Scr could not be evaluated as potential covariates on clearance, given 39% of Scr samples were 
below quantification limit (BQL). Selected covariates were then separately entered into the 
model and evaluated by use of OFV via forward inclusion (p<0.05) and backwards elimination 
methods (p<0.001). In addition, a clinically relevant reduction in the magnitude of BSV on the 
Scr could not be evaluated as potential covariates on clearance, given 39% of Scr 
samples were below quantification limit (BQL). Selected covariates were then separately 
entered into the model and evaluated by use of OFV via forward inclusion (p<0.05) and 
backwards elimination methods (p<0.001). In addition, a clinically relevant reduction in 
the magnitude of BSV on the parameter of interest, acceptable precision of the model 
parameters, and visual inspection of the goodness-of-fit plots were used to support the 
additional inclusion of additional covariates into the model.
Model evaluation
Model performance, stability and robustness were evaluated using a nonparametric 
bootstrap analysis (n = 1000 samples), a stratified visual predictive check (pcVPC) strati-
fied for weight (n = 1000 simulations), and the normalised prediction distribution error 
(NPDE) (n = 1000 simulations).30,31 
PTA simulation analysis 
Monte Carlo simulations were performed to simulate piperacillin and tazobactam expo-
sures for 3500 patients (Table 1).22,32 The simulation dataset was created using a function 
described by Sumpter et al., in order to simulate weights based on postmenstrual age 
and sex, evenly distributed within the age range of our patient population (n = 250 boys 
and 250 girls each, for the age categories 1 to 6 monts, 6 months to 1 year, 1 to 2 years, 
2 to 4 years, 4 to 8 years, 8 to 12 years, 12 to 15 years).33 
Based on these simulations, fT>MIC and fT>CT were calculated for the first 48 h of treat-
ment, as early and appropriate therapy is most critical.34 The target efficacy exposure for 
piperacillin was defined as 60% fT>MIC and PTA was calculated for MICs between 1 to 64 
mg/L.16 A PTA ≥ 90% was defined as optimal. To evaluate proposed dosing regimens, an 
infection with Pseudomonas aeruginosa and MIC of 16 mg/L was used, according to the 
EUCAST breakpoint for piperacillin.35 For tazobactam, the reference target efficacy expo-
sure values included 40%, 60% and 80% fT>CT and PTA was calculated for CTs between 
0.25 and 8 mg/L. Given that tazobactam is given in a fixed combination with piperacillin 
(ratio 8:1), only those dosing regimens with a PTA≥90% for piperacillin were appraised 
(Table 1). Mean protein binding of piperacillin and tazobactam is 30%, and this was 
used to simulate unbound concentrations.36
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Table 1. Simulated dosing scenarios
Intermittent dosing regimena Infusion duration
75 mg/kg every 4 h 0.25, 0.5, 1, 2 h
75 mg/kg every 6 h 0.25, 0.5, 1, 2 h
75 mg/kg every 8 h 0.25, 0.5, 1, 2 h
100 mg/kg every 4 h 0.25, 0.5, 1, 2 h
 100 mg/kg every 6 h 0.25, 0.5, 1, 2 h
100 mg/kg every 8 h 0.25, 0.5, 1, 2 h
Continuous infusion dosing regimena
LD of 75 mg/kg over 1 h, followed by CI 300 mg/kg over 24 h
LD of 75 mg/kg over 1 h, followed by CI 350 mg/kg over 24 h
LD of 75 mg/kg over 1 h, followed by CI 400 mg/kg over 24 h
aBased on piperacillin component and a fixed ratio of piperacillin:tazobactam of 8:1.
Abbreviations: LD: loading dose; CI: continuous infusion.





Age (years) 2.83 (0.17-15)
Weight (kg) 14 (3.40-45)
PRISM II score 8 (0-40)
Primary reason for ICU admission
respiratory 11 (23.4)
gastro-intestinal 10 (21.3)
neurologic  7 (14.9)
postoperative  7 (14.9)




Mechanical ventilationb 25 (53.2)
Vasopressor treatmentb 15 (31.9)
PELOD scorec 1 (0-32)
Serum Creatinine (mg/dL)c,d   0.21(<0.17-0.55)
Plasma Cystatin Cc,d (mg/L) 0.66 (0.38-1.13)
Serum CRPe (mg/L) 7.8 (0.1-147)
aAbbreviations: PRISM, Pediatric Risk of Mortality; PELOD, Pediatric Logistic Organ Dysfunction; CRP, C-Re-
active Protein.
 bDuring ICU stay. 
cAt day(s) of sampling.
dBelow quantification limit in 14 patients.  
eBased on values from 44 patients.
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RESULTS
A total of 47 patients were included; demographic, clinical and treatment characteristics 
are summarized in Table 2. Patients younger than 2 years accounted for 42.5% of the 
study population (n = 20). Of a total of 317 piperacillin and 125 tazobactam plasma 
samples collected, 7 piperacillin (2%) and 4 tazobactam (3%) concentrations were 
excluded from pharmacokinetic analysis due to sampling errors. Median number of 
samples available for analysis per patient was 7 for piperacillin and 6 for tazobactam.
A two-compartment model with first-order elimination best described the data of both 
piperacillin and tazobactam. BSV for piperacillin and tazobactam was described using 
















































































Figure 1A. Goodness-of-fit diagnostic plots for piperacillin: observations versus population predictions 
and individual predictions and conditional weighted residuals (CWRES) versus time after dose and popula-
tion predictions. 
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an exponential model and was identified on clearance and all volume parameters. A 
proportional error model was used to describe residual variability for both compounds. 
Neither saturable elimination nor IOV on clearance and volume of distribution was 
identified on piperacillin. BSV on the central volume of distribution of the piperacillin 
compound was estimated to be close to a value of 0 after inclusion of allometric scaling. 
No significant change in OFV was noted when it was fixed to 0 for subsequent model 
building steps. Implementation of a concomitant vancomycin treatment covariate on 
piperacillin clearance resulted in a drop in OFV of 18.57 points with a marginal decrease 
of BSV on clearance. With only six individuals receiving vancomycin, and a potential 
confounding by age differences between those who received vancomycin and those 














































































Figure 1B. Goodness-of-fit diagnostic plots for tazobactam: observations versus population predictions 
and individual predictions and conditional weighted residuals (CWRES) versus time after dose and popula-
tion predictions. 
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who did not (median age [range] 4.71 [3.08-11.92] years, versus 2.17 [0.17-15] years), 
this covariate was not included in the fi nal model. In addition, the more parsimonious 
fi nal model incorporating weight and PMA as described above performed reasonably 
well, with only slight deviations in the higher concentration range (Figure 1A-B). No 
other collected clinical variables were deemed necessary for further statistical covariate 
testing, based on visual inspection of the covariate plots.
The fi nal covariate equations, population PK parameter estimates and their precision are 
summarized in Table 3. All structural model parameters were estimated with adequate 
precision, which was further confi rmed with the bootstrap analysis. The pcVPC plots are 
presented in Figure 2; the 5th, 50th and 95th percentiles of the predicted concentra-
tions closely follow the percentiles of the observed data, suggesting a good model fi t in 
both cases. The NPDE mean and variance were not signifi cantly diff erent from 0 and 1, 
respectively (p>0.1) (Figure not shown).
The PTA for piperacillin by MIC after 48 h of treatment for diff erent dosing scenarios 
(Table 1) are presented in Figure 3 (intermittent dosing) and Figure 4 (continuous dosing 
regimens). With a MIC value of 16 mg/L, PTA for intermittent dosing regimens ranged from 
5.9% (75 mg/kg piperacillin every 8 h, 15 min infusion) to 99% (100 mg/kg piperacillin 
every 4 h, 2-h infusion). Three intermittent dosing regimens met the PTA criterion of 90% 
(75 mg/kg piperacillin every 4 h, infusion over 2 h; 100 mg/kg every 4 h over 1-2 h). For all 
continuous dosing regimens, PTA was 100% for the time after the loading dose.
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Figure 2. Stratifi ed visual predictive check (n = 1000 simulations) for piperacillin (left panel) and tazobac-
tam (right panel): grey shaded areas are 95% confi dence intervals of simulated 5th, 50th and 95th percen-
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PTA for tazobactam by CT after 48h of treatment are presented in Figure 5 (selection of 
intermittent dosing regimens with PTA>90% for piperacillin) and Figure 6 (continuous 
dosing regimens). For a CT below 2 mg/L, PTA was >90% for all selected intermittent 
dosing scenarios, regardless of the target fT>CT (12.5 mg/kg tazobactam every 4h, 1-2h 
infusion, 9.375 mg/kg every 4 h, 2 h infusion). For all continuous dosing regimens, PTA for 
a CT of 4 mg/L was 100% for the time after the loading dose, regardless of the target fT>CT. 
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100 mg/kg q4h over 0.25h
100 mg/kg q6h over 0.25h
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100 mg/kg q4h over 0.5h
100 mg/kg q6h over 0.5h
100 mg/kg q8h over 0.5h
75 mg/kg q4h over 0.5h
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1 2 4 8 16 32 64
100 mg/kg q4h over 1h
100 mg/kg q6h over 1h
100 mg/kg q8h over 1h
75 mg/kg q4h over 1h
75 mg/kg q6h over 1h
75 mg/kg q8h over 1h




















1 2 4 8 16 32 64
100 mg/kg q4h over 2h
100 mg/kg q6h over 2h
100 mg/kg q8h over 2h
75 mg/kg q4h over 2h
75 mg/kg q6h over 2h
75 mg/kg q8h over 2h
A B
C D
Figure 3. PTA  for piperacillin (n = 3500 patients) according to following intermittent dosing regimens: (A) 
75 mg/kg every 4, 6, 8 h or 100 mg/kg every 4, 6, 8 h over 0.25 h, (B) 75 mg/kg or 100 mg/kg every 4, 6, 8 
h over 0.5 h, (C) 75 mg/kg or 100 mg/kg every 4, 6, 8 h over 1 h, (D) 75 mg/kg or 100 mg/kg every 4, 6, 8 h 
over 2 h. Piperacillin target was defined as 60% of time above a MIC of 16 mg/L. The solid horizontal line 
represents 90%.
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1 2 4 8 16 32 64
300 mg/kg/24h continuous Infusion
350 mg/kg/24h continuous Infusion
400 mg/kg/24h continuous Infusion
Figure 4. PTA for piperacillin (n = 3500 patients) according to following continuous dosing regimens: load-
ing dose of 75 mg/kg over 1 h, followed by (i) a continuous infusion (CI) of 300 mg/kg/24h, (ii) CI of 350 mg/
kg/24h, (iii) CI of 400 mg/kg/24h. Piperacillin target was defined as 60% of time above a MIC of 16 mg/L. The 
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0.25 0.5 1 2 4 8
12.5 mg/kg q4h over 1h
12.5 mg/kg q4h over 2h
9.375 mg/kg q4h over 2h
A B C
Figure 5. PTA for tazobactam (n = 3500 patients) according to following intermittent dosing regimens: (i) 
9.375 mg/kg every 4 h, 2 h infusion, (ii) 12.5 mg/kg every 4 h, 1 h infusion, (iii) 12.5 mg/kg every 4 h, 2 h 
infusion. Tazobactam target was evaluated for (A) 40%, (B) 60% and (C) 80% of time above the threshold 
concentration. The solid horizontal line represents 90%.
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DISCUSSION
This is, to our knowledge, the largest study to date in which the pharmacokinetics of 
piperacillin and tazobactam has been characterized in critically ill infants and children 
(n = 47). This is also the first time that pharmacokinetic data have been collected in 
children between the ages of 2 months and 1 year (n = 14) and 9 and 15 years (n = 10).  
Of note is the fact that we have characterized the effect of growth and organ matura-
tion on the pharmacokinetics of both compounds, as demonstrated by the functions 
describing the clearance of both piperacillin and tazobactam. A similar model describ-
ing the effect of organ maturation was proposed by Tornoe et al., who analysed pooled 
data from hospitalized children with a suspected or proven infection, and Rhodin et al., 
who described the maturation on glomerular filtration rate.37,38 The maturation half-life, 
which is the age associated with 50% maturation of clearance, and the age associated 
with full maturation in our study were 5.5 months and 4.8 years, respectively (Table 3). 
These estimates were significantly lower than previously reported by the forementioned 
authors, (maturation half-life: 2.2 months; full maturation around 2 years of age) and 
suggest that critical illness could cause a (temporary) impairment of the underlying 
renal maturation process.37,38  
When comparing the maturation parameter estimates of piperacillin versus tazobactam 
in our population, it seems that maturation of tazobactam clearance was less affected 
when compared to piperacillin clearance, with a maturation half-life and age of full-mat-
uration closer to Tornoe and Rhodin estimates.37,38 Although more data from neonates 









































































Figure 6. PTA for tazobactam (n = 3500 patients) according to following continuous dosing regimens: load-
ing dose of 9.375 mg/kg over 1 h, followed by (i) a continuous infusion (CI) of 37.5 mg/kg/24h, (ii) CI of 43.75 
mg/kg/24h, (iii) CI of 50 mg/kg/24h. Tazobactam target was evaluated for (A) 40%, (B) 60% and (C) 80% of 
time above the threshold concentration. The solid horizontal line represents 90%.
94 CHAPTER 4
questions about the impact of fixed-dose combinations of piperacillin/tazobactam in 
seriously ill young children. 
Since both compounds are renally cleared, one cannot exclude the role of organ func-
tion on the elimination of either compound. Hence, while the relationship between 
markers of renal function is plausible and expected, variations in drug clearances in this 
group of patients were captured primarily by body weight and the maturation function, 
which is in agreement with findings from previous studies in critically ill children.14,15 
Cystatin C is a low molecular weight protein which is completely filtered through the 
glomeruli, rendering it a promising biomarker for measuring Glomerular Filtration Rate 
(GFR) in children. Recently, it was found to predict elimination of the renally cleared 
amoxicillin/clavulanic acid with a similar covariate model as ours, in a comparable 
population PK study in critically ill children (n = 50 patients).39 One could only speculate 
why, in this study, we were not able to identify cystatin C as a drug clearance descriptor. 
Potential explanations include (i) serum cystatin C may be affected by the underlying 
disease (septic conditions), which may mask the effect of age on organ function (i.e., 
GFR),  (ii) too narrow variation in cystatin levels to identify a statistically significant cor-
relation, since no patients with renal insufficiency were included, (iii) both compounds 
are cleared substantially more through tubular secretion (besides glomerular filtration), 
when compared to amoxicillin/clavulanic acid. As mentioned previously, we were not 
able to evaluate serum creatinine (and estimated glomerular filtration rate based on 
serum creatinine) as a potential covariate due to the large portion of BQL values. In this 
study, the Jaffe reaction was used for creatinine bio-analysis, a method which is still 
very popular due to its simplicity and low cost. Due to a standardisation of creatinine 
measurements in 2006, analyzers automatically now correct through the use of a fixed 
correction factor to adjust for interfering protein content in adults. Unfortunately, due 
to lower total protein reference ranges, this overcorrection can potentially lead to 
undetectable creatinine levels in infants and children.40 No further clinically relevant 
covariates on PK parameters were found.
As β-lactam antibiotics are time-dependent antibiotics with fT>MIC the PK/PD parameter 
of interest, drug clearance is the most important PK parameter related with adequate 
exposure. The observed population estimate for piperacillin clearance (0.25 L/h/kg) is 
within the observed range in 47 non-ICU children (0.20-0.35 L/h/kg) and comparable to 
what has been observed in 16 critically ill adults with hyperfiltration (0.25 L/h/kg).7,41 It 
is noticeably higher (>20%) when compared to studies in neonates (0.08-0.14 L/h/kg), 
non-ICU oncology children (0.20 L/h/kg), healthy adults (0.14-0.16 L/h/kg), and a cohort 
of 12 critically ill children (0.20 L/h/kg), but substantially lower (>20%) than observed in 
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another cohort of 13 critically ill children (0.30 L/h/kg).10,11,13-15,42 The observed tazobac-
tam clearance (0.13 L/h/kg) is lower to what has previously been observed in children of 
the same age.7,15 Despite the limitations for a direct comparison of the results, disease-
driven changes in drug disposition can have major impact on drug clearance. In several 
subpopulations of critically ill adults, augmented renal clearance (ARC) of antibiotics 
leading to subtherapeutic concentrations has been extensively described.43 Despite 
increasing appreciation of this phenomenon, scarce data are available in children receiv-
ing β-lactam antibiotics.14,40,44 
In our study population clearance values higher than expected were observed in some 
patients with observed individual piperacillin clearances up to 0.35 L/h/kg. We hypoth-
esize that such an apparent variation in clearance results from an increase in renal blood 
flow, leading to hyperfiltration in those patients with sepsis. The hypothesis of ARC was 
also supported by the fact that a large proportion of measured renal biomarkers was un-
detectable (Scr) or low (CysC) compared to age-corrected reference values.45 A plausible 
explanation, besides the analytical challenges for creatinine described above, could be 
a faster renal clearance of these endogenous compounds. Moreover, trough concentra-
tions from maintenance doses remained very low in most patients. This phenomenon 
suggests that no accumulation occurs during steady-state conditions, probably due to 
the enhanced renal capacity. Although our study was not powered for the evaluation of 
efficacy, we speculate that children admitted to the ICU with lower disease severity and 
organ failure scores are most at risk for ARC and subsequent subtherapeutic antibiotic 
concentrations, as previously observed in adults.41 Notably, children admitted to a gen-
eral paediatric ward, may also experience ARC since high piperacillin clearances (upper 
range of 0.35 L/h/kg) have also been reported in non-ICU children with suspected or 
proven infection.7 Further investigation is needed to identify patient risk factors for 
developing hyperfiltration in children.
Regarding the observed population estimate of volume of distribution for piperacillin 
(0.25 L/kg), our observation is within the observed range in non-ICU children (0.24-0.33 
L/kg). It is noticeably higher (>20%) when compared to healthy adults (0.14-0.18 L/kg) 
but substantially lower than reported in (pre-)term neonates (0.37-0.42 L/kg), non-ICU 
oncology children (0.41 L/kg, two other studies in critically ill children (0.43-0.55 L/kg) 
and critically ill adults (0.35 L/kg).7,11-15,41 The observed volume of distribution of tazobac-
tam (0.24 L/kg) is lower to what has previously been observed in children of the same 
age (0.30-0.39 L/kg).7,15  Also here, it is unclear whether these differences in volume of 
distribution are due to differences in body composition of the study population (e.g. 
larger total and extracellular body water content in neonates compared to infants and 
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children), differences in disease severity (e.g. vascular leakage), and/or different sam-
pling and PK parameter estimation methods. 
Treating infections in the seriously ill child without evidence-based dosing recommen-
dations remains a huge challenge and may lead to an increased morbidity and mortal-
ity.46 Our analysis challenges currently used dosing regimens (75-100 mg/kg piperacillin 
every 6 to 8 h, given as a short infusion), as they only yield a PTA between 5.9% to 34% 
for piperacillin, thereby potentially leading to subtherapeutic treatment (Figure 3).14 
These findings of underdosing are consistent with previously reported exposure data in 
critically ill children of the same age.14,15 
For the treatment of Pseudomonas infections, no clear-cut fT>CT target values are 
available for tazobactam, in combination with piperacillin. Therefore, we performed a 
PTA analysis appraising different targets (40%-60%-80% fT>CT) (Figure 5,6). The choice 
was based on the only properly designed in vitro study in which the pharmacodynam-
ics of tazobactam was characterised in combination with piperacillin.5 Further studies 
are required to confirm the appropriate target. Our analysis should be interpreted with 
caution, but it does provide insight into how differences in exposure may affect antimi-
crobial response.
More frequent dosing, prolonged infusions and continuous infusions have been pro-
posed as dose optimization strategies for β-lactam antibiotic treatment.47 However, it 
should be noted that, we have specifically chosen not to select higher amounts per dose 
for intermittent dosing regimens (max. 100/12.5 mg per kg piperacillin/tazobactam) 
than currently recommended. This was done to mitigate potential safety risks related 
to higher peak concentrations, thereby avoiding the potential for saturation of the 
elimination processes which determine the clearance of piperacillin. This ‘same amount 
per dose’ approach should also prevent a higher degree of reduced tazobactam clear-
ance, as it is known that both piperacillin and tazobactam interact by a competitive 
inhibition at the level of the tubular anion transporter system.48 Regarding the safety of 
continuous infusions, Delvallée et al. reported the use of a 400 mg/kg/day infusion on a 
paediatric haematology unit without any observed adverse events.44 
Our simulations showed that, four hourly dosing regimens (given as a prolonged 
infusion), and all continuous dosing regimens met the PTA criterion for piperacillin 
(Figure 3,4). Despite the higher PTA with these prolonged and continuous infusions, 
we acknowledge that these dosing regimens may have important implications on drug 
administration practices, as intravascular access is frequently limited and drug incom-
patibilities with piperacillin/tazobactam often occur.50,52 Therefore, a rational choice in 
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dosing regimen is advised, depending on the individual patient characteristics, site of 
infection and target MIC. In our opinion, prolonged and continuous infusions seem a 
preferable option whenever possible, especially when antibiotic therapy is started em-
pirically or when higher fT>MIC targets are needed (e.g. neutropenic children).
This research has some notable limitations. First, the studied population included a 
heterogeneous group of children with regard to possible differences in (suspected) 
infecting organism and tissue involvement/penetration. Second, total drug plasma 
concentrations were mathematically corrected for protein binding instead of free drug 
concentration measurement in plasma, or drug measurement at the site of infection. 
However, this simplification was previously found to be acceptable for β-lactam antibi-
otics with low protein binding like piperacillin and tazobactam.50 Third, MIC values were 
not prospectively determined in order to be able to calculate individual target drug con-
centrations in culture-proven infections. Instead, a worst-case scenario using the clinical 
breakpoints for P. aeruginosa was chosen as reference to explore dosing regimens by 
fT>CT. This approach is suitable for β-lactam antibiotics and tazobactam, which are 
known to have a wide therapeutic index. Consequently, there should be limited concern 
about potentially supra-therapeutic dosing. Moreover, from our simulation studies, we 
concluded that there is no risk for accumulation of piperacillin and tazobactam, when 
using any of the alternative dosing scenarios (Table 2). Fourth, notwithstanding that a 
substantial number of younger patients were recruited, more extensive PK data from 
neonates and infants are needed to estimate maturation parameters more precisely on 
both clearances and refine dosing regimens in these age categories. 
In conclusion, our study shows that current dosing recommendations for piperacillin 
and tazobactam can result in subtherapeutic treatment in critically ill children, thereby 
risking treatment failure. We proposed alternative, model-based dosing regimens that 
increase the PTA from 5.9% to 100 % for P. aeruginosa infections with a MIC of 16. A 
prospective, randomized controlled trial evaluating efficacy and safety for the proposed 
optimized dosing strategies may be required to further substantiate these results.  
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ABSTRACT 
Objectives: The objective of this study was to characterize cefazolin serum pharmaco-
kinetics in children before, during and after cardiopulmonary bypass (CPB), in order to 
derive an evidence-based dosing regimen.
Patients and Methods: This study included children who received cefazolin before 
surgical incision, before cessation of CPB and after surgery. Blood samples of total and 
unbound cefazolin concentrations were collected before, during and after CPB. The 
cefazolin concentration-time profiles were analysed using population pharmacokinetic 
modelling and predictors for interindividual variability in pharmacokinetic parameters 
were investigated. Subsequently, optimized dosing regimens were developed using 
stochastic simulations. Clinicaltrials.gov: NCT02749981.
Results: A total of 494 total and unbound cefazolin concentrations obtained from 56 
children (age 6 days to 15 years) were included. A two-compartment model with first-
order elimination plus an additional compartment for the effect of CPB best described 
the data. Clearance (1.56 L/h), central volume (1.93 L) and peripheral volume (2.39 L) 
were allometrically scaled by body weight. The estimated glomerular filtration rate 
(eGFR) was identified as a covariate on clearance and the serum albumin concentration 
was associated with maximum protein binding capacity. Our simulations showed that 
an additional bolus dose at start of CPB improves the PTA in typical patients from 59% 
to >94%. Prolonged surgery and preserved renal function (i.e. drop in eGFR <25 %) had 
a negative impact on PTA.
Conclusions: We propose an optimized dosing regimen for cefazolin during cardiac 
surgery in paediatric patients to avoid treatment failure due to inadequate antibiotic 
prophylaxis.
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INTRODUCTION
Post-operative infection in cardiac surgical patients is a cause of major morbidity and 
mortality and has a considerable financial impact.1,2 In paediatric cardiac surgery, the 
rate of surgical site infections (SSI) is sometimes even higher, when compared with adult 
procedures.1 One key prevention strategy is appropriate use of antibiotic prophylaxis. 
Shah et al.3 recently showed that failure to administer a correct antibiotic prophylactic 
dose resulted in a 2-fold increase in the risk of developing an SSI in children undergoing 
surgery. Moreover, suboptimal prophylactic dosing likely results in the emergence of 
antimicrobial resistance necessitating later broad-spectrum antibiotic treatment.4 To 
date, there is no consensus on optimal antibiotic dosing regimens in children undergo-
ing cardiac surgery with cardiopulmonary bypass (CPB) and current recommendations 
are based on extrapolation from adults.1 
CPB and post-operative renal function changes have been shown to have a major impact 
on drug disposition.5,6 Moreover, maturational changes in drug pharmacokinetics from 
birth towards adulthood further complicate optimal drug treatment in the paediatric 
population.7 
The efficacy of β-lactam antibiotics most strongly relates to the time during which the 
unbound drug concentration (fT) is above the MIC for the pathogen, i.e. fT>MIC. The phar-
macokinetic/pharmacodynamic target (i.e. fT>MIC) index associated with positive clinical 
outcomes for β-lactams in critically ill patients is an fT>MIC between 50% to 100% of the 
dosing interval.8 Although pharmacokinetic/pharmacodynamic targets for surgical an-
tibiotic prophylaxis are not established, the goal should be to achieve blood and tissue 
concentrations that exceed pathogen MICs for the entire duration of surgery, until a few 
hours after skin closure.1 
To date, only sparse data on the pharmacokinetics of unbound cefazolin are available in 
children during CPB with mild to moderate hypothermia (n=5 patients) and no data are 
available after paediatric cardiac surgery.9 Previously, it has been shown that with tradi-
tional untested dosing schemes, antibiotic concentrations in children could be severely 
altered, increasing the risk of treatment failure and increased antibiotic resistance.10,11 
The primary aims of this study were: (i) to quantitatively characterize intravenous ce-
fazolin serum pharmacokinetics, protein binding and predictors of interindividual vari-
ability in critically ill children before, during and after CPB; (ii) to evaluate the PTA for the 
current standard dose regimen; and (iii) to assess if further improved evidence-based 
practical dosing regimens can be developed for this patient population. 
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PATIENTS AND METHODS
Study design and ethics
A prospective pharmacokinetic study was conducted at Ghent University Hospital, Gh-
ent, Belgium between November 2012 and May 2014. Patients between 1 day and 15 
years of age undergoing cardiac surgery with CPB and receiving cefazolin as standard-
care surgical antibiotic prophylaxis were eligible. Patients were excluded if they did 
not have, other than the drug infusion line, an arterial or intravenous access available 
for blood sampling. The research was conducted in accordance with the guidelines of 
the Declaration of Helsinki, approved by the institutional Ethics Committee and was 
registered at Clinicaltrials.gov (NCT02749981). Written informed consent was obtained 
from the parents or legal representatives and from the patients if older than 12 years. 
No formal power analysis was performed; the number of patients was based upon 
similar paediatric pharmacokinetic studies which showed adequate characterization 
of the pharmacokinetics. Collected demographic and clinical variables included: sex, 
body weight, postmenstrual age (PMA), height, body surface area, primary reason for 
admission, priming solution volume, laboratory chemistry at three fixed time points 
before, during and after CPB (serum albumin, creatinine, total protein), lowest body 
temperature on CPB (oesophageal, arterial, venous blood temperature), CPB pump flow 
rate, co-treatment with vasopressors/inotropes/vasodilators (dobutamine, adrenaline, 
norepinephrine, phenylephrine, milrinone, nitroprusside, nitroglycerine), type of cath-
eter used for drug administration and blood sampling, time of skin incision, CPB start 
and stop time and time of skin closure. 
CPB procedure
Anticoagulation was achieved by unfractionated heparin (300 IU/kg) given before 
initiation of CPB, in order to maintain an activated clotting time above 400 seconds (He-
motec; Medtronic, Brussels, Belgium). Saint Thomas II cardioplegic solution was used for 
cardiac protection (15-20 mL/kg). CPB circuits were primed with PLASMA-LYTE A (Baxter 
International, Deerfield, Ill), 20% albumin, mannitol (0.5 g/kg), sodium bicarbonate, 
heparin sodium and furosemide. Packed red cells were added when necessary to main-
tain a haematocrit between 25%-30% during bypass. Fresh frozen plasma was added if 
the post dilution calculated fibrinogen concentration was below 120 mg/dL. The CPB 
circuit consisted of a membrane oxygenator (D100 or D101; Liva Nova, Mirandola, Italy), 
polyvinylchloride tubing (Liva Nova, Mirandola, Italy), and roller pumps (S5; Liva Nova, 
Munchen, Germany). Moderate hypothermia (28 - 32 °C) was used in most cases. No 
ultrafiltration was used.
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Drug dosing and administration
Cefazolin (Mylan®, Hoeilaart, Belgium) was prescribed at a dose of 25 mg/kg body weight 
(maximum 2000 mg), administered intravenously as a bolus within 1 h before surgical 
incision, at start of rewarming on CPB, 8 h after the second dose and 8 h after the third 
dose, according to current institutional dosing guidelines. Immediately after drug ad-
ministration, infusion lines were flushed with normal saline with a minimum of twice 
the dead space volume.
Blood sampling
Serial blood samples (0.5 mL) were obtained before, during and after CPB from an arterial 
catheter (or from the arterial CPB circuit sampling port if a sample was taken just prior 
to the second dose). The total number of samples collected (per patient) was limited by 
the predefined total maximum blood volume permitted for pharmacokinetic sampling 
per individual patient, defined as 2.4 mL/kg bodyweight.12 Sampling times focussed 
peri-operatively, pre- and immediately post-drug administration to characterize clear-
ance and volume of distribution parameters. A full sampling scheme typically included 
a sample just before dosing (t=0), a sample 5 min after the first dose, a sample at skin 
incision, a sample immediately after arterial cannulation or on full-flow CPB, a sample 
just prior to aorta clamping, a trough sample just prior to the second dose, a sample just 
before venous decannulation, a sample just before skin closure, a sample just prior to 
the third dose, and a sample 5 min after the third dose. All samples were immediately 
centrifuged (15 min, 1885g) after which the resulting serum was frozen at -80°C before 
shipping to the clinical laboratory for assay. Unbound drug was separated at 37°C using 
a validated ultrafiltration method with an Amicon Ultra 0.5ml 30,000-molecular-weight-
cutoff centrifugal filter device.13
Drug and biochemical assays 
Cefazolin serum total and unbound concentrations were quantified using a validated 
HPLC-ultraviolet spectrophotometric method.14 Total and unbound concentrations were 
analysed in three different batches and both concentrations per sample were measured 
within one day. Repeat analysis of unbound concentrations was performed on 8% of 
samples within one day of the first measurement. The lower limit of quantification 
(LLOQ) was 0.1 mg/L and the imprecision was < 10% at all concentrations. The percent-
age of unbound fraction (fu%) was calculated as ultrafiltrate concentration divided by 
total concentration, multiplied by 100. Serum total protein (biurete), albumin (bromo-
cresol green), creatinine (rate blanked, compensated Jaffe technique), total bilirubin 
(diazonium, colorimetric) and urea (kinetic urease) concentrations were measured on 
the Cobas 8000 (c502/c701) analyzer (Roche Diagnostics, Mannheim, Germany). Serum 
creatinine concentrations were afterwards recalculated towards enzymatic values, 
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based on the equation from Speeckaert et al.15 Glomerular Filtration Rates (eGFR) were 
estimated using the Modified Schwartz formula.16 
Pharmacokinetic analysis
Cefazolin pharmacokinetics was evaluated using the non-linear mixed-effects modelling 
software NONMEM version 7.2 (ICON, Ellicott City, MD, USA). The first-order conditional 
estimation method with the interaction option was used to estimate pharmacokinetic 
parameters and variability. R (version 3.1.1) and PsN (version 5.18.2) were used for pre- 
and post-processing. One, two-, and three-compartment disposition models with zero 
order input were tested to fit serum concentrations of bound and unbound concentra-
tions using the NONMEM library, subroutine ADVAN6 TOL=9.17 The effect of CPB was 
modelled using a separate on/off compartment. Intercompartmental clearance from 
this CPB compartment was fixed to the CPB pump flow rate and volume of distribution 
to the CPB priming volume (Figure 1). Clearance and volume parameters were estimated 
using unbound concentrations.  
The total cefazolin concentrations (Ct) and unbound concentrations (Cu) were modelled 
simultaneously and related to each other, taking into account saturable serum protein 
binding (Figure 2), using the following equation:
 






 Vcentral  Vperi  VCPB 





Figure 1. Schematic presentation of the structural three-compartment pharmacokinetic model of un-
bound cefazolin concentrations. CPB, cardiopulmonary bypass; Vc, Vp, VCPB, volumes of distribution; Q12, QCPB, 
inter-compartmental clearances; CLu, clearance of unbound cefazolin. The study dosing regimen consisted 
of a dose of 25 mg/kg, given within one hour before surgical incision, at start rewarming on CPB, and 8 and 
16 h after the second dose (Table 1).
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The total cefazolin concentrations (Ct) and unbound concentrations (Cu) were modelled 
simultaneously and related to each other, taking into account saturable serum protein binding 
(Figure 2), using the following equation: 
 
�� � ������	������� � � ��	 (1) 
 
where Bmax is the maximum protein binding (mg/L) and KD the dissociation constant (mg/L).  
 
where Bmax is the maximum protein binding (mg/L) and KD the dissociation constant 
(mg/L). 
In the pharmacokinetic model, all observations were assumed to be from the central 
compartment. A decrease in objective function value (OFV) of 3.84 points (p<0.05) or 
more was considered statistically significant assuming a χ2 distribution for nested mod-
els (1 degree of freedom). In addition, visual inspection of goodness-of-fit plots was per-
formed for diagnostic purposes: observed versus population predicted concentrations, 
observed versus individual predicted concentrations, conditional weighted residuals 
versus time, conditional weighted residuals versus population predicted concentra-
tions. A Wilcoxon signed-rank test was used to compare the serum unbound fraction 
just before and after initiation of CPB (maximum 25 min before and 5 min after initiation 
of CPB). 
A log-normal distribution was assumed for the between-subject variability (BSV). Re-
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Figure 2. Bound versus unbound concentration plot. A Loess smooth line (solid line) was added to the plot.
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As total and unbound concentration measurements were obtained from the same 
sample, correlations in residual errors associated with simultaneous total and unbound 
concentration samples were handled using the L2 method in NONMEM.17
Covariate model development
The covariate model was constructed in a stepwise fashion, through forward inclusion 
(p<0.05), and subsequent backwards elimination (p<0.001). In addition, a clinically 
relevant reduction in the magnitude of BSV on the parameter of interest, acceptable 
precision of model parameters, and visual inspection of the goodness-of-fit plots were 
used to support the inclusion of additional covariate terms into the model. Continuous 
covariates were evaluated as follows:
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where �� represents the individual parameter estimate of the ith subject, ���� represents the 
population parameter estimate, cov is the covariate of interest and k the exponent, which could 
be fixed to 1 for a linear function or estimated. 
Dichotomic covariates were evaluated using the following equation: 
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where m was estimated for one of the dichotomic covariate values (e.g. males). 
where pi represents the individual parameter estimate of the ith subject, ppop represents 
the population parameter estimate, cov is the covariate of interest and k the exponent, 
which could be fixed to 1 for a linear function or estimated.
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Body weight was a priori included as a covariate using a power function with a fixed 
exponent of 0.75 on (intercompartmental) clearance parameters and 1 on volume pa-
rameters, normalized by the median body weight.18 The potential impact of remaining 
clinical covariates was explored by visual inspection of post hoc individual pharmacoki-
netic parameter estimates and deviations from population-predicted pharmacokinetic 
parameters estimates versus covariate plots. Only clinically relevant associations were 
considered: sex, age, renal function, temperature and comedication covariates for clear-
ance and age and sex for volumes of distribution. Total protein and albumin concentra-
tions were tested on maximum binding protein (Bmax). Specifically for the impact of age 
on clearance, we tested a sigmoidal maturation function based on post-menstrual age: 
 
Body weight was a priori included as a covariate using a power function with a fixed exponent 
of 0.75 on (intercompartmental) clearance parameters and 1 on volume parameters, 
normalized by the median bo y weight.13 The potential impact of remaining clinical covariates 
was explored by visual inspection of post ho  individual pharmacokinetic parameter estimates 
and deviati ns from pop lation-predicted pharmacokinetic parameters estimates versus 
covariate plots. Only clinically relev nt associations were considered: sex, age, renal function, 
temperature and comedication covariates for clearance and age and sex for volumes of 
distribution. Total protein and albumin concentrations were tested on maximum binding 
protein (Bmax). Specifically for the impact of age on clearance, we tested a sigmoidal maturation 







where Fmat is the maturation function, PMA is post-menstrual age, Hill is the Hill coefficient, and 
TM50 is the maturation half-life. 
Model evaluation 
The final population pharmacokinetic model was evaluated as follows. A non-parametric 
where Fmat is the maturation function, PMA is post-menstrual age, Hill is the Hill coef-
ficient, and TM50 is the maturation half-life.
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Model evaluation
The final population pharmacokinetic model was evaluated as follows. A non-parametric 
bootstrap analysis (n = 1000 samples) was used to assess parameter precision. Adequate 
description of time course and variability was assessed using a prediction-corrected vi-
sual predictive check (pcVPC) stratified for total and unbound concentrations (n = 1000 
simulations) and by assessment of the normalized prediction distribution error (NPDE) 
distribution (n = 1000 simulations).19,20 
PTA simulation analysis
Stochastic simulations were performed to simulate unbound cefazolin concentration-
time profiles for the study dose regimen (SDR) and for three alternative dose regimens 
(ADR1-ADR3) in 1000 individuals (Table 1). 
Table 1. Simulated dosing scenarios
SDR: 25 mg/kg, 30 min before surgical incision; 25 mg/kg, at the start rewarming on CPB; 25 mg/kg, 8 h 
after the second dose; 25 mg/kg, 8 h after the third dose
ADR1: 30 mg/kg, 30 min before surgical incision; 30 mg/kg, at the start rewarming on CPB; 30 mg/kg, 8 h 
after the second dose; 30 mg/kg, 8 h after the third dose
ADR2: 30 mg/kg, 30 min before surgical incision; 15 mg/kg, at start of CPB; 15 mg/kg, at the start 
rewarming on CPB; 30 mg/kg, 8 h after the third dose; 30 mg/kg, 8 h after the fourth dose
ADR3: 40 mg/kg, 30 min before surgical incision; 20 mg/kg, at start of CPB; 20 mg/kg, at the start 
rewarming on CPB; 40 mg/kg, 8 h after the third dose; 40 mg/kg 8 h after the fourth dose
All simulations included a bolus administration. SDR, study dosing regimen; ADR, alternative dosing regimen.
Table 2. Patient study demographics stratified by body weight, used for the stochastic dose regimen simu-
lations.
Median (percentile)a
Patient characteristics <6 kg 6-11 kg >11 kg
Body weight (kg) 4.85 7.50 17.2
eGFR pre-CPB (ml/min/1.73 m2) 89 112 112
Serum albumin pre-CPB (g/L) 44 45 46
CPB pump flow rate (L/h) 40.9 54.8 102.5
Priming volume (L) 0.17 0.35 0.35
Time from first dose to incision (h) 0.57 (0.77)
Time from first dose to start CPB (h) 0.97 (1.27)
CPB duration (h) 1.33 (1.60)
Time from first dose to the start of rewarming on CPB (h) 1.77 (2.34)
Time from first dose to skin closure (h) 2.75 (3.31)
Fractional albumin change before/during/post CPB 100%/-25%/-10 % (100%/-33%/-19%)
Fractional eGFRb change before/during/post CPB 100%/-24%/-34% (100%/-18%/-24%)
aPercentiles shown are 75th, except for fractional eGFR, which is 25th percentile.
bAccording to the modified Schwartz formula.
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Dose regimen simulations were conducted, stratified by three body weight groups. The 
associated median patient-specific covariates and CPB/surgery characteristics for each 
of these weight groups, as observed in our clinical study, were used (Table 2). In addition 
to these typical, median values, we also included a number of additional conservative 
subscenarios. These scenarios consisted of: (i) patients with a smaller drop in renal func-
tion [observed 25th percentile instead of the median estimated glomerular filtration 
rate (eGFR) fractional change from before to during and after CPB]; (ii) patients with a 
longer CPB and surgical procedure (observed 75th percentile of time to skin incision/
CPB duration/time to skin closure); and (iii) a larger drop in serum albumin concentra-
tions (observed 75th percentile of fractional change in albumin from before to during 
and after CPB). 
Based on these scenarios, the simulated fT>MIC was calculated for the perioperative 
period and the period from skin closure to 24 h after skin incision. The target efficacy 
exposure was defined as 100% fT>MIC during surgery1 and 50% fT>MIC after surgery.21 
PTA was calculated for MICs between 0.125 and 16 mg/L. A PTA ≥90% was defined as 
optimal.22 To evaluate proposed dosing regimens, an infection with staphylococci and 
worst-case MIC breakpoint of 8 mg/L was used.1,23 
Table 3. Demographic and clinical characteristics of the study population




Age (years) 2.8 (0.013-15)
Weight (kg) 6.8 (2.7-70)
Procedure duration (h) 2.15 (1.21-8.50)
CPB duration (h) 1.33 (0.37-5.10)
CPB pump flow rate (L/h) 44.8 (18.4-249)
Lowest venous temperature on CPB (°C) 30 (16-34)
Priming volume (mL) 175 (150-1000)
eGFRa before CPB (ml/min/1.73 m2) 108 (32-187)
eGFRa during CPB (ml/min/1.73 m2) 80 (29-112)
eGFRa after CPB (ml/min/1.73 m2) 74 (27-135)
Serum albumin before CPB (g/L) 45 (32-53)
Serum albumin during CPB (g/L) 33 (22-41)
Serum albumin after CPB (g/L) 39 (25-51)
aAccording to the modified Schwartz formula.
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Table 4. Parameter estimates of the population pharmacokinetic model.
Bootstrap estimates (n=1000)a






    Bootstrap estimates 
(n=10 )a 
Description Parametera Estimate RSE (%) Median 2.5%ile 97.5%ile 
Structural model parameters 




× �����91.6 �   
Clearance CL (L/h) 1.56 (11.7)b 5 1.56 1.40 1.73 





Inter-compartmental clearances Q12 (L/h) 5.44 (31.3)b 6 5.42 4.80 6.06 
 QCPB (L/h) fixed to CPB pump flow ratec 





Central volume of distribution Vc (L) 1.93 (19.9)b 6 1.93 1.68 2.17 
Peripheral volume of 
distribution 
Vp (L) 2.39 (24.6)b 7 2.40 2.04 2.76 
CPB volume of distribution VCPB (L) fixed to priming solution volumed 





Maximum binding protein Bmax (mg/L) 210 6 209 189 238 
Exponent m 0.571 15 0.572 0.394 0.723 
�� = �
���� ×	��
�� � �� �	 
Dissociation constant KD (mg/L) 53.7 11 53.8 43.7 66.9 
 
Between-subject variability  
Clearance CL (% CV) 33.5 29 32.7 23.7 43.0 
Central volume of distribution Vc(% CV) 31.8 38 31.2 18.7 42.9 
Peripheral volume of distribution Vp  (% CV) 48.2 26 47.5 34.5 60.5 
Dissociation constant KD (% CV) 36.6 30 35.8 25.6 46.7 
 
Residual variability 
Unbound concentration � u, proportional 28.1 11 28.0 25.9 31.4 
Total concentration � t, proportional 16.6 15 16.5 14.0 19.1 
WT, patient weight 
Population parameters estimated for the median values in the population  for body weight of 6.8 kg, 
eGFR of 91.6 mL/min/1.73m2 and serum albumin concentration of 39 g/L 
aNon-parametric bootstrap: 988 runs minimization successful. 
bEstimated parameters for a 70 kg person, eGFR rate of 120 mL/min/1.73 m2 and serum albumin 
concentration of 39 g/L. 
c CPB pump flow rate target value: 144 L/h/m2 body surface area. 
d Depending on CPB pump flow rate: <30 L/h, 150 ml ; >30 and < 48 L/h, 170 mL;>48 L/h and <120 L/h, 
350 mL; and >120 L/h, 800-1000 mL. 
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Maximum binding protein Bmax ( g/L) 210 6 209 189 238
Exponent m 0.571 15 0.572 0.394 0.723
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    Bootstrap estimates 
(n=1000)a 
Description Parametera Estimate RSE (%) Median 2.5%ile 97.5%ile 
Structural model parameters 




× �����91.6 �   
Clearance CL (L/h) 1 56 1 7  5 1 56 1 4  1 73 





Inter-compartmental clearances Q12 (L/h) 5 44 31 3 5 42 4 80 6 06
 QCPB (L/h) fixed to CPB pump flow ratec 





entral volu   istribution c (L) 1. 3 (19.9)b 6 1.93 1.68 2.17 
Peripheral volume of 
distr bution 
Vp (L) 2.39 (24.6)b 7 2.40 2.04 2.76 
CPB volu e of distribution VCPB L) fixed to priming solution volumed 





Maximum binding protein Bmax (mg/L) 210 6 209 189 238 
Exponent m 0.5 1 5 0.572 0.394 0.723 
�� = �
���� ×	 �
�� � �� �	 
Dissociation constant KD mg/L 5 7 11 53 8 4 66
 
B tween-subject variability  
Clearance CL   3.5 29 2.7 3.7 3.0 
C ntral volume of distribution Vc(% CV) 31.8 38 31.2 18.7 42.9 
P ripheral v lume of d stribution Vp  (% CV) 4 2 26 47 5 34 5 60 5
Diss iation cons ant KD (% CV) 3 30 35 8 6 46 7
 
Residual vari bility 
Unbound concentration � u, proportional 28.1 11 28.0 25.9 31.4 
Total concentration � t, proportional 16.6 15 16.5 14.0 19.1 
WT, pati nt weight 
P pulation  estimated for the edian values in the population  for body weight of 6.8 kg, 
eGFR of 91.6 mL/min 1.73m2 nd serum albumin concentration of 39 g/L 
aNon- arametric bootst ap: 988 runs minimizati n successful. 
bEsti ated parameters for a 7  kg person, eGFR rate of 120 mL/min/1.73 m2 and serum lbumin 
conc ntr tion of 39 g/L. 
c CPB pump flow rat  target value: 144 L/h/m2 body surface area. 
d Depending on CPB pu p flow rate: <30 L/h, 150 ml ; >30 and < 48 L/h, 170 mL;>48 L/h and <120 L/h, 
350 mL; and >120 L/h, 800-1000 mL. 
Table 4. Parameter estimates of the population pharmacokinetic model. 
  
Dissociation constant KD (mg/L) 53.7 11 53.8 43.7 66.9
Betwee -subject variability 
learance CL (% CV) 33.5 29 32.7 23.7 43.0
Central volume f distribution Vc(% CV) 31.8 38 31.2 18.7 42.9
Peripheral volume of distribution Vp  (% CV) 48.2 26 47.5 34.5 60.5
Dis ociation constan KD (% CV) 36.6 30 35.8 25.6 46.7
Residual variability
nbound concentra ion C u, proportional (% CV) 28.1 11 28.0 25.9 31.4
Total conce tration C t, proportional (% CV) 16.6 15 16.5 14.0 19.1
WT, patient weight
Population parameters estimated fo  the edian values in th  population  for body weight of 6.8 kg, eGFR 
of 91.6 mL/min/1.73m2 and serum albumin concentration f 39 g/L
aNon-parametric bootstrap: 988 runs minimization successful.
bEstimated arameters for a 70 kg p rson, eGFR rate of 120 mL/min/1.73 m2 and serum albumin concentra-
tion of 39 g/L.
c CPB pump flow rate target value: 144 L/h/m2 body surface area.
d Depending on CPB pump flow rate: <30 L/h, 150 ml ; >30 and < 48 L/h, 170 mL;>48 L/h and <120 L/h, 350 
mL; and >120 L/h, 800-1000 mL.
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RESULTS
A total of 56 patients were included. Demographic, clinical and treatment characteristics 
are summarized in Tables 2 and 3. Patients younger than 2 years (n=38) accounted for 
67.8%  of the study population. Some 497 total and 494 unbound cefazolin concentra-
tions were available for pharmacokinetic analysis with all samples having a concentration 
above the lower limit of quantifi cation (median of 9 samples per patient) (n = 130/129 
total/unbound concentrations before, n = 229/228 during, n = 138/137 after CPB). The 
median unbound fraction was 28% (IQR = 23%-36%) and a median unbound fraction 
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Figure 3. Goodness-of-fi t diagnostic plots for unbound (red dots) and total (black dots) concentrations ver-
sus population predictions and individual predictions and conditional weighted residuals (CWRES) versus 
time after dose and population predictions. A line of identity (black solid line) was included in the observa-
tion versus prediction plots as a reference and a Loess smooth line (blue solid line) in all plots.  
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A two-compartment model with fi rst-order elimination plus an additional compartment for 
the eff ect of CPB best described the data (Figure 1, 3). Only a slight bias beyond 15 h of 
treatment was observed in the plot of conditional weighted residuals over time, potentially 
due to the sparse nature of the data in this time period. The equations, population pharma-
cokinetic parameter estimates and their precision are summarized in Table 4. All structural 
model parameters were estimated with adequate precision (relative standard error <15%) 
and adequate precision was further confi rmed with the bootstrap analysis. Between-subject 
variability (BSV) was estimated for clearance, volume parameters and the serum protein-
binding dissociation constant. A proportional error model was used to describe residual vari-
ability for both total and unbound concentrations. A more parsimonious covariate model 
for clearance incorporating weight and GFR performed better compared with a model 
incorporating weight and an age-based maturation function, with one extra parameter to 
be estimated (see Patients and methods section). It had a lower BSV [coeffi  cient of variation 
(CV) 33% versus 37% on terminal clearance parameter and improved precision on estimated 
parameters]. Subsequently the GFR model was chosen as the fi nal model. Albumin was 
implemented as a covariate to describe saturable protein binding. No other collected clinical 
variables were selected for further statistical covariate testing, based on changes in objective 
function value and/or visual inspection of the covariate plots and clinical plausibility. 
The pcVPC plots are presented in Figure 4; the 5th, 50th and 95th percentiles of the 
predicted concentrations closely follow the percentiles of the observed data, suggest-
ing a good model fi t in both cases. The NPDE mean and variance were not signifi cantly 
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Figure 4. Prediction-corrected visual predictive check (n =1000 simulations) for unbound (left panel) and 
total cefazolin concentrations (right panel): grey shaded areas are 95% confi dence intervals of simulated 
5th, 50th and 95th percentile; lines are 5th, 50th and 95th percentile of raw data.
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PTA analyses for different dosing scenarios in patients with median patient character-
istics (see Tables 1, 2) are presented in Figure 5 (during surgery) and Figure 6 (after 
surgery). PTA for the SDR was between 62% and 70% during surgery and between 89% 
and 98% after surgery. Also, the impact on PTA of a longer procedure duration (75th 
percentile of time to skin incision/CPB duration/time to skin closure), a preserved renal 
function (25th percentile of eGFR fractional change from before to during and after CPB) 
and drop in albumin concentration during and after CPB (75th percentile of albumin 
fractional change from before to during and after CPB) are illustrated. Prolonged surgery 
had a significant negative effect on PTA during surgery (maximum drop of 19%) (Figure 
5); the effect of a preserved renal function was smaller (maximum drop of 10%) and 
mainly after surgery (Figure 6). Changes in albumin concentration did not show any 
effect on PTA.
WT <6 kg WT 6−11 kg WT >11 kg






































































































Figure 5. PTA (n = 1000 patients) for cefazolin during surgery, according to weight category and dosing 
scenario (Tables 1 and 3). Impact on PTA of a minor drop in eGFR (25th percentile) during and after CPB, a 
longer CPB/surgery duration (75th percentile) or a larger drop in albumin concentration (ALB) during and 
after CPB (75th percentile) were also shown. Target was defined as 100% of time above MIC.
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Figure 6. PTA (n = 1000 patients) for cefazolin after surgery, according to weight category and dosing 
scenario (Tables 1 and 3). Impact on PTA of a minor drop in eGFR (25th percentile) during and after CPB, a 
longer CPB/surgery duration (75th percentile) or a larger drop in albumin concentration (ALB) during and 
after CPB (75th percentile) were also shown. Target was defined as 50% of time above MIC. 
WT <6 kg WT 6−11 kg WT >11 kg































Figure 7. PTA (n = 1000 patients) for cefazolin during and after surgery, according to weight category and 
dosing scenario (Tables 1 and 3). Simulated patient scenarios consisted of a longer CPB/surgery duration 
(75th percentile) in combination with a minor drop in eGFR (25th percentile) during and after CPB. The 
combined target was defined as 100% above MIC during surgery and 50% of time above MIC after surgery 
until 24 h after skin incision.
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The probability of achieving the target pharmacokinetic/pharmacodynamic index both 
peri- and post-operatively in conservative patient scenarios (75th percentiles on CPB 
and surgery duration combined with a 25th percentile on fractional eGFR change) are 
presented in Figure 7. PTA with the SDR was within the range of 40% to 54%, whilst the 
ADR3 dosing regimen (Table 1) provided the most optimal PTA between 88% to 99%.
DISCUSSION
To the best of our knowledge, this is the first population pharmacokinetic model de-
scribing the serum pharmacokinetics and protein binding of cefazolin in a large cohort 
of children before, during and after CPB. The developed population pharmacokinetic 
model was based on rich data from a relevant cohort of infants and children (n = 56 
patients). Patients were recruited over a full paediatric age range (6 days to 15 years) and 
both total and unbound cefazolin concentrations were measured, using an informative 
blood sampling schedule that was not restricted to the intraoperative period.
We identified an increase in the volume of distribution during CPB, as observed by a lim-
ited drop in serum antibiotic concentrations, which is consistent with previous reports 
on antibiotic pharmacokinetics in children on CPB.24,25 It is known that the fairly large 
ratio of priming volume to the child’s circulating blood volume can have an impact on 
the volume of distribution of hydrophilic antibiotics (e.g. cefazolin) when initiating CPB.5 
To account for this change, a separate CPB compartment was modelled, as previously 
suggested by Eaton et al.26 (Figure 1).
The volume of distribution of the CPB compartment was estimated to be equal to the 
priming volume and may suggest that there was little or no adsorption of drug to the 
polymeric components of the circuit. This is in contrast to earlier in vitro findings of 
moderate adhesion of cefazolin to paediatric extracorporeal membrane oxygenation 
(ECMO) circuits.27 Potential reasons include: (i) absence of a relevant effect due to shorter 
antibiotic-circuit contact times when compared with ECMO; and (ii) our data were too 
sparse to identify such a parameter. 
We were able to quantify concentration-dependent (saturable) cefazolin serum protein 
binding, with serum albumin concentrations as a covariate on maximum protein-
binding capacity in our paediatric population (Equation 1). This is in agreement with 
previous studies in neonates and adults.28–30 Following initiation of CPB, protein binding 
decreased significantly (p=0.02) (median ratio unbound fraction just before versus just 
after CPB: 0.88). A drop in albumin concentration (median = 25%; IQR = 19%-33%) due to 
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haemodilution, competition with other highly bound compounds and pH changes dur-
ing CPB may have contributed to this reduced protein binding.5 As pH values were not 
collected, pH changes could not be tested as covariate on protein-binding affinity (KD). 
A covariate model on unbound clearance including renal function (as estimated by 
eGFR) was finally chosen, which is in line with previously published adult pharmaco-
kinetic studies.31–35 It performed better than a model including a sigmoidal maturation 
function on clearance, a method that is commonly used in paediatric population 
pharmacokinetic modelling. In our opinion, the maturation model would mainly reflect 
maturation on renal clearance and would be more applicable to a stable patient popula-
tion, whereas our eGFR model is a more precise and direct measure of renal maturation 
and disease-driven alterations of renal function in a population with rapidly changing 
renal function. This is also in agreement with Illamola et al.,36 who compared renal func-
tion and age as predictors of amikacin clearance in neonates and showed that creatinine 
clearance predicted more BSV.
Worsening renal function during and immediately after CPB is common37,38 and leads 
to decreased renal drug elimination.6 In our patient population, eGFR decreased by a 
median of 24% during CPB (IQR = 17%-38%), after which it further decreased during 
the first post-operative hours by a median of 10% (IQR = 0.5%-15%). The reduced serum 
clearance of cefazolin resulted in more unbound drug being available for redistribution 
into tissues and the CPB circuit. A similar trend of reduced plasma clearance was previ-
ously observed for cefazolin and other renally cleared antibiotics in children during and 
after CPB.24,25 
In children undergoing CPB, only one small study (n = 12 patients weighing < 10 kg) on 
plasma unbound cefazolin pharmacokinetics has been published.9 Given the differences 
in weight range, priming solution volume and content, CPB circuit material, CPB proce-
dure (including hypothermia and pH management) and pharmacokinetic analysis, no 
valid comparisons of pharmacokinetics parameters between these studies can be made.
With regard to the potential toxicity of our optimized dosing regimens, it should be 
noted that we specifically chose not to evaluate doses greater than that currently rec-
ommended for children (50 mg/kg given as a bolus infusion), to avoid potential safety 
risks related to higher peak concentrations.39 Dosing regimens with prolonged infusion 
times were not tested as they were regarded as impractical in the operation theatre 
setting.40 The first alternative dose scenario (ADR1) included the same dosing times as 
the current paediatric and adult hospital dosing guideline; two alternatives (ADR 2 and 
ADR 3) included a supplemental dose at the onset of CPB. The rationale for this timing 
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was 2-fold: from a pharmacokinetic point of view, the start of CPB results in an increase 
in the distribution volume, leading to an immediate drop in antibiotic concentrations; 
from a more practical point of view, selecting a fixed timepoint during surgery might 
also reduce the risk of simply forgetting this extra dose (Table 1). 
Optimal targets for surgical prophylaxis wtih β-lactam antibiotics are currently un-
known.1 Because only a few surgical patients develop a wound infection, we used the 
conservative pharmacokinetic/pharmacodynamic target indices for antibiotic treat-
ment, given the immature immune response in younger children, the knowledge that 
CPB may contribute to immunoparesis and the broad therapeutic range of β-lactam 
antibiotics.41,42 Due to the higher chance of microbial contamination during surgery, 
a more conservative target (100% fT>MIC) was chosen for the perioperative period, 
compared to the immediate post-operative period (50% fT>MIC). Target attainment was 
evaluated within a 24 h window after skin incision, as longer post-operative antibiotic 
courses do not modify the SSI risk.1 
Our analysis challenges the current dosing regimen; for a typical (median) patient 
population and a MIC of 8 mg/L for staphylococcal infections, the PTA was between 
62% and 70% during surgery and between 89% and 98% after surgery (Figures 5, 6). 
The simulation studies also revealed that it was primarily the duration of surgical (CPB) 
procedure that reduced the likelihood of achieving optimal cefazolin exposure during 
surgery (Figure 5). This is in accordance with previously reported findings in adults.43 In 
this context, interestingly, various studies identified operative and CPB duration as an 
independent risk factor for SSI after paediatric cardiac surgery.44–47 None of these studies 
measured antibiotic concentrations. A potential relationship between subtherapeutic 
antibiotic prophylaxis and SSI was, however, confirmed in two studies in adults under-
going cardiac surgery.48,49 Although the present study was not powered to estimate an 
accurate incidence, one patient developed an SSI, which is within the reported range 
of 1.7-15 SSI per 100 cases.9 Deep sternal wound infections are serious complications 
leading to higher morbidity and mortality and maximal precautions should be taken to 
avoid them. Renal function, as estimated by the eGFR, also had a significant influence on 
PTA, mainly in the post-operative period (Figure 6). These results are also in agreement 
with previously published data in adults undergoing cardiac surgery.32 Although albu-
min concentration was identified as a covariate on protein binding and protein binding 
slightly decreased on initiation of CPB, varying albumin concentrations had a negligible 
impact on PTA.
For final dose selection, the PTA in both the peri- and post-operative period was evalu-
ated for patients with prolonged surgery combined with a minor drop in renal func-
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tion, as the risk of underdosing was considered of greater importance than potential 
overdosing with a compound like cefazolin, which has relatively low toxicity. In those 
scenarios, the combined PTA for the current dosing guideline was even lower (between 
40% and 54% for a MIC value of 8 mg/L) (Figure 7), thereby potentially leading to 
subtherapeutic treatment. Only the ADR3 with a higher initial dose (40 mg/kg) at induc-
tion and a supplemental dose at start of CPB (20 mg/kg) was deemed appropriate. One 
recent study investigating tissue cefazolin concentrations in infants (n = 12) undergoing 
CPB also suggested the use of such supplemental dose(s) as potential dose optimiza-
tion, although without distinct evaluation.9 Current international dosing guidelines 
on antibiotic prophylaxis for adults and children aged > 1 year recommend a single 
pre-incision dose (25-50 mg/kg) and a supplemental redosing interval of 4 h (i.e. two 
times the cefazolin half-life in adults) during prolonged surgery (or whenever there is 
extensive blood loss). According to this dosing scenario, and assuming that the half-life 
in children is equal to that in adults, only one patient in our study population would 
have been redosed during surgery. Evidently, this dosing regimen would result in an 
even lower PTA than the current SDR with fixed redosing at the start rewarming on CPB 
(PTA between 40% and 54% for conservative patient scenarios).
Tissue concentrations were not measured in our study. However, a fairly good tissue 
penetration was described in a comparable subgroup of infants on CPB and moderate 
hypothermia (n = 5), with remarkably similar plasma unbound and interstitial tissue 
concentrations (interstitial fluid to plasma unbound AUC ratio: 0.8-1.3).9 These tissue 
penetration characteristics for cefazolin were comparable to what has previously been 
observed in several adult studies.34,50-52 Moreover, unbound serum concentrations are 
also informative for antimicrobial efficacy, as blood can bathe the incision site and 
therefore provide antibiotic distribution at the possible site of infection. 
Our analysis is based on data from paediatric patients with mild to moderate hypother-
mia; therefore, these dose recommendations may not apply to conditions with deep 
hypothermic circulatory arrest. A ≥ 50% lower tissue penetration could be expected in 
this subpopulation.9 
Using creatinine-based Schwartz formula to accurately estimate GFR has some limita-
tions, especially in young and critically ill children.53 However, this is still a well-estab-
lished, bedside method and has been applied in studies of pharmacokinetics in critically 
ill children as well the pRIFLE criteria for defining acute kidney injury.54 
In conclusion, we demonstrated that the current paediatric dose recommendation of 
cefazolin in patients may result in subtherapeutic concentrations, especially in those 
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patients with preserved renal function and prolonged cardiac surgery. We provided a 
rational, model-based dose regimen improvement that increases the PTA in this at-risk 
subpopulation from 40% to >88% for infections with staphylococci. A prospective, ran-
domized controlled trial evaluating efficacy and safety for the optimized dosing strategy 
is warranted. 
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ABSTRACT 
Objectives: The objectives of this observational study were to investigate plasma pro-
tein binding and to evaluate target attainment rates of vancomycin therapy in critically 
ill children.
Patients and Methods: Paediatric ICU patients, in whom intravenous intermittent (ID) 
or continuous (CD) dosing with vancomycin was indicated, were included. Covariates 
on unbound vancomycin fraction and concentration were tested using a linear mixed 
model analysis and attainment of currently used pharmacokinetic/pharmacodynamic 
(PK/PD) targets was evaluated. Clinicaltrials.gov: NCT02456974.
Results: One hundred and eighty-eight plasma samples were collected from 32 pa-
tients. The unbound vancomycin fraction (median = 71.1%; IQR = 65.4%-79.7%) was 
highly variable within and between patients and significantly correlated with total 
protein and albumin concentration, which were both decreased in our population. Total 
trough concentration (ID) and total concentration (CD) were within the aimed target 
concentrations in 8% of patients. The targets of AUC/MIC≥400 and fAUC/MIC≥200 were 
achieved in 54% and 83% of patients, respectively. Unbound vancomycin concentra-
tions were adequately predicted using the following equation: unbound vancomycin 
concentration(mg/L) = 5.38 + [0.71 x total vancomycin concentration(mg/L)] – [0.085 
x total protein concentration(g/L)]. This final  model  was externally validated using 51 
samples from another six patients. 
Conclusions: The protein binding of vancomycin in our paediatric population was lower 
than reported in non-critically ill adults and exhibited large variability. Higher target 
attainment rates were achieved when using PK/PD indices based on unbound concen-
trations, when compared to total concentrations. These results highlight the need for 
protein binding assessment in future vancomycin PK/PD research.
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INTRODUCTION
The emergence of MRSA strains has led to an extensive use of vancomycin in the 
treatment of serious infections in critically ill children.1 Vancomycin is a glycopeptide 
antibiotic with a narrow therapeutic range.2 Achievement of pharmacokinetic (PK) 
and pharmacodynamic (PD) indices associated with maximum bacterial killing are 
recommended to increase the probability of clinical cure and decrease the likelihood 
of toxicity.2 Studies in adults have shown that the advocated PK/PD index of favour-
able clinical outcome is an AUC over a 24 h period in steady-state divided by the MIC of 
the suspected pathogen (AUC/MIC) of at least 400.3 Despite its use in children, clinical 
studies currently lack to validate this target value.4–6 In routine clinical practice, trough 
concentrations are used as a ‘surrogate’ parameter to optimize vancomycin dosing regi-
mens, because AUC/MIC calculations are labour- and cost-intensive.2,7 Both targets are 
based on total drug concentrations, whereas only the ‘unbound’ or ‘free’ drug exerts a 
pharmacological effect.8 A more direct fAUC/MIC target ≥200 has been advocated as PK/
PD target assuming a fixed unbound vancomycin fraction of 50%.2,9  However, critically 
ill children exhibit marked variability in plasma protein concentrations (with albumin 
concentration ranging between 15-54 g/L), which may alter the protein binding.10,11 To 
date, no studies have investigated the implications of altered protein binding on target 
attainment rates. 
The study had three aims: (i) to document plasma protein binding and factors that 
modulate the protein binding of vancomycin in critically ill children; (ii) to compare 
target attainment rates of three different currently used targets: total (trough) concen-




This two-centre, prospective, observational study enrolled children between 12 days and 
15 years of age, admitted to the ICU of the Ghent University Hospital (Ghent, Belgium) 
and Queen Fabiola Children’s University Hospital (Brussels, Belgium) between May 2012 
and April 2016 in whom intravenous vancomycin therapy was indicated, independently 
of the indication. 
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Ethics 
The research was conducted in accordance with the Declaration of Helsinki and approved 
by the Ethics Committee of Ghent University Hospital (EC2012/172). This study was reg-
istered at Clinicaltrials.gov (NCT02456974). Written informed consent was obtained from 
parents or a legally authorized representative and also from the patient themselves if older 
than 12 years. If patients older than 12 years were not able to give assent during the study, 
they were informed about their participation afterwards. Samples were only analysed if 
written patient informed consent was obtained; otherwise samples were destroyed.
Vancomycin treatment 
Patients received a weight-based dosing regimen [either intermittent dosing (ID) or 
continuous dosing (CD)] (Vancomycine Mylan®, Hoeilaart, Belgium; Vamysin Teva®, 
Wilrijk, Belgium; Vancomycine Actavis®, Gentofte, Denmark). Vancomycin doses were 
prescribed according to current institutional guidelines: ID of 15 mg per kilogram body 
weight was administered intravenously over 60 min four times daily; CD consisted of a 
loading dose of 15 mg/kg over 60 min, immediately followed by a maintenance dose of 
40 mg/kg over 24 h. Dosing regimens were adjusted using therapeutic drug monitoring 
(TDM) as part of routine clinical care. 
Samples 
In case of ID, blood samples were collected during first and/or assumed steady-state 
doses (at least after three administered doses). The total number of samples collected 
(per patient) was limited by the predefined total maximum blood volume permitted for 
PK sampling per individual patient, defined as 2.4 mL/kg bodyweight, according to the 
EMA guidelines.12 A full sampling scheme (ID) per dose included a sample just before 
dosing, a peak sample immediately after drug infusion, a sample between 60 min and 
180 min after the start of infusion, a mid-dose-interval sample 180 min after the drug 
infusion start time and a trough sample just prior to the next dose. For patients who 
received CD, samples were drawn at 12 h, 24 h and 48 h after the start of the loading 
dose. 
Patient data 
Patient data included age, gender, bodyweight, primary reason for admission, II (Paedi-
atric Risk of Mortality) score at admission and measures of organ function, and patient 
severity of illness as described by the PELOD (Pediatric Logistic Organ Dysfunction) 
score at day(s) of sampling. Data on drugs, with a plasma protein binding higher than 
80%, administered 12 h before sampling until the time of sampling were collected. Each 
blood sample collected for vancomycin measurement was also analysed for albumin, 
total bilirubin, urea and total protein concentration; other biochemical data (serum 
Vancomycin dosing in critically ill children 131
creatinine, serum C-reactive protein (CRP)) were collected from the routine laboratory 
measurements. 
Analytical methods 
Samples were collected in lithium-heparin tubes and centrifuged (1885 g, at 20°C 
for 8 min) on arrival in the laboratory within 60 min after sampling. The supernatant 
was separated immediately and frozen at -80°C until analysis. The unbound plasma 
vancomycin concentration was determined using a validated ultra-filtration method.13 
Therefore samples were incubated in a capped Centrifree Centrifugal Filter Device 
(Millipore, Billerica, MA) at 37°C for 30 min. The filter with a molecular weight cut off of 
30.000 Da was placed in a preconditioned Heraeus Labofuge 400 R Centrifuge (Thermo 
Fisher Scientific, Asheville, NC) and spun for 30 min (1885 g, at 37°C). Subsequently the 
vancomycin plasma concentrations were measured by the Architect i2000SR Plus analy-
ser (Abbott diagnostics, Illinois, US) using a validated chemiluminescence microparticle 
immunoassay technique. The lower limit of quantification for vancomycin was 3.0 mg/L, 
with an interassay coefficient of variation lower than 6.4%. The unbound vancomycin 
fraction was calculated using the following equation13:
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The funbound represents the unbound vancomycin fraction, Cultrafiltrate the vancomycin con-
centration in the ultrafiltrate and Cplasma the vancomycin concentration in plasma. Total 
protein (biurete), albumin (bromocresol green), creatinine (rate blanked, compensated 
Jaffe technique), t tal bilirubin (diazonium, colorimetric), urea (kinetic urease) and CRP 
(particle enhanced immunoturbidimetric) concentrations were performed on the Cobas 
8000 (c502/c701) analyser (Roche Diagnostics, Mannheim, Germany).  
Data analysis 
Statistical analysis was performed using SPSS Statistics version 22 (IBM, New York, USA). 
Normality of the data was visually confirmed by generating Quantile-Quantile plots. 
The potential covariate(s) on unbound vancomycin fraction and unbound vancomycin 
concentration were tested sequentially by forward inclusion in a linear mixed model 
analysis. In such a model the respons s fr m a subject are thought to be the sum of 
the fixed and random effects. These random effects only contribute to the covariance 
structure of the data. This model was used because more than one sample per patient 
was taken and the observations are therefor  depe dent. Evaluation of p-values and of 
the Akaike’s Information Criterion (AIC) score were used to select the models that were 
the best approximate of the reality given the recorded data. The total and unbound van-
comycin concentration, age, gender, bodyweight, biochemical data and co-medication 
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were tested as covariates on the unbound vancomycin fraction. Serum creatinine levels 
were in 25% of samples (45 samples) lower than the limit of quantification (<0.17 mg/
dl) and therefore could not be tested as potential covariate. The same covariates minus 
the unbound vancomycin concentration were tested on the unbound vancomycin 
concentration. Concerning the co-medication, each different drug was given a score of 
1 and the summations were included in the covariate analysis. A p-value of <0.05 was 
considered to indicate statistically significant difference. Correlation was assessed by 
means of a scatterplot and Spearman’s rank correlation coefficient. 
PK/PD target attainment analysis 
Evaluated PK/PD targets included total trough concentration between 10-15 mg/L (ID), 
total concentration between 20-25 mg/L (CD), AUC/MIC≥400, and fAUC/MIC≥200.2,3,7,14,15 
Samples taken after TDM-guided dosing were not included in the target attainment analy-
sis. For patients receiving ID the (f)AUC was calculated for total and unbound vancomycin 
concentrations using a non-compartmental analysis based on the log-linear trapezoidal 
rule with the PK Solver Excel add-in program (Microsoft Office Excel version 2013).17 The 
(f)AUC was calculated using steady-state condition samples by the following equation18: 
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The (f)aucfirst dose represents the (f)AUC over 6 h from the first dose interval and (f)
auc6h-∞ the extrapolated (f)AUC from 6 h to infinity. The AUC was not calculated if the 
extrapolated (f)auc6h-∞ to infinity exceeded 25% of the total (f)AUC and if less than four 
samples per dose interval were available, due to the risk for imprecise AUC calculations. 
For patients receiving CD the (f)AUC was calculated using the average of total and 
unbound vancomycin concentrations multiplied by a 24 h time interval. The AUC/MIC 
index was calculated presuming a MIC of 1 mg/L. 
Model validation 
The final prediction model for the unbound vancomycin concentration was validated 
using separate patient samples. In a Bland-Altman analysis the differences between 
calculated and measured unbound vancomycin concentration were plotted against 
the averages of calculated and measured unbound vancomycin concentration to iden-
tify outliers and consistent bias. Through a Passing-Bablok regression analysis of the 
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measured unbound vancomycin concentration and calculated unbound vancomycin 
concentration the systematic and proportional differences were evaluated. The analyses 
were performed using MedCalc version 16.4.3 (MedCalc, Ostend, Belgium).
RESULTS
Thirty-two patients were included resulting in a total of 188 plasma samples. All 
samples were analysed for total and unbound vancomycin concentration. Six samples 
were excluded from the analysis because there was an implausible result (unbound 
concentration being higher than total concentration). Demographic and clinical data, 
sampling characteristics and disease severity are summarized in Table 1. The median 
unbound fraction was 71.1% (IQR = 65.4%-79.7%) ranging from 49.4% until 98.1%. The 
median difference between the lowest and highest value of the unbound fraction within 
patients was 14.3% (IQR = 8.7%-18.9%) ranging from 3.1% to 41.8%. The median differ-
ence results are based on values from 31 patients, because one patient had only one 
sample. Saturation of plasma protein binding did not occur within the range of clinically 
achieved concentrations. Pathogens were isolated in nine patients and included seven 
Staphylococci infections, one infection with Streptococcus pyogenes and one infection 
with Enterococcus faecalis.
Mixed model analysis on unbound vancomycin fraction 
Total protein (p<0.001) and albumin concentration (p<0.001) were found to be signifi-
cant covariates on the unbound fraction. 
PK/PD target attainment evaluation (Figure 1 and 2)
We evaluated 32 trough samples for patients who received ID and 6 samples for patients 
who received CD. The median total trough (ID) and total concentrations (CD) were 6.7 
mg/L (IQR = 4.7-8.7 mg/L) and 14.5 mg/L (IQR = 10.2-18.7 mg/L), respectively. Only three 
trough samples (ID) achieved the target range (one after first dose and two after steady-
state dose) and all of the measured total concentrations (CD) were below the target 
range. For 24 patients the (f)AUC was accurately calculated (8 were excluded as the AUC 
could not be precisely calculated). The median AUC/MIC and fAUC/MIC were 425 (IQR = 
293-497) and 294 (IQR = 222-357), respectively.
Mixed model analysis on unbound vancomycin concentration
The model with total vancomycin (p<0.001) and total protein concentration (p=0.001) 
(AIC:790) performed slightly better than the model with total vancomycin (p<0.001) and 
albumin concentration (p=0.008) (AIC:792); including a third covariate did not lead to a 
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Table 1. Demographic, clinical, treatment and sampling characteristics of patients.
Demographic
Study group Validation group
Value for characteristicb
Number of patients 32 6
Number of samples 182 51
Male 18 (56) 3 (50)
Female 14 (44) 3 (50)
Age (years) 4.1 (1.3-6.3) 9.0 (1.9-15.7)
Weight (kg) 17 (10-23) 30 (13-64)
Clinicala Value for characteristicb






Primary reason for ICU admission
         neurologic 7 (22) 2 (33)
         cardiovascular 7 (22) 0 (0)
         respiratory 6 (19) 0 (0)
         postoperative 3 (9) 1 (17)
         gastro-intestinal 2 (6) 3 (50)
         other 7 (22) 0 (0)
PELOD scorec,d 1 (0-11) 0 (0-0)
Empirical start 23 (72) 5 (83)
Number of co-medicatione 2 (1-3) 3 (1-4)
Albumin concentration (g/L) 30.6 (26.9-33.8) 36.5 (33.2-39.0)
Total bilirubin concentration (mg/dL) 0.21 (0.16-0.35) 0.46 (0.27-2.81)
Urea (g/L) 18.3 (11.4-24.5) 25.5 (19.5-32.2)
Total protein concentration (g/L) 55.8 (49.8-60.9) 62.3 (56.3-68.3)
Serum creatinine d (mg/dL) 0.22 (0.19-0.29) 0.34 (<0.17-0.48)
Serum CRP d (mg/L) 48.2 (11.4-138.1) 33.5 (25.0-79.6)
Total vancomycin concentration (mg/L) 16.6 (8.7-30.3) 17.0 (12.9 – 21.2)
Unbound vancomycin concentration (mg/L) 12.2 (6.2-21.7) 12.5 (8.0-15.3)
Unbound vancomycin fraction (%) 71.1 (65.4-79.7) 71.8 (63.1-77.1)
Treatment and Sampling Value for characteristicb
Length of vancomycin therapy (days) 6 (4-9) 9 (5-10)
Intermittent dosing
         Number of patients 29 (91) 4 (67)
         Number of samples 176 (97) 34 (67)
         Collected samples per dose 5 (4-5) 5 (4-5)
Continuous dosing
         Number of patients 3 (9) 2 (33)
         Number of samples 6 (3) 17 (33)
         Collected samples per patient 2 (2-2) 9 (6-11)
aAbbreviations: PRISM, Pediatric Risk of Mortality; PELOD, Pediatric Logistic Organ Dysfunction; CRP, C-
Reactive Protein.  bValues are median (IQR) or number (percentage). cBased on values from 26 patients for 
study group and all patients for validation group. dAt day(s) of sampling. eBased on values from all samples 
of the study group and 43 samples of the validation group.
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better fi t of the data. The unbound vancomycin concentration in our patient population 
could be predicted by the following equation: 
cunbound = 5.38 + (0.71 × ctotal) - (0.085 × ctp)
In this equation cunbound represents the unbound vancomycin concentration (mg/L), ctotal 
the total vancomycin concentration (mg/L) and ctp the total protein concentration (g/L). 
Model validation
The prediction model for the unbound vancomycin concentration was validated using 
another six patients (51 samples). Demographic and clinical data of the validation group 
are summarized in Table 1. The median total vancomycin and total protein concentration 
were 17.0 mg/L (IQR = 12.9-21.2 mg/L) and 62.3 g/L (IQR = 56.3-68.3 g/L), respectively. Excel-














Total trough concentration (mg/L)
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Figure 1. Correlation between total trough concentrations and (f)AUC/MIC for patients who received ID (n 
= 21). The broken line indicates the target AUC/MIC of 400, the continuous line indicates the target fAUC/
MIC of 200, fi lled circles represent the calculated AUC/MIC and open circles represent the calculated fAUC/
MIC. Spearman’s rank correlation coeffi  cients: AUC/MIC, R = 0.85 (p<0.01); and fAUC/MIC, R = 0.82 (p<0.01). 
Twelve (57%) patients reached the AUC/MIC of 400 (above the broken line) and 17 (81%) patients reached 
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Slope: 0.97 (95% CI: 0.94-1.01) 
Intercept: 0.26 (95% CI: -0.27-0.55) 
Figure 3. A Passing-Bablok regression analysis of the measured unbound vancomycin concentration and 
calculated unbound vancomycin concentration for 51 samples from 6 patients. The solid black line repre-
sents the Passing-Bablok regression line (Y = 0.26 + 0.97X), the two dashed grey lines represent the 95% 















Figure 2. Target attainment based on AUC/MIC and fAUC/MIC for patients who received ID (n = 21) and 
CD (n = 3). The vertical broken line indicates the target AUC/MIC of 400 and the  horizontal continuous line 
indicates the target fAUC/MIC of 200. Spearman’s rank correlation coeffi  cient: R = 0.88 (p<0.01). Thirteen 
(54%) patients reached the AUC/MIC of 400 (fi rst quadrant), 20 (83%) patients reached the fAUC/MIC of 200 
(fi rst and second quadrant) and 4 (17%) patients did not reach the (f)AUC/MIC (third quadrant). 
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shown in Figure 3 and Figure 4 showed no proportional or systematic bias. The mean dif-
ference was 0.13 mg/L with the limits of agreement being -2.6 mg/L to 2.9 mg/L (Figure 4). 
DISCUSSION
The present study revealed that protein binding of vancomycin in critically ill children is 
comparable to what has been described in critically ill adults, but is substantially lower 
in comparison to healthy volunteers and non-critically ill adults (50%-55%).13,19,20,21 The 
lower vancomycin binding may be explained by diff erences in protein concentrations 
as we found that protein binding depended on total protein concentrations (of which 
albumin is the most important fraction). Both total protein (range = 21.1-74.2 g/L) and 
albumin concentrations (range = 14.2-45.1 g/L) were decreased in our study popula-
tion and exhibited a marked variability.10,11,22 Oyaert et al.19 observed a similar trend of 
reduced protein binding in children, when compared to adults. Besides the observation 
of reduced protein binding a considerably high intra- and intervariability in protein 
binding was found. 
As protein binding was altered and highly variable, our study aimed to compare target 
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+1.96 SD: 2.9 
95% CI: 2.2 to 3.6 
Mean: 0.13 
95% CI: -0.27 to 0.52 
-1.96 SD: -2.6 
95% CI: -3.3 to -2.0 
Figure 4. A Bland-Altman analysis of the diff erences between calculated and measured unbound vanco-
mycin concentration were plotted against the mean of calculated and measured unbound vancomycin 
concentration. The solid black line indicates the mean diff erence, solid grey represents the line of equality 
and the two dashed black lines denotes upper and lower limits of agreement. SD: Standard deviation. 
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and (f)AUC/MIC. The most commonly used PK/PD parameter, i.e. total (trough) concen-
tration, was within the aimed target ranges in only 8% of cases. Since trough concentra-
tions of 10-15 mg/L are believed to be a good surrogate to achieve an AUC/MIC≥400, 
it would be reasonable to assume that the latter target would not be achieved in the 
majority of patients.2 However, our study revealed that an AUC/MIC≥400 was achieved 
in 54% of patients. Total trough concentrations correlated well with the calculated AUC/
MIC (R = 0.85) and a total trough concentration of ~7 mg/L corresponded to an AUC/MIC 
of 400. This is in agreement with two previous studies in children, which predicted that 
achievement of an AUC/MIC of 400 (assuming MIC = 1 mg/L) corresponded with lower 
trough concentrations (8-10 mg/L) due to altered PK.23,24 More importantly, our target 
attainment analysis showed that in the same group of patients, the fAUC/MIC≥200 
target was reached in an even larger proportion (83%) of our study population. The 
fAUC/MIC target reflects directly the exposure to the unbound pharmacologically active 
concentration. Consequently, attempts to achieve the AUC/MIC target of 400, for the 
29% of cases who already achieved the fAUC/MIC target, may not result in additional 
clinical benefit but may lead to unnecessary drug exposure and potential toxic effects 
(Figure 2; quadrant 2). 
Despite the fAUC/MIC target value of 200 being a more arbitrary goal, based on the most 
conservative and fixed protein binding of 50%, to our knowledge there is no superior 
alternative target available.9 In each case, these findings question the magnitude of 
underdosing as suggested in previous studies, which only used total trough concentra-
tion and AUC/MIC for target attainment analysis.7,25,26 In clinical practice, monitoring 
vancomycin exposure by fAUC (with MIC if available), and thereby taking into account 
the protein binding, might be a more justified target to prevent underdosing or overex-
posure. Furthermore, given the high variability in protein binding in our study popula-
tion, it seems not advisable to assume a fixed unbound fraction to calculate this fAUC/
MIC ratio. In this heterogeneous population with different types of infection we were 
able to accurately predict the unbound vancomycin concentration in plasma based on 
total vancomycin and total protein concentration. 
Our study has a number of limitations to consider. First, we did not determine actual 
vancomycin MIC values to accurately calculate the (f)AUC/MIC, mainly because in 72% 
of cases therapy was started empirically. Instead, we used a commonly used MIC break-
point of 1 mg/L to compare target attainment with previous study results.23,24 Second, 
a small number of subjects on CD were included, so no definite conclusions could be 
drawn with regard to target attainment. Third, tissue concentrations were not measured 
and higher targets may be needed to ensure adequate penetration in tissues. 
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In conclusion, our study demonstrates that the unbound vancomycin fraction in our 
population is higher than generally assumed, exhibiting high intra- and intervariabil-
ity. The number of patients achieving target vancomycin concentrations varied widely 
depending upon the type of PK/PD target used. These results argue against currently 
used PK/PD indices for making quantitative exposure-response assessments in critically 
ill children. Further clinical and bacteriological outcome studies should be performed in 
specific populations to define appropriate PK/PD indices based on unbound concentra-
tions. We provided a validated prediction tool for unbound vancomycin concentrations 
and offer an easy alternative for measuring unbound concentrations in clinical practice. 
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The response to drugs may be different in neonates, infants and children when com-
pared to adults. These differences are mainly caused by differences in PK and/or PD. From 
birth up to adulthood, maturational changes in body composition, drug metabolising 
enzymes, cardiac output, blood flow, function of eliminating organs and functionality/
expression of drug receptors occur, leading to major changes in disposition and effect 
(Chapter 1, Figure 1).1,2 Moreover, both disease and treatment can also affect drug PK 
and PD (Chapter 1, Figure 2).3
Notwithstanding the improvement in paediatric drug research 10 years after implemen-
tation of the European Regulation, drug dosing in critically ill children remains a real 
challenge. To date, the impact of major pathophysiological (e.g. sepsis) and treatment 
related changes on PK/PD are rarely studied.4 Finally, off-patent drugs remain completely 
orphaned in terms of evidence-based dosing.4,5
Given the ethical issues and practical constraints (e.g. limited number of blood samples) 
trials in critically ill children are more difficult to perform.6–9 The introduction of M&S 
tools in drug research (e.g. mixed effects modelling) enabled the analysis of sparse and 
unbalanced datasets, thereby opening new horizons for paediatric drug research.10–13 
In this doctoral dissertation, the disposition and target attainment of four intravenous 
antibiotics and two BLIs were studied in critically ill children (using mixed effects model-
ling), with the aim to develop evidence-based dosing regimens. The antibiotics were 
selected based on their frequency of use in combination with their empirical use in clini-
cal practice. Here, we critically appraise the relevance and limitations of our research and 
reflect on future perspectives, also in a broader international context.
What have we learnt from these studies?
In Chapter 3, the population pharmacokinetics of the β-lactam antibiotic amoxicillin in 
combination with the BLI clavulanic acid were studied in 50 critically ill children. After 
scaling for size and age, renal function was identified as a significant covariate on the 
clearance of both compounds. Treatment with vasopressors was also associated with 
a 18% reduced amoxicillin clearance. Stochastic simulations showed that lower CysC 
resulted in a lower PTA and that at least four hourly dosing of 25 mg/kg (based on 
amoxicillin; as a bolus infusion for CysC > 1mg/L or 1 hour infusion for CysC< 1 mg/L) 
was required to achieve the therapeutic target (40% fT>MIC). This is, to the best of our 
knowledge, the first population PK study on amoxicillin/clavulanic acid, and the first to 
detect augmented renal clearance in this patient population, with serum CysC used as a 
novel predictor for renal drug clearance. 
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The PK of the piperacillin/tazobactam combination was characterized in 47 critically ill 
children in Chapter 4. To account for size and maturation, allometric scaling and a Hill 
function on clearance were implemented. Also here, high individual clearances were 
identified in some patients, which prompted to a change in regimen with more frequent 
dosing to ensure optimal piperacillin exposure (60% fT>MIC). Monte Carlo simulations 
showed that an intermittent infusion of 75 mg/kg (based on piperacillin) given four 
hourly over 2 hours, 100 mg/kg given four hourly over 1 hour or a loading dose of 75 
mg/kg followed by a continuous infusion of 300 mg/kg/24h were minimally required to 
achieve the therapeutic target. 
Chapter 5 described the population PK and protein binding of cefazolin in 56 children 
undergoing cardiac surgery before, during and after CPB. Besides body weight which 
accounted for the change in size, eGFR was identified as a covariate on clearance. An 
increase in the volume of distribution was identified during CPB and modelled using 
a separate CPB compartment. Moreover, saturable plasma protein binding of cefazolin 
was quantified with serum albumin concentration as a covariate on maximum protein 
binding capacity. Prolonged surgery and preserved renal function had a negative im-
pact on PTA. When aiming at target concentrations of 100 % fT>MIC during and 50% fT>MIC 
shortly after surgery, more frequent and higher dosing appeared to be needed (40 mg/
kg, 30 min before surgical incision; 20 mg/kg, at start of CPB; 20 mg/kg, at the start of 
rewarming on CPB; 40 mg/kg, 8 h after the third dose; 40 mg/kg 8 h after the fourth 
dose). This is, to the best of our knowledge, the first population PK study on cefazolin in 
children undergoing cardiac surgery with cardiopulmonary bypass. 
In Chapter 6, a pilot study on the role of plasma protein binding and impact on target 
attainment of vancomycin in 38 critically ill children was performed. Our study revealed 
that the unbound fraction was comparable to what has been published in critically ill 
adults, but substantially lower in comparison with healthy volunteers and non-critically 
ill adults. Furthermore, protein binding was highly variable and correlated with plasma 
protein concentration, which was also decreased and exhibited large variability. Target 
attainment rates were also compared in this study using different proposed PK/PD tar-
gets based on total and unbound concentrations. We found that trough concentrations 
and (f )AUC correlated well with each other but that target attainment rates were largely 
dependent on the individual target: 8% within the trough concentration range of 10-15 
mg/L, 54% reaching an AUC/MIC of 400, and 83 % reaching a fAUC/MIC of 200. To the 
best of our knowledge, this was the first study to evaluate plasma protein binding and 
target attainment based on unbound concentrations in critically ill children.
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All studies described above clearly illustrate that, besides developmental changes, 
co-treatment modalities (e.g. vasopressors, CPB), altered organ function (e.g. hyper-
filtration) and other disease related changes (e.g. protein binding) always need to be 
considered as potential covariates on drug disposition. Moreover, whilst performing the 
clinical trials, we concomittantly evaluated how renal function (Chapter 3, 4, 5) and 
protein binding (Chapter 5,6) change in these patient populations. These data can be 
incorporated in future PK/PD research using more (semi-)mechanistic approaches (e.g. 
physiologically-based pharmacokinetic modelling). 
The leitmotiv through the methodology section in our studies was the use of a mixed 
effects modelling approach for analysis and interpretation of the results. Despite the 
widespread acceptance of population pharmacokinetic methods in the drug ap-
proval process, relatively few population pharmacokinetic studies have been conducted 
among critically ill children.3,11,14 From our studies we can conclude it was a powerful 
tool to analyse unbalanced (and in some patients sparsely collected) data. Through this 
approach we were able to propose evidence-based dosing regimens (Chapter 3, 4, 5) 
and identify covariate factors on protein binding (Chapter 6). 
What are the direct clinical implications on drug dosing and monitoring?
Since fatal tragedies happened in the past (e.g. gray baby syndrome due to chloram-
phenicol overdosing), physicians are more prudent to prescribe drugs to children, in 
the absence of evidence-based paediatric dosing guidelines.15,16 As they are mostly 
concerned about the potential toxicity risks of drug overdosing, currently, paediatricians 
often tend to prescribe the “lowest known effective dose”. In particular with regard to 
renally excreted drugs, paediatricians are traditionally more focussed on the potential 
impact of renal failure on drug levels than on the consequences of augmented renal 
clearance. However, our study results on β-lactam antibiotics in critically ill children 
(Chapter 3, 4 and 5) demonstrated that the current dosing recommendations do not 
always apply to this dosing paradigm. To avoid subtherapeutic treatment in our patient 
population, new dosing regimens were suggested using a shorter dosing interval with 
a higher cumulative daily dose, taking into account the PK/PD parameter of interest i.e. 
fT>MIC. 
On the other hand, higher doses may not always be necessary and special attention 
is warranted for drugs with a smaller therapeutic range than β-lactam antibiotics. In 
the case of vancomycin, the most commonly proposed target PK/PD parameter for 
beneficial clinical outcome in adults is an AUC/MIC of 400.17 Total trough levels of 10-15 
mg/L are aimed for as a proxy for an AUC of 400, assuming a MIC <= 1 mg/L.18 Recently, 
Le et al. demonstrated a strong relationship between higher AUC and the occurrence 
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of nephrotoxicity.19 Vancomycin trough levels >=15 mg/L and AUC >=800 mg.h/L 
were also independently associated with a 2.5 and 3.7 fold increased risk, respectively. 
Furthermore, ICU stay and concomitantly receiving nephrotoxic agents were found to 
significantly increase the absolute risk. While the above mentioned threshold values are 
still substantially higher than the highest AUC and trough level observed in our study, 
these results highlight the importance of precision dosing. From our pilot results, we 
could confirm previous findings which showed that, in routine clinical practice, lower 
target trough levels (~7-10 mg/L) were required to reach an AUC/MIC of 400 (Chapter 
6). Furthermore, since only the unbound drug is pharmacologically active and a con-
servative target of fAUC/MIC of 200 was reached in the majority of patients, our results 
question the previously claimed magnitude of underdosing.20–22 Further clinical and 
bacteriological outcome studies should be performed to define appropriate PK/PD tar-
gets. Finally, we provided a validated prediction tool for unbound concentrations based 
on total vancomycin concentrations and offer hereby an easy alternative for measuring 
unbound concentrations in clinical practice. 
In summary, the findings in this PhD dissertation contributed to the knowledge on fac-
tors influencing antibiotic disposition and dose optimisation in seriously ill neonates, 
infants and children. 
What are the limitations and future perspectives of this research?
Model validation
All PK models within this PhD dissertation are internally validated, as described under 
the methods section of each chapter. Preferentially, the population PK/PD models 
should also be validated using data from another similar patient population before 
implementation into the clinic.23 This external validation step is particularly important to 
ensure that the model reflects the parameter distributions in the overall population and 
is not only descriptive for the study sample of patients. Ideally, a subsequent prospective 
validation of the new dosing regimen is performed in another set of patients to make 
sure the desired target concentrations are reached and dosing regimens are safe.11,24 
As described in Chapter 6, external validation of the model describing the unbound 
vancomycin concentration was performed using data from another 6 patients. 
However, it was decided to implement our revised β-lactam dosing regimens before 
such validation data are available, after having rigorously outweighed potential benefits 
and risks: (i) there is evidence that subtherapeutic antibiotic dosing leads to clinical 
failure and extra morbidity and mortality; (iii) β-lactam antibiotics have a broad thera-
peutic range and toxicity with a high dose of amoxicillin/clavulanic acid, piperacillin/
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tazobactam and cefazolin is not frequently reported in adults. However, proper safety 
data on (intensified) dosing in (critically ill) children are currently lacking; (iii) we have 
specifically chosen not to select higher amounts per dose than currently recommended 
to mitigate potential safety risks related to higher peak concentrations; (iv) we aimed for 
rather conservative fT>MIC targets in the case of amoxicillin/clavulanic acid (40% fT>MIC) 
and piperacillin/tazobactam (60% fT>MIC); (v) the total treatment duration for surgical 
prophylaxis with cefazolin is limited to 24 hours.25,26
Extrapolation 
Notwithstanding the relatively high number of younger patients included in our stud-
ies, PK data from additional neonates and infants are needed to estimate maturation 
parameters more precisely on clearances of amoxicillin, piperacillin, clavulanic acid and 
tazobactam and refine the dosing regimens in these age categories (Chapter 3, 4). Fur-
thermore, our study results (including proposed dosing regimens) may not apply to pa-
tients with characteristics that differ from our patient population. Additional studies are 
therefore required to study the impact of moderate to severe kidney injury, severe burn 
injuries, ECMO, RRT, body cooling and septic shock on antimicrobial pharmacokinetics. 
Bio-analytical aspects
Differences in pre-analytical sample handling (e.g. ultrafiltration for separation of un-
bound and bound antibiotic) and interassay variation in antibiotic measurement, can 
lead to large differences in measured (unbound) concentration and may compromise 
the applicability of the PK/PD model in other clinical settings.27 Stove et al. identified 
temperature as a critical variable during ultrafiltration for determining unbound van-
comycin concentration and concluded that 37°C should be preferred for temperature 
stable compounds.28 Oyaert et al. and Samardzic et al. demonstrated a disconcordance 
in vancomycin concentration measurement up to 20 % when comparing different 
vancomycin assays.29,30 In our study on vancomycin plasma protein binding (Chapter 
6), the unbound vancomycin fraction was approximately 10% lower than described by 
Oyaert et al. in non-critically ill children, despite comparable albumin and total protein 
concentrations. Apart from dissimilarity in patient characteristics and sample size, pre-
analytical and analytical variation may explain this difference. These methodological 
issues may also be applicable to our study measuring unbound cefazolin concentrations 
in children on CPB (Chapter 5); however similar clinical studies are currently lacking.
The generalisability of our results also depends on the similarity of assays used for CysC 
and creatinine. In Chapter 3, CysC as a marker of renal function was found to be a covari-
ate on amoxicillin and clavulanic acid clearances. Currently, this promising biomarker 
is not commonly used in routine practice and several commercially available measure-
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ments remain unsatisfactory in terms of calibration to the European reference material 
of the international federation of clinical chemistry and laboratory medicine (ERM-D471/
IFCC). .31 In Chapter 5, serum creatinine was used to calculate an eGFR based on the 
modified Schwartz formula. Serum creatinine was measured using the (Isotope Dilution 
Mass Spectrometry traceable) compensated Jaffe method and recalculated towards en-
zymatic values, as this is currently the most advocated method in children.32,33 Although 
these corrected creatinine values have shown a large interchangeability with enzymati-
cally measured serum creatinine for children between 3 and 14 years, the applicability 
might be lower depending on the patient age and the type of creatinine assay used.23,32 
Although serum creatinine is still frequently used as a renal biomarker, in two of our 
studies, we were not able to test serum creatinine as a covariate on clearance (Chapter 3, 
4), due to a large proportion of values remaining below the quantification limit. Analyti-
cal challenges (overcorrection of interfering protein in the compensated assay) as well 
as augmented renal clearance of this biomarker were suggested as potential causes. 
Consequently, future assessment of serum creatinin as covariate in PK studies should 
include a more sensitive enzymatic creatinine assay.33 Furthermore, alternative renal 
biomarkers (e.g. serum cystatin C, beta-trace protein) and new GFR estimation methods 
(e.g. derived eGFR formula, urinary creatinine clearance) are to be further explored as 
covariate on drug clearance in critically ill children. 34–37
In Chapter 3 and 4, total drug concentrations were measured and mathematically 
corrected for protein binding. Although small changes of low protein bound drugs are 
thought to only have a minor effect on the unbound concentration, a direct measure-
ment of unbound drug concentrations may still be more advantageous for PK/PD studies 
in children with highly variable protein binding, as illustrated for vancomycin in Chapter 
6. Also the 2015 draft EMA guideline on the use of pharmacokinetics and pharmacody-
namics in the development of antibacterial medicinal products explicitly states that PK/
PD indices should be expressed as a function of unbound concentrations.38
PK/PD relationship – risk/benefit ratio
For our dosing recommendations, antibiotic target attainment was evaluated against 
commonly used summary PK/PD target indices (Chapter 3, 4, 5, 6), using MIC values 
that were not prospectively collected. Instead, commonly used (Chapter 6) or worst-
case MIC scenarios (Chapter 3, 4, 5) based on EUCAST clinical breakpoints were chosen. 
Although this is still the most commonly used method for dose evaluation, we recog-
nise that these indices are only simplifications of the underlying PK/PD relationship. 
Many drawbacks have been described and mainly relate to the lack of measurement 
of time-related PD effects and inaccuracy in MIC determination. Moreover, it carries 
Discussion And Future Perspectives 151
the assumption that target PK/PD indices are not affected by differences in PK, dosing 
regimen and bacterial susceptibility.39,40 Therefore, the building of more sophisticated 
mechanistic PK/PD models is encouraged by the EMA and should be the next step in 
our antibiotic dose optimisation process.38 In these models, typically, the PK is linked 
to the microbiological response over time (growth and killing rate of bacteria) from in 
vitro or animal infection experiments, taking into account the development of antibiotic 
resistance, the immune response from the host and/or the magnitude of the inoculum 
(Figure 1).39 Ideally, effects and side-effects over time of the antibiotic treatment are 
modelled using data from real patients to assess benefit-risk ratios. Measurement of 
bacterial killing and development of antimicrobial resistance over time, however, is 
still a challenge and valuable biomarkers are currently lacking. Ultimately, the impact 
of model-based dose optimisation on morbidity and mortality should be investigated 
in a blinded, randomised controlled trial design comparing both the ‘old’ and ‘revised’ 
dosing regimens. These kind of studies require patient recruitment on a large scale.
Figure 1 : Role of preclinical infection models, PK/PD modelling and clinical PK studies to optimise dosing in 
critically ill patients (Reproduced with permission from Tängdén T. et al.41 , Copyright SpringerOpen)
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In our PK/PD studies on amoxicillin/clavulanic acid and piperacillin/tazobactam (Chap-
ter 3 and 5), we used very crude fT>threshold measures in an attempt to evaluate the BLI 
dose. Hence, we are aware that the corresponding PTA results for BLI are only explorative 
in nature and further in vitro and animal PD studies are needed to define the target in 
infections of interest.38,42,43 Initially, BLI dose fractionation studies are needed to identify 
indices with maximum activity (Cmax/MIC, AUC/MIC, fT>MIC). Subsequently, as described 
above for antibiotic components, mechanistic modelling to include the time course 
of bacterial killing and the conduct of clinical studies are encouraged (Figure 1). In all 
those studies, administration of β-lactam compounds should mimic its clinical use as 
PK/PD indices for BLI may depend on the β-lactam antibiotic dosing regimen.
Establishing BLI targets in future studies will enable to further adapt dosing recommen-
dations using our PK data.
Tissue penetration
We studied serum/plasma PK in heterogeneous groups of children, with regard to pos-
sible differences in tissue involvement/penetration. In patients with compromised tissue 
penetration, higher doses may be needed to ensure adequate treatment. Further studies 
should focus on these aspects. Microdialysis enables direct measurement of antibiotic 
concentrations in the interstitial space and has gained a lot of popularity in the last few 
years.40,44 Using this technique, a microdialysis probe is first inserted in the interstitial 
space of the target tissue, after which, a carrier fluid is infused at a fixed rate through this 
probe, which is then collected outside the body. The outer wall of the probe consists of a 
semi-permeable membrane allowing the antibiotic to diffuse from the interstitual fluid 
toward the carrier fluid. Tissue antibiotic concentrations are subsequently measured at 
prespecified time intervals in aliquots of the dialysate. Despite the technical challenges 
and invasiveness of the technique, it has been successfully used to measure cefazolin 
skeletal muscle concentrations in children undergoing cardiac and spinal surgery.45,46 
 What is the broader context of this research?
Some future perspectives of our research deserve attention in a broader context. As 
encountered in our studies, performing clinical research in an ICU environment is chal-
lenging. Below, we identify priorities and discuss promising developments to improve 
and accelerate pharmacological research within the NICU/PICU environment.
Networking and collaboration
In the 10-year EMA report on the paediatric regulation, the lack of sustained funded 
research infrastructure, coordination of research activities at a network level, and aware-
ness of existing networks to the industry were identified as some of the main hurdles to 
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tackle.4 As we encountered in our studies, this is especially the case for the ICU setting, 
due to the high population heterogeneity and the relatively low number of admissions 
per single centre. 
To date, few (inter)national research networks, addressing the specific pharmacological 
needs of critically ill children, exist. The Foundation Paediatric Intensive Care (Stichting 
Kinder Intensive Care) is an example of a national academic research network in the 
Netherlands between 8 paediatric intensive care units in which, currently, 2 medication 
trials were initiated. Within Europe, only the European Society on Neonatal and Paediat-
ric Intensive care medicine Research Network (ESPNIC) is a dedicated research network 
recognized by the European network of paediatric research and specialist networks at 
the EMA (Enpr-EMA). Currently, no collaborative medication trials were initiated yet 
within this ESPNIC network. In the future, such sustainable collaborative research efforts 
should be more actively encouraged as they undoubtedly increase patient recruitment. 
Furthermore, they may raise more awareness amongst regulatory agencies for this vul-
nerable subpopulation and challenge the pharmaceutical industry to the setup of more 
clinically relevant research in critically ill children. 
Essential for the prosperity of such multicentric collaborations, will be a more stream-
lined ethics board review and harmonised informed consent and assent procedure to 
guarantee a same level of information, protection from risks and potential benefit of the 
drug between trial participants.47,48
Ethical conduct – trial participation
Ethically performing research is of utmost importance, including the requirement of a 
high standard of informed consent. NICU/PICU researchers, however, may face several 
practical barriers to implement a valuable informed consent, as described in Chapter 1. 
Although the informed consent procedure was conducted with maximal integrity, some 
of these problems were also encountered in our studies. Regularly, parents (or legal 
guardians) were informed and asked to participate in fraught circumstances, shortly 
before or after an antibiotic was administered, leaving them a relatively short timeframe 
to decide whether they wanted their critically ill child to participate or not. In some 
patients, trial participation was not considered as the treating physician felt not comfort-
able with asking for informed consent (e.g. highly perceived emotional parental stress, 
language barrier, complex family situation, child that was too sick etc). Excluding these 
patients holds a risk of impairing the validity of study results because of selection bias. 
In this context, Garde et al. clearly indicated room for improvement as only one third of 
clinical trials in critical care reported on consent rates.49 Moreover, children included in 
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our studies were only asked to give assent, if they were older than 12 years of age and 
physically capable, at a convenient time at the discretion of the treating physician. In 
most patients, this was only possible a while after inclusion, when the child’s clinical 
condition enabled to do so. Only the study described in Chapter 5 was an exception 
in that sense that the study could be proposed by the treating surgeon in less stressful 
conditions, the day before cardiac surgery.
All these hurdles illustrate the limitations of the standard consent and assent procedure 
in this setting and highlight the importance of alternative strategies to be studied. 
Essential to improve this process in terms of voluntariness and patient recruitment, is 
the input of parents and children on both procedures and trial design.50 To date, the 
insight in encouraging and discouraging factors for participating in drug research in the 
NICU/PICU is, however, rather small and sometimes conflicting.51 Characteristics of the 
consent encounter, individual parent, child and study have been reported to be related 
to the decision making process.50 
Regarding the timing and modalities of consent and assent, some alternative options 
to the standard method have been proposed. Allmark et al. demonstrated that a step-
wise designed parental consent procedure improved the quality of the consent in a 
randomised, controlled trial in critically ill neonates.52 In this approach, a selection of 
crucial information is given before asking for consent to enrol the patient, due to the 
time constraints and potential impaired ability of parental decision making. As time 
goes on, more detailed information and explicit choice to opt out is given, both on a 
continuous basis. Deferred consent is another method to deal with the emergency of 
decisions to be taken in an acute care setting like NICU/PICU and implies that the con-
sent is requested after the patient is recruited. This approach is currently only allowed 
when, owing to the urgency of the treatment and the trial, it is impossible to obtain 
prior consent from the patient or legal representative, provided that an ethics commit-
tee has given its approval.53 Preliminary research suggests that parents can appreciate 
this way of consenting, if appropriately timed and explained.54–56 A waiver of consent is 
another method and implies that consent is not required. To date, this method has only 
been used in paediatric resuscitation research. Many of these studies used community 
consultation and public disclosure on the unit to inform parents and caregivers that 
children could be enrolled in a clinical trial.57,58 Overall, there is a reluctance of caregiv-
ers and parents towards this practice. Innovations in communication technology may 
also contribute to solving some issues with the informed consent process. The newest 
method is the so-called ‘dynamic consent’ in which online communication platforms 
(e.g. video calls, webinars, websites) are used for personalised consenting.59 Usually, it is 
designed to facilitate the dialogue between researchers and parents (or children) before, 
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during and after the study through online communication. It also enables the parents or 
children to refine their consent to specific parts of the study (e.g. data sharing with drug 
companies) or change it at any time. Finally, such platforms may offer the possibility to 
provide updates on study results and outcomes. Regarding alternative methods to ask 
for assent of minors, video game technology support is currently under development.60 
To date, studies on the use of new communication technology in a paediatric intensive 
care setting are lacking.
Amongst the characteristics related to the parent and child, the perceived risk and ben-
efit for the individual child and society, additional burden for the child, anxiety, attitude 
towards research and illness severity were most commonly cited as influential factors to 
participate in clinical research.51,61–63 
In the Ghent University Hospital consent is usually asked by the treating physician. How-
ever, during the patient recruitment in our studies, some physicians reported that they 
had some moral objections against this common practice. Current ethical guidelines 
are also cautious with regard to dependent relationships between patients or parents 
and the study team professional. Especially, the voluntary informed consent may be 
compromised, due to a potential conflict of interest.64 Interestingly, however, it was 
previously reported that parents preferred their treating physician to advise on their de-
cision, rather than to take it independently.62 Menon et al. also reported that introducing 
the researcher to the patient’s family by any member of the patient’s intensive care team 
resulted in higher consent rates.61 This suggests that the existing relationship with and 
trust in the treating care team, may increase the parents’ decision rate to participate. To 
the best of our knowledge, no studies on ICU are available investigating the influence of 
the above mentioned factors on the decision process.
In order to guide regulatory agencies, ethics committees and NICU/PICU researchers on 
the most valuable approach to ask for consent and assent, more knowledge is needed 
on the wishes and preferences on trial design, decision making process of both parents 
and children (including capabilities) and the roles of the treating physician and research 
team.
Minimal risk designs 
As described in Chapter 1, blood sampling volume limits PK/PD research to be performed 
in young and critically ill children. Potentially beneficial blood sampling techniques for 
facilitating PK studies in this protected population are currently under investigation.14 
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Microsampling, which is the collection of smaller-than-normal plasma samples for bio-
analysis, may provide a solution and includes mainly dried blood spots (DBS), dry plasma 
spots (DPS), volumetric absorptive microsampling (VAMS) and capillary microsampling 
techniques. In DBS or DPS, a small volume of blood or plasma is applied on an absorbent 
paper which is dried after saturation has occurred. In the laboratory, the blood or plasma 
is eluted out of the paper and subsequently analysed. Cohen-Wolkowiez et al. recently 
reported on the feasibility of using DBS concentrations in combination with plasma 
samples for PK model building of piperacillin and tazobactam in infants.65 A quite simi-
lar, optimized technique is VAMS, in which a fixed volume of blood is absorbed by the 
porous, hydrophilic tip of the device. After the tip is dried, it is sent to the lab for drug 
extraction and bio-analysis. In capillary microsampling blood is collected in a capillary 
tube and subsequently centrifuged in this tube before bio-analysis of the sample. Over-
all, microsampling in critically ill children seems promising as it would allow a significant 
reduction in the blood volume required, thereby reducing the risk of further upsetting 
fluid balance which may already be compromised. 
Another non-invasive technique for measuring drug exposure is using saliva as matrix. 
The advantages of saliva monitoring in paediatric PK trials are acknowledged by the FDA 
and mainly relate to the fact that saliva sampling potentially reduces blood sampling, 
is easy to collect and causes minimal patient discomfort.66 The usefulness of saliva for 
TDM has been studied for several drugs including mainly anti-epileptics, antiretrovirals, 
antipsychotics, antibiotics and antifungals.67–71 To date, however, the majority of studies 
concerning antibiotics lack sufficient PK data to evaluate the suitability.70  
Opportunistic sampling, also known as scavenged sampling or left-over sampling, 
salvages remaining blood, plasma or other body fluids from routine biochemical tests 
for measurement of drug concentrations. Several studies in children have successfully 
used opportunistic sampling alone or in combination with timed blood sampling to 
characterize the PK of anti-infective treatment.72–76 Interestingly, this process can also 
be useful in the opposite direction: Germovsek et al. presented a PK model that allows 
healthcare providers to take a gentamicin TDM sample at a time that is convenient (i.e. 
during a routine blood test) rather than needing to take a specific “trough” sample to 
determine whether drug levels are low enough.77 Finally, routinely collected TDM data 
can also provide useful data to build PK/PD models for the monitored drug, as illustrated 
for gentamicin by Medellín-Garibay et al.78
Microdosing is another promising method to minimize patient burden while efficiently 
studying the pharmacokinetic behaviour of a drug under development. Commonly, 
the given dose is 1/100th of the No Observed Adverse Effect Level and is labelled with 
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a microtracer [14C] for quantification using the most sensitive HPLC techniques. A pre-
requisite is the dose linearity from the magnitude of the microdose up to therapeutic 
ranges. In children, only two proof-of-concept PK microdosing studies, characterising 
paracetamol PK were published.79,80 
Modelling and simulation
Over the last few years, M&S is rapidly evolving in the design and data analysis of paedi-
atric PK/PD experiments, as it may overcome most challenges encountered in paediatric 
drug development.81 
One increasingly important method to optimize a clinical trial is the use of mathematical 
algorithms to design the study in such a way that the collected information is maximally 
informative.82,83 In these algorithms, prior knowledge on the structure of the model 
and parameter distributions are mandatory as input (e.g. published PK/PD model from 
older children). Typically, in PK/PD trials, the total number of patients, sampling times 
and/or number of samples are optimised for, taking into account the ethical (e.g. blood 
sampling volume limits) and practical constraints (e.g. minimum timeframe between 
two blood sampling times). In our PK studies, we did not use an optimal sampling 
design. Instead, we used an informative sampling design in which the sampling times 
were based on a combination of knowledge on common PK principles and target PK/PD 
indices. However, we acknowledge that the benefit of these optimal design algorithms 
is worth exploring in future NICU/PICU study designs. 
Quantitative extrapolation of PK and/or PD for first-dose estimation is recognized by 
ICH, FDA and EMA as another valuable study design aid to explore dosing scenarios in-
creasing the benefit-risk ratio, before even enrolling children into the clinical trial.81,84–86 
Through the use of extrapolation, also unnecessary studies can be avoided and the 
number of children minimised (e.g. fewer data needed in adolescents when reasonably 
similar to adults).85 Still, bridging PK, efficacy and safety data from older age categories 
to the youngest age categories (neonates and infants) has shown variable success, 
mainly depending on the modelling approach and individual compound.87,88 Also, the 
usefulness of extrapolation to children with serious pathophysiological changes and/or 
comorbidity needs further study.
Overall, a strong trend of moving from pure “empirical” models towards more mecha-
nistic models is noticeable in the field of M&S, with the ultimate goal to create gen-
eralisable PK/PD models that distinguish between drug and system parameters.11 De 
Cock et al. showed that the GFR mediated clearance of 4 renally cleared antibiotics in 
neonates (netilmicin, tobramycin, vancomycin, gentamicin) could be predicted using a 
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covariate model on amikacin clearance, which is a molecule with similar physicochemi-
cal and disposition characteristics.89 This so-called semi-physiological approach beyond 
compound specific observations may eventually lead to a further reduction in patient 
burden. However, at the other extreme, it is known that the predictive performance of 
full PBPK and systems pharmacology models in children is currently fairly low, due to 
the lack of precise system parameter estimates.12 Therefore, more knowledge on the 
time course of physiological processes (e.g. maturation in renal transporter activity) and 
disease specific changes (e.g. sepsis) is first needed to be applicable to the paediatric 
intensive care setting.12,90,91 
A final promising development in the M&S area, is the use of software combining the 
population PK/PD model as Bayesian prior information and the individual response to 
refine the model parameter predictions for a particular patient.83 Typically, this response 
is measured using a biomarker e.g. antibiotic concentration using therapeutic drug 
monitoring. Although, prospective, randomised controlled clinical trials are needed 
to compare traditional dose adaptation strategy (standard of care) with PK/PD model- 
based dose adaptation strategy, such software programs have the potential to be used 
as a bedside dose adaptation tool to ensure efficacious treatment.92–94 In this revolu-
tionary field of personalised medicine, clinical pharmacists and pharmacologists with a 
sound understanding of pharmacometrics are ideally placed to take the lead.95 
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Bacterial infections are commonly encountered in children admitted to the ICU and 
require adequate antibiotic treatment. Growth, development and pathophysiological 
changes may alter disposition of antibiotics. Due to a lack of knowledge, most antibiotic 
dosing regimens are currently extrapolated from adults, relatively healthy and /or older 
children.
In this dissertation, the altered pharmacokinetics and target attainment of four com-
monly used antibiotics and two BLIs were investigated in critically ill children. It was 
demonstrated that current published dosing regimens of amoxicillin/clavulanic acid 
and piperacillin/tazobactam result in subtherapeutic concentrations in the early period 
of sepsis, due to augmented renal clearance, thereby risking clinical failure. Underdos-
ing was also observed for cefazolin in children undergoing cardiac surgery with CPB. 
Hence, dose optimization strategies were suggested, based on population M&S. In a 
pilot study on vancomycin, it was found that its plasma protein binding was lower than 
generally assumed and depended on the plasma protein concentration. Target attain-
ment was the highest when using a target based on unbound concentrations. Because 
only the unbound concentration exerts a pharmacological effect, the risk of underdos-
ing in critically children is potentially lower than previously assumed. Finally, a validated 
prediction tool for unbound vancomycin plasma concentrations was developed.
In conclusion, the complex interplay between physiology and pathophysiology needs 
to be considered when assessing antibiotic disposition in critically ill children. Popula-
tion M&S provides an effective tool to optimize antibiotic treatment in this vulnerable 
patient population. 
Many questions are to be resolved. First, the proposed antibiotic dosing regimens require 
a prospective validation. Additional studies should focus on the tissue penetration of 
unbound antibiotic and link the PK with microbiological response and development of 
antimicrobial resistance over time. In the longer term, the impact of model-based dose 
optimisation on clinical outcome needs to be studied using a randomised, controlled 




Bacteriële infecties komen vaak voor bij kinderen opgenomen op de intensieve zorg 
afdeling, en vereisen een adequate antibioticatherapie. Groei, ontwikkeling en pathofysio-
logische veranderingen bij kinderen kunnen leiden tot een veranderde farmacokinetiek 
van antibiotica. Echter, tot op vandaag worden geneesmiddelen, in casu antibiotica, vaak 
aan kritiek zieke kinderen voorgeschreven zonder adequaat bewijs van het benodigd 
doseerschema. Clinici grijpen dan ook vaak terug naar ‘op ervaring’ gebaseerde doserings-
aanbevelingen. 
In dit proefschrift werd de dispositie onderzocht van vier antibiotica en twee BLIs bij kritiek 
zieke kinderen, alsook de kans op het bereiken van vooropgestelde doelconcentraties. Er 
werd aangetoond dat de huidige doseerregimes van amoxicilline/clavulaanzuur en piper-
acilline/tazobactam vaak leiden tot subtherapeutische concentraties in de initïele periode 
van sepsis, tengevolge van een verhoogde renale klaring. Een onderdosering werd ook 
waargenomen voor cefazoline bij kinderen die cardiochirurgie ondergingen met CPB. 
Om therapiefalen te vermijden, werden geoptimaliseerde doseerregimes voorgesteld, 
met behulp van populatie farmacokinetische methodes. In een laatste pilootstudie werd 
vastgesteld dat de plasma eiwitbinding van vancomycine bij kritiek zieke kinderen lager 
is dan algemeen werd aangenomen en afhankelijk is van de plasma eiwitconcentratie. 
Vancomycine doelconcentraties werden het vaakst bereikt, wanneer deze werden afge-
toetst ten opzichte van een target op basis van ongebonden concentraties. Aangezien 
het farmacologisch effect gerelateerd is aan de ongebonden concentratie, is bijgevolg 
het risico van onderdosering bij kritiek zieke kinderen mogelijks lager dan voorheen werd 
aangenomen. Tot slot werd een gevalideerde formule ontwikkeld voor het voorspellen 
van ongebonden vancomycine plasmaconcentraties op basis van totale concentraties.
Samengevat kunnen we stellen dat zowel fysiologische processen van groei en ontwikke-
ling als pathofysiologie in rekening moeten worden genomen bij het bestuderen van de 
PK van antibiotica bij kritiek zieke kinderen. Populatie modellering en simulatie methodes 
zijn een effectieve tool om antibiotica dosering te optimaliseren in deze kwetsbare popu-
latie.
Vele vragen dienen nog te worden beantwoord. Ten eerste moeten de nieuw voorgestelde 
doseerregimes prospectief gevalideerd worden. Aanvullend onderzoek moet zich boven-
dien toespitsen op weefselpenetratie van ongebonden antibioticum, om dit vervolgens te 
linken met een microbiële respons en ontwikkeling van antibioticaresistentie over tijd. Tot 
slot dient de impact van dosisoptimalisatie te worden onderzocht op klinische uitkomst in 




Dit werk was nooit mogelijk geweest zonder de hulp van anderen. 
“A leader is one who knows the way, goes the way, and shows the way” - john C. 
Maxwell
Tijdens mijn doctoraatstermijn had ik het voorrecht omringd te zijn met een dreamteam 
van vier promotoren.
Beste Peter, duizendmaal dank voor de coaching, steun en eindeloos vertrouwen de 
afgelopen zes jaar. Klinisch farmacologen met PK/PD expertise zijn dun bezaaid in ons 
ziekenhuis en het is dan ook een voorrecht om onder jou te mogen promoveren. Je gaf 
me de kans om mijn eigen weg te gaan maar keek geduldig over mijn schouder mee 
om bij te sturen waar nodig. Ondanks je drukke agenda en de vaak krappe deadlines 
kon ik steevast snel op je uitgebreide en scherpe review en feedback rekenen (ook ’s 
avonds laat en in het weekend). Jouw innovatieve idee omtrent de opstart van het dex-
medetomidine PK onderzoek bij kritiek zieke kinderen (dex was zelf nog niet in België 
beschikbaar op dat moment) lag tevens aan de basis van een definitieve heroriëntatie 
van mijn doctoraatsonderzoek. Bedankt ook voor de nuchterheid wanneer ik weer eens 
met een zot onderzoeksidee kwam aandraven en bemoedigende woorden wanneer het 
es minder ging. Het tegenwoordig bijna dagelijks “Dag Peter, stoor ik?” zal waarschijnlijk 
even wat in frequentie afnemen maar ik hoop dat we ons daarna terug kunnen concen-
treren op de vervolgprojecten J! 
Beste Johan, van harte dank dat ik deel mocht uitmaken van jouw “SAFEPEDRUG project 
kindje”. Het pediatrisch farmacologisch onderzoek in ons ziekenhuis nam sinds jouw 
initiatief een enorm hoge vlucht. Dankjewel dat ik mocht “meevliegen” en genieten van 
bijkomende financiering voor verdere uitbouw van de NICU/PICU farmacologie onder-
zoekslijn. Jouw enthousiasme en positivisme apprecieer ik enorm.
Beste Oscar, te land, ter zee en in de lucht. Bezige bij. Door jou is voor mij het woord 
“TC” (teleconferentie n.v.d.r.) een alledaags begrip geworden. Ondanks je drukke jobs 
nam je steeds snel en ruim de tijd voor teaching en overleg. Van harte dank dat ik stage 
mocht lopen aan het gerenommeerde LACDR in Leiden en in je ruime appartement 
mocht verblijven gedurende deze tijd (er zijn niet veel doctoraatsstudenten die kunnen 
zeggen dat ze in het huis van hun promotor gewoond hebben J). Mille grazie. 
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Beste Hugo, mijn officieuze vierde promotor. Jouw peetvaderschap van de klinische 
farmacie in België en (besmettelijke) passie voor wetenschap waren kiemen voor de 
start van dit onderzoek. Van harte dank hiervoor. Super bedankt ook voor de talrijke 
kansen om me bij te scholen in binnen-en buitenland. 
Beste leden van de begeleidingscommissie Professor Van Bortel, Professor Vanhae-
sebrouck, Professor Smets, vakgroepvoorzitter Farmacologie Professor Lefebvre en 
Professor Buylaert. Van harte dank voor jullie waardevolle input, opbouwende kritiek en 
bemoedigende woorden de afgelopen tijd. 
“The proper route to an understanding of the world is an examination of our errors 
about it” - Errol Morris
Een woord van dank aan de voorzitter Professor Van de Voorde en leden van de examen-
commissie Professor Boussery, Professor De Waele, Professor Stove, Professor Allegaert, 
Professor de Wildt en Professor Sherwin voor het kritisch nalezen van dit boekje, het 
onderscheppen van fouten en het delen van nieuwe inzichten. Dear Catherine, thank 
you for coming all the way from Utah to both the internal and public defense.
“Never spend your money before you have earned it” - Thomas jefferson
Van harte dank aan de commissieleden van het Klinisch Onderzoeksfonds van het 
Universitair Ziekenhuis Gent om me de kans te geven dit onderzoek tot een goed einde 
te brengen. Zonder dit fonds zou het schrijven van mijn boekje ongetwijfeld heel wat 
langer geduurd hebben. Ook het Agentschap voor Innovatie door Wetenschap en Tech-
nologie ben ik zeer erkentelijk voor de financiering van het SAFEPEDRUG project.
“Individuals play the game, but teams beat the odds.” - SEAL Team saying 
Annick, dit project zou nooit tot stand gekomen zijn mocht ik niet zo hartelijk ontvangen 
zijn op de PICU/PIMCU. Piet, Koen, ook in jullie NICU team voelde ik me enorm gewaar-
deerd en kreeg ik altijd “carte blanche” voor opstart van mijn onderzoek. Oprechte dank.
Annick, Ann, Patrick, Jef, Evelyn (artsen intensieve zorg pediatrie), Ingrid, Harlinde, 
Wim (artsen intensieve zorg cardiochirurgie), Piet, Koen, Claudine, Linde, Kris, Annelies, 
Sophie, Lara (artsen intensieve zorg neonatologie), Katrien, Thierry (cardiochirurgen) en 
alle betrokken ASO artsen. Super bedankt om telkens opnieuw ons onderzoek te willen 
voorstellen aan de ouders (in niet altijd evidente omstandigheden). Dankjewel aan alle 
cardio-anesthesisten, perfusionisten en ((adjunct)-hoofd)verpleegkundigen van de IZP, 
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NICU and CSICU afdelingen voor de logistieke organisatie en het consciëntieus afnemen 
van de vele bloedstalen!
Merci beaucoup Professor Biarent, dr. Vens, Barbara, Caroline et tous les autres méde-
cins et infirmières de l’hôpital universitaire Reine Fabiola pour l’aide avec recruter des 
patients dans nos études.
I had the opportunity to collaborate with researchers and clinicians from various places 
and departments. Thank you to all co-authors for sharing your expertise. Professor 
Verstraete, Professor Delanghe, Professor Biarent, Professor Stove, Professor De Somer, 
Professor Ungerer, Professor McWhinney, Professor Moerman, dr. Carlier, dr. Vens, dr. 
Colman. A special word of gratitude to Joe, Hussain (my paediatric clinical pharmacist-
partners from London and Leicester) and Charlotte for the smooth collaboration in the 
amoxiclav and cefazolin project. Sven, jouw computer and R skills zijn mindblowing en 
waren onmisbaar voor het piptazo project. Dankjewel voor de gastvrijheid (ook voor 
mama en papa van Dijkman en Kate), vriendschap en geduld. Neen, ik zeg dit niet “voor 
de grap” ;-). Coen, je hulp bij de cefazoline simulaties werd enorm geapprecieerd! 
Sarah, woorden schieten gewoon tekort om jou te bedanken. Toen ik geveld was met 
klierkoorts vorig jaar was jij diegene die samen met de studieverpleegkundigen de boel 
wist draaiende te houden. De vancomycine paper is mede jouw verhaal. De kauwgom is 
bijna op, tijd om terug te komen uit de Filippijnen ;-). 
Evelyn, Tatjana en Laura ik ben ontzettend blij dat jullie nu ook mee aan de kar trekken 
en een vervolgverhaal breien aan dit boekje.
Het SAFEPEDRUG studieteam Daphne, Alien, Fien en Anca dank ik voor alle hulp en 
betrokkenheid. Jullie zijn TOP! Het IZ studieteam bedankt voor de logistieke hulp bij de 
opstart van de ADIC studie en Sandrine en Joline voor de hulp bij het samenstellen van 
de ADIC en CEFA datasets. 
Hugo, Sabrina, Marijke, Johan, Annemie en Sarah, dank voor het vertrouwen en het 
scheppen van de nodige ruimte. Alle (ex-)apotheekcollega’s (al of niet gepensioneerd), 
super bedankt voor de poortwachtruils en meermaals inspringen, alsook voor de op-
rechte interesse! 
Alle SAFEPEDRUG collega’s, en in het bijzonder Pauline, ik ben blij dat ik met zulk gedre-
ven team mag samenwerken.
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Dankjewel aan de studenten Kim, Karen en Louise, die een bijdrage leverden aan de 
cefazoline en vancomycine studie in het kader van hun masterproef. 
Hartelijk dank aan Danielle voor de hulp bij de boekhouding, Linda voor de logistieke 
organisatie van deze dag alsook Anita en Isabelle voor de verdeling van de boekjes.
“Looking after a very sick child was the Olympics of parenting” - Chris Leave
Een oprechte dankjewel aan alle ouders om - in vaak emotioneel moeilijke omstandig-
heden - toestemming te geven voor afname van een aantal bloedstalen. Deze studies 
konden geen onmiddellijk voordeel betekenen voor de behandeling van jullie kind. Ook 
aan alle patiëntjes, superbedankt.
“Gun jezelf toch een dagje lummelen” - Bond zonder Naam
Hup hup Holland! I would like to thank all staff, postdoc and PhD colleagues at the LACDR 
and in particular: Sven, Wilbert, Verena, Jantine, Rick, Coen, Pyry, Willem, Laura, Esther, 
Francesco, Margreke, Anne, Eric, Asa, Elisa, Jan, Michiel and Rob. My staying in Leiden 
was a once in a lifetime experience! De avondlijke racefietstochtjes doorheen de duinen 
van Noordwijkerhout en de Bosbaan triathlons in Amsterdam: leuke herinneringen!
Bloedbroeders en zusters Dikkie, Stoffels, Arni, Whoopie, Eva, Marie, Carolina en Rosy 
(aka boys and girls without a smartphone), petekind Helder en alle andere kleine spo-
ken. Moesjamaramaramara. Dank voor de jarenlange vriendschap, de vele reisjes en 
sorry voor de afwezigheid het voorbije jaar. Nu is het terug tripstickers time: volgend 
weekend picknick op 51.042063°, 3.726826°, check? 
“Family is not an important thing. It is everything.” - Michael j. Fox
Peter Erpe en Peter Lebbeke, ik hoop dat jullie fier zijn gindsboven. Dank voor de vele 
levenswijsheden die jullie me meegaven.
Papa, mama, jullie bewegen al een leven lang hemel en aarde voor Roosmarijn, Frederik 
en mezelf. L’histoire se répète: ook de kleinkinderen boffen met zulke oma en opa. Ik zeg 
het ongetwijfeld veel te weinig: dankjewel voor alle wijze raad, kansen, schouderklopjes 
en hulp! Ik zie jullie graag!
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Roos, dank voor de ontelbare aanmoedigingen en babbels. Mijn petekindje Felix mag in 
zijn handjes wrijven met zulke lieve mama. Sorry Frederik, Annabel, Jordy omdat Roos 
en ik jullie verveelden met “theta’s”, “eta’s”, “shrinkage” en “residuals” aan de kerstavond 
feestdis.
Jef, Andrea, Katrien, Mikael, Ilse, Bart, Leen, Bram, Tibo, Thor, Rune, Myrthe, Warre, Lou, 
Lopke: het is leuk om zo’n hechte (schoon)familie erbij te hebben. 
Prinses Lara, lieverd, dankjewel voor het ontwerp van de cover. Zo ben ik zeker dat toch 
1 iemand binnen 10 jaar nog eens naar dit boekje zal kijken J! De voorbije tijd was ik 
vaak op mijn “werkje”; dat maken we vanaf morgen samen met mama weer goed! O que 
achas de começarmos por comer um gelado mais logo?






First names: Pieter Albert Jozef Guido
Mailing address: Ghent University Hospital, Pharmacy, -1K12C,
De Pintelaan, 185
9000 Gent, Belgium 
Phone number:  +32 09 332 29 69 (work)
E-mail:  pieter.decock@uzgent.be
2. QUALIFICATIONS
2001 Pharmacist, Ghent University, graduated with honours
2002 Hospital pharmacist, Ghent University, graduated with great honours
2016  Certified clinical pharmacologist, Dutch Society for Clinical Pharmacol-
ogy and Biopharmacy, The Netherlands
3. jOB DESCRIPTION
2003-present  accredited hospital pharmacist staff member at Ghent University Hospital
· medication distribution pharmacist (1/4 FTE)
· clinical pharmacist (1/4 FTE)
· hospital pharmacy researcher (1/2 FTE)
4. ADDITIONAL TRAINING
2004  Certificate “Clinical Pharmacy”, Université Catholique de Louvain (exam 
passed) (15-day course)
2004-2005  Certificate “Antibioticabeleidsdeskundige” [expert in antibiotic policies] 
: interuniversity course Ghent University, Catholic University of Leuven, 
Antwerp University (5-day course)
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2005-2016  Training initiated with an eye to obtaining a clinical pharmacologist 
degree (Dutch Society of Clinical Pharmacology and Biopharmacy; 
supervisor: prof. L. Van Bortel) 
2006 Course on Good Clinical Practice + EU law on clinical trials, Ghent Univer-
sity Hospital (exam passed)
2007 Course on paediatric drug research, Rotterdam, the Netherlands (Eras-
mus Winter Programme)(4-day course)
2007 5th European summer school in clinical pharmacology and therapeutics, 
Ghent, Belgium (4-day course)
2008 Course biostatistics, Ghent, Belgium (5-day course)
2008 Pharmmed course: criteria for first dose in men, Brussels, Belgium (1/2-
day course)
2009 Mylan management course for hospital pharmacists, Waasmunster (6-
day course)
2009  Training Pharmonitor (dosing recommendations from PC-pharmacoki-
netic calculations), UZA, Antwerp (1/2-day course)
2009 Course on pharmacokinetics: introduction to NONMEM (population 
kinetics), Université Catholique de Louvain, Brussels (3-day course)
2009 Course on pharmacokinetics (Leiden-Amsterdam Centre For Drug Re-
search), Oegstgeest, the Netherlands (4-day course)
2010 Postuniversity course on biostatistics (SPSS software), Ghent University 
(5-day course)
2010 Fisher/Shafer introductory course on non-linear mixed effects modelling 
(NONMEM), Bethesda, USA (4-day course)
2012 A statistical approach to PK-PD analysis in practice. Workshop of the Eu-
ropean Society of Clinical Microbiology and Infectious Diseases, Athens, 
Greece (4-day course)
2012 Introductory course on population PK-PD modeling. Centre for Human 
Drug Research, Leiden, the Netherlands (3-day course)
2013 Global Research in Pediatrics (GRIP) roadshow- training course: medi-
cines in children – what you need to know, organised by European Soci-
ety of Developmental, Paediatric and Perinatal Pharmacology, Salzburg, 
Austria (1-day course)
2013 Postgraduate course on pharmacotherapy, 24th Annual Meeting of the 
European Society of Paediatric and Neonatal Intensive Care, Rotterdam, 
The Netherlands (1- day course)
2013 Introductory course on pharmacokinetics. Kinesis Pharma, Breda, the 
Netherlands (3- day course)
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2014 Sheiner/Rowland advanced course in pharmacokinetics/pharmacody-
namics, Silz-Maria, Switzerland (5-day course)
2014 Uppsala pharmacometrics summer school, Uppsala, Sweden (scientific 
project selected for presentation/workshop)
2014 PKPD modelling of continuous and categorical data in NONMEM, Ali-
cante, Spain (3-day course)
2014 Pharmacometric statistics workshop (TACCA Training), Dublin, Ireland 
(3-day course)
2015 Global Research in Pediatrics (GRIP) roadshow: Basic concepts of pe-
diatric pharmacokinetics/pharmacodynamics, organized by the GRIP 
network, Brussels, Belgium (1-day course)
2015 Global Research in Pediatrics (GRIP) roadshow - training course: Medi-
cines in children, organized by the European Society of Developmental, 
Paediatric and Perinatal Pharmacology (ESDPP) and GRIP network, 
Belgrade, Serbia (1-day course)
2015 Comprehensive interuniversity course in pharmacokinetics : Funda-
mental principles and application to contemporary drug development. 
Leuven University, Leuven, Belgium (3-day course)
2015 Management course, organised by the Flemish Society for Hospital 
Pharmacists, Westerlo, Belgium (1 day course)
2016 Good Clinical Practice certificate, Ghent University Hospital (exam 
passed) (1/2 day course)
5. CLINICAL-SCIENTIFIC ExPERIENCE
2005 Clinical internship at the paediatric intensive care unit, Texas Children’s 
Hospital, Houston, USA (2 months)
2007-2008 Clinical internship at the phase I research DRUG unit as part of the clini-
cal pharmacology training (80hrs)
2008-2009 Clinical internship at the geriatric department and emergency depart-
ment as part of the clinical pharmacology training (20hrs)
2014-2015 Scientific Internship in population PK-PD modelling at the division of 
Pharmacology, Leiden Academic Centre for Drug Research, Leiden, the 
Netherlands (supervisor: prof. dr. O. Della Pasqua) (10,5 months)
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6. TEACHING ExPERIENCE
2008-2011 “Geneesmiddelendocumentatie en informatieverstrekking in het 
ziekenhuis: inleiding en workshop” [Drug information in the hospital : 
introduction and workshop] to hospital pharmacy students (person in 
charge: Prof. H. Robays; 2 hrs/academic year; Ghent University)
2008-2011 “Inleiding tot de klinische farmacie in het ziekenhuis” [Introduction to 
hospital clinical pharmacy services] to pharmacy students (person in 
charge: Prof. H. Robays; 2hrs/academic year; Ghent University)
2010-2012 “Medicatie bij kinderen: alles wat u wil weten over concentraties en 
toedieningswijze” [Paediatric drug therapy: everything you want to 
know about concentrations and drug administration] to bachelor nurs-
ing (2,5hrs/academic year; Vesalius Hogeschool, Ghent)
2012-present “Pharmacogenetics and influence on pharmacokinetics and pharma-
codynamics of medicinal products” (lecture for clinical pharmacology 
trainees, Heymans Institute for Clinical Pharmacology; 1,5h/2 yearly)
2012 “Rationeel, evidence-based geneesmiddelengebruik bij kinderen” [Ra-
tional, evidence-based drug therapy in children] (lecture as part of an 
interuniversitary course for pediatrician fellows; 2h/academic year) 
2012-present Tutor and examination of medical students in various clinical pharmacol-
ogy topics (person in charge: Prof. dr. T. Christiaens; 6-15 hrs/academic 
year; Ghent University)
2012-present “Klinische farmacokinetiek, therapeutic drug monitoring en farmaco-
genetica” [Clinical pharmacokinetics, therapeutic drug monitoring and 
pharmacogenetics] interuniversity course master in hospital pharmacy 
(coordinator: Prof. dr. I. Spriet; 4h/academic year)
2013-present “Rationeel, evidence-based geneesmiddelengebruik bij kritiek zieke 
kinderen” [Rational, evidence-based drug therapy in children] (lecture as 
part of an Bachelor after Bachelor program in Intensive Care and Emer-
gency Medicine, KAHO Sint-Lieven, Aalst, Belgium; 2h/academic year)
2013-present “Rationeel, evidence-based geneesmiddelengebruik bij kinderen” 
[Rational, evidence-based drug therapy in children] (lecture as part of 
Postgraduate training in Pediatric Nursing, HOGent, Ghent, Belgium; 3h/
academic year)
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7. MASTER THESIS SUPERVISION
2007 “Medicatiefouten op een afdeling intensieve zorgen pediatrie” [Medica-
tion errors on a pediatric intensive care unit] – master after master in 
hospital pharmacy (daily supervisor) (promotor: prof. apr. H. Robays) 
(Leen Ronsyn)
2008 “Medicatiefouten op een afdeling medium-care pediatrie” [Medication 
errors on a pediatric medium-care unit] – master after master in hospi-
tal pharmacy (daily supervisor) (promotor: prof. apr. H. Robays) (Peter 
Declercq)
2008 “Beleid Totale Parenterale Nutritie op een afdeling intensieve zorgen 
pediatrie” [Evaluation of the Total Parenteral Nutrition prescription on a 
paediatric intensive care unit] - master after master in hospital pharmacy 
(daily co-supervisor with apr. J. De Cloet) (promotor: prof. apr. H. Robays) 
(Evelien Haegeman)
2009 “Medicatiefouten op een afdeling intensieve zorgen pediatrie na 
implementatie van een elektronisch voorschrift” [Medication errors on 
a paediatric intensive care unit after implementation of a computerized 
physician order entry system] – master after master in hospital pharmacy 
(daily supervisor) (promotor: prof. apr. H. Robays) (Kim Pieters)
2009 “Onderzoek naar de kwaliteit van therapeutic drug monitoring van 
antibiotica op de afdelingen pediatrie” [Evaluation of the quality of 
therapeutic drug monitoring of antibiotics in children] – master in phar-
maceutical sciences (daily supervisor) (promotor: prof. apr. H. Robays) 
(Nele Goerlandt)
2009 “Medicatiefouten op een afdeling intensieve zorgen neonatologie” 
[Medication errors on a neonatal intensive care unit] – master after 
master in hospital pharmacy (daily supervisor) (promotor: prof. apr. H. 
Robays) (Maïté Vandaele)
2011-2012 “Dexmedetomidine als analgosedativum op intensieve zorgen” [Dexme-
detomidine used as analgosedative drug on intensive care] – master in 
medical sciences (co-promotor) (promotor: prof. dr. P. De Paepe)(Sofie 
Herregods)
2012 “Effecten van hypoalbuminemie en hyperfiltratie op de dosering van 
antibiotica bij kritisch zieke kinderen” [Effects of hypoalbuminemia and 
hyperfiltration on antibiotic dosing in critically ill children] – master in 
pharmaceutical sciences (daily supervisor) (promotor: prof. apr. H. Ro-
bays) (Nicky Boeykens)
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2013-2014 “Cefazolin disposition in children undergoing cardiac surgery with car-
diopulmonary bypass”- master in medical sciences (co-promotor) (other 
promotors prof. dr. P. De Paepe – prof. dr. K. Francois) (Kim Vanderburght 
– Karen Jacobs)
2013-2014 “Hyperfiltration in the paediatric intensive care unit” - master in medical 
sciences (co-promotor) (other promotors prof. dr. P. De Paepe – dr. A. de 
Jaeger) (Benjamin Leenknegt – Karlien Roelandt)
2013-2014 “Dispositie van cefazoline en vancomycine bij kritisch zieke kinderen” 
[disposition of cefazolin and vancomycin in critically ill children] – mas-
ter after master in hospital pharmacy (daily supervisor) (promotor: prof. 
apr. A. Somers) (Sarah Desmet)
2015-2017 “Dispositie van teicoplanine en meropenem bij kritiek zieke 
kinderen”[disposition of teicoplanin in critically ill children] – master 
after master in hospital pharmacy (daily supervisor) (promotor: prof. apr. 
A. Somers) (Margot Wollaert)
2016-2017 “Dispositie van ciprofloxacine en amikacine bij kritiek zieke kinderen” 
[disposition of ciprofloxacin and amikacin in critically ill children] – mas-
ter in medical sciences (co-promotor) (promotor prof. dr. P. De Paepe) 
(Kamilya Jakipbayeva) 
2016-2017 “Prospectieve validatie van model-based cefazoline doseringsregime bij 
kinderen die cardiochirurgie ondergaan met cardiopulmonaire bypass” 
[prospective validation of model-based cefazolin dosing regimen in 
children undergoing cardiac surgery with cardiopulmonary bypass] – 
master in medical sciences (co-promotor) (other promotors prof. dr. P. 
De Paepe – prof. dr. K. Francois) (Gerrit van Vliet)
8. SCIENTIFIC AWARDS – PROjECT FUNDING
2006 Amgen Scientific Award. Best Poster Award “Crushing the tablet? De-
velopment of guidelines and information database.” Flemish Society for 
Hospital Pharmacists
2011-2016 Clinical Research Fund Ghent University Hospital
(funding personnel cost ½ FTE)
2013 Amgen Scientific Award. Best Poster Award “Penicillin dosing regimens 
are inadequate in critically ill children”. Flemish Society for Hospital 
Pharmacists 
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2014-present Funding for work package ‘Altered drug disposition and effect in paedi-
atric critical illness’ within the interuniversity/university hospital research 
project funded by the Agency for Innovation by Science and Technology 
(IWT/SBO130033) (WP leader: Prof. dr. P. De Paepe)
2014 Travel grant, Research Foundation Flanders, Belgium (K218614N)
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